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Autotaxin is an extracellular phospholipase D that catalyses the hydrolysis of lysophosphatidyl 
choline (LPC) to bioactive lipid lysophosphatidic acid (LPA). LPA has been implicated in many 
pathological processes relevant to cancer, including cell migration and invasion, proliferation, and 
survival. Patients with ovarian cancer often present with an accumulation of ascites fluid in the 
intraperitoneal cavity which contains LPA at concentrations up to 80 micromolar. Autotaxin is also 
found at increased levels in the ascites fluid of patients with ovarian cancer and is over-expressed in 
ovarian cancer tumours that are resistant to chemotherapy. Maintaining a high local concentration of 
an autotaxin inhibitor within the peritoneal cavity is likely to be important to ensure sufficient and 
prolonged inhibition of autotaxin. The residence time of small molecular weight drugs in the 
peritoneal cavity may not be adequate because they are quickly absorbed through the peritoneal 
capillaries into systemic circulation. Polymers are becoming an increasingly useful tool in the 
delivery of drugs and have the potential to improve the properties of small molecules, including 
intraperitoneal residence time. In this thesis, the synthesis of polymer-autotaxin inhibitor conjugates 
is described, followed by the biological evaluation of the conjugates.  
Firstly, the synthesis of a dendrimer-S32826 conjugate and its biological evaluation is reported. 
S32826 is a LPA analogue with a high potency against autotaxin. This dendrimer-autotaxin inhibitor 
conjugate was found to inhibit autotaxin activity using two different substrates and two different 
sources of autotaxin, and to decrease the migration of an ovarian cancer cell line modified to 
overexpress autotaxin. Furthermore, the conjugate potentiated activation of caspase 3/7 induced by 
carboplatin. However, conjugation of the drug to the dendrimer significantly reduced its potency. 
Subsequently the synthesis of an icodextrin-autotaxin inhibitor conjugate and its biological 
evaluation was undertaken. Structure-based drug design was used to identify an appropriate locus to 
cross link icodextrin to an autotaxin inhibitor described by Albers et al. with a thiazolidinedione core. 
The icodextrin-autotaxin inhibitor conjugate was also found to inhibit autotaxin activity using two 
different substrates and two different sources of autotaxin. Furthermore, the conjugate was found to 
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reduce migration of an ovarian cell line modified to over express autotaxin. Conjugation to icodextrin 
led to an increase in solubility and a decrease in permeability compared to the free drug. Finally, the 
icodextrin-autotaxin inhibitor conjugate was administered to the peritoneal cavity of mice. After 24 
hours, 30% of the drug was still detected in the peritoneal cavity. These observations suggest that the 
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1.1 Ovarian cancer 
1.1.1 Introduction 
Ovarian cancer is the fifth most common cancer in women, with approximately 7,000 women being 
diagnosed with ovarian cancer in 2011 in the U.K and approximately 4,200 deaths in 2012.1 
Worldwide in 2008 there were approximately 225,000 new cases of ovarian cancer diagnosed, and 
140,000 recorded deaths from ovarian cancer.2 For patients diagnosed between 2008 and 2012 in the 
U.K survival to five years is 47% with resistance to chemotherapy and reoccurrence of tumour 
growth a major issue in the long term survival of ovarian cancer patients.1 Ovarian cancer is a disease 
produced by the rapid growth and division of one of the three major cell types; germ cells, stromal 
cells or epithelial cells, with cancer of epithelial origin being the most common.3 Epithelial ovarian 
cancer (EOC) has four main histological subtypes, serous (70% of cases), endometrioid (10-15% of 
cases), clear cell (10% of cases) and mucinous (3% of cases).4 These subtypes are characterised by 
their resemblance of differentiated cells found in the fallopian tube (serous), endometrium 
(endometrioid), endocervix (mucinous) and vagina (clear cell). Serous carcinomas are high grade in 
90% of these cases and also account for 70% of deaths from ovarian cancer.4 Ovarian cancer has few 
distinctive early symptoms, and is therefore usually diagnosed at an advanced stage of disease with 
patients presenting with peritoneal metastases. Thus earlier diagnosis would be beneficial and this 
would be facilitated by an improved understanding of the origin of ovarian cancer.  
1.1.1 Origin and histopathology 
The epithelial surface of the ovaries was originally identified as the primary origin of ovarian cancer 
due to the location of the bulk of the tumour and because frequent ovulation has been identified as a 
major risk factor for ovarian cancer.3 However, this theory has not been verified and no precancerous 
lesions have been observed in the ovary.5 Furthermore, high grade serous carcinomas (HGSC) have 
the same appearance as fallopian epithelium not ovarian surface epithelium.5 These observations 




a link between BRCA1 and BRCA2 mutations and fallopian tube carcinomas led to the analysis of 
fallopian tubes and ovaries of women with a BRCA1/2 mutation whom had undergone preventative 
surgery.7-8 From these studies early serous carcinomas were found in the fallopian tubes.9-11 Early 
serous lesions of the fallopian tubes have also been identified in 64-71% of non-hereditary HGSC.12 
Further support for the fallopian tube origin of EOC includes a gene expression analysis which 
indicated a high degree of similarity between high grade serous ovarian cancer and tubal 
carcinomas.13 However, not all HGSC present with tubal carcinomas therefore the origins of EOC 
require further investigation.14-17 
Advances in the histology and molecular genetics of ovarian cancer have also changed the idea that 
ovarian cancer is one disease with many epithelial subtypes and suggest it is several separate 
diseases.18 Currently ovarian cancer is classified into two types of tumours.19 Type I tumours are low 
grade tumours (well differentiated and slow growing), typically with mutations in BRAF, KRAS and 
PTEN, including endometrioid, mucinous and clear cell carcinomas. These are slow growing and 
often resistant to chemotherapy. Type II tumours are high grade tumours (poorly differentiated and 
fast growing), including serous and endometrioid carcinomas, typically with mutations in p53, 
BRCA1 and BRCA2.5 These tumours often grow more rapidly, but are usually sensitive to 
chemotherapy. 
1.1.2 Epidemiology and genetic predisposition 
One of the main risk factors associated with ovarian cancer  is frequent ovulation,3 consistent with 
this observation epidemiological studies have shown a decreased risk of developing ovarian cancer 
with oral contraceptives, multiple pregnancies and lactation, which reduce ovulation.20-22  
Furthermore, tubal ligation has also been linked with a decrease in ovarian cancer incidences.23 
Fertility treatments have been associated with an increased risk of ovarian cancers; however, more 
recent studies have disputed this.24-27 Other risk factors identified include an increase in ovarian 
cancer incidences in women with endometriosis28-29 and polycystic ovaries.30 Further to these 




However, potential risk factors are still disputed such as talcum powder31 and smoking32 which were 
previously linked with an increased risk, have more recently been discounted as a cause for ovarian 
cancer.33 
A family history of breast or ovarian cancer is another important risk factor for the development of 
EOC; 10-15 % of ovarian cancer cases are hereditary in origin.34  Mutations in the genes BRCA1 and 
BRCA2 are involved in the development of ovarian cancer; this is seen in women with hereditary 
breast-ovarian cancer syndrome (HBOC).35 A small number of families present with hereditary 
ovarian cancer but not breast cancer; this is called site-specific ovarian cancer syndrome.36 This has 
been linked to specific mutations in BRCA1, and is a unique phenotype of HBOC.37 BRCA1 and 
BRCA2 are located on chromosome 17q and 13q respectively, and are responsible for the production 
of DNA repair proteins.38 These BRCA1/2 DNA repair proteins participate in the homologous 
recombination pathway. Mutations in BRCA1/2 can cause a loss of function of these proteins, 
ultimately preventing DNA repair through the faulty homologous recombination pathway leading to 
an increased risk of ovarian cancer. In most populations these mutations are rare, approximately 1 in 
500; however, in some ethnic groups the incidence rate can be as high as 1 in 40.39 The lifetime risk 
of developing ovarian cancer in women with a germline BRCA1 mutation is approximately 40%; a 
germline BRCA2 mutation carries a smaller risk of 10-20%.40 Another hereditary factor linked to 
ovarian cancer is hereditary non-polyposis colon cancer (HNPCC), which accounts for 1% of all 
ovarian cancers.40 HNPCC is also linked with an increased lifetime risk of developing colorectal 
cancers and endometrial cancers.41 It originates from inherited mutations in DNA mismatch repair 
genes.40-41 
1.1.3 Current treatment 
Current treatment generally comprises of cytoreductive surgery in combination with a chemotherapy 
regime.14 The course of treatment is dependent on the stage of cancer with which the patient presents. 
If the patient presents with stage Ia-b and surgical resection is optimal, then no adjuvant systemic 




recommended that adjuvant chemotherapy is administered.42 If the patient presents with advanced 
ovarian cancer (stage II-IV), complete resection of all macroscopic disease is carried out either before 
or after chemotherapy.42 First line chemotherapy currently consists of a platinum-based drug, usually 
carboplatin in USA and European Union due to reduced toxicity compared to cisplatin, in 
combination with paclitaxel.43 Platinum based drugs bind to and cause crosslinking of DNA initiating 
apoptosis. Paclitaxel is part of the taxane class of drugs which act as a mitotic inhibitor by disrupting 
microtubule function, which is essential to cell division. This combination therapy is effective in 
approximately 80% of cases; however most patients present with reoccurrence within 3 years of 
treatment.42 
Current recommendations on further chemotherapy for ovarian cancer are categorised according to 
platinum sensitivity.42 Platinum sensitive or partially platinum sensitive patients, considered to be 
those who do not relapse within 6 months of initially responding to first line platinum treatment, 
again receive paclitaxel in combination with carboplatin or cisplatin.42 For partially platinum 
sensitive, platinum resistant or platinum refractory advanced ovarian cancer, PEGylated Liposomal 
Doxorubicin Hydrochloride (PLDH) is considered.42 Doxorubicin belongs to the class of drugs 
known as anthracycline these drugs intercalate with DNA, inhibiting DNA synthesis. Doxorubicin 
is given as a liposomal formulation PLDH, due to increased circulation time and enhanced 
localisation to the tumour. Furthermore, free doxorubicin accumulates leading to cardiotoxicity and 
local necrosis, which is reduced in liposomal form. However, liposomal doxorubicin has its own 
profile of side effects including hand-foot-syndrome.44 Paclitaxel is recommended for patients who 
are allergic to platinum based therapy and platinum-resistant patients as a second line option; if the 
patient is both allergic to platinum and paclitaxel is not deemed appropriate, topotecan may be 
administered; topotecan is a topoisomerase I inhibitor which works by intercalating DNA bound to 




1.1.4 New treatments 
Olaparib is a poly ADP ribose polymerase (PARP) inhibitor which has recently been approved for 
the treatment of ovarian cancer.46 PARP is an enzyme involved in DNA repair. Patients with a 
BRCA1/2 mutation are at an increased risk of developing ovarian cancer and are often resistant to 
conventional chemotherapy.47 However, their cancers also have an increased reliance on PARP to 
repair double stranded DNA damage. In the absence of BRCA, repair by homologous recombination 
is prevented. If PARP is also inhibited, DNA repair depends on the error-prone non-homologous 
end-joining pathway which leads to further DNA damage. As a result, PARP inhibitors are 
particularly beneficial for patients with the BRCA1/2 mutation.48 Several clinical trials have shown 
therapeutic benefit with the PARP inhibitor Olaparib, for the treatment of ovarian cancer.49-51 
Approval in the European Union and USA has been granted for the treatment of patients with 
advanced ovarian cancer who have a BRCA1/2 mutation and have previously received 3 or more 
lines of treatment.  
Bevacizumab, is an anti-VEGF antibody which has shown promise in clinical trials.52-56 
Angiogenesis is an important factor in tumour growth and its inhibition slows tumour progression.57 
Vascular endothelial growth factor (VEGF) is the main target for antiangiogenic treatment.57 
Bevacizumab sequesters VEGF, preventing it from driving angiogenesis and consequently from 
providing the vascular network necessary for nutrient supply to the tumour. However, NICE have 
not recommended bevacizumab for treatment of ovarian cancer as they do not believe the benefit 
justifies the high cost.58-59 
Although new treatments for ovarian cancer which have been approved are limited, there are many 
new ovarian cancer treatments currently in development. Often they are targeting specific molecular 
pathways known to be involved in the pathogenesis of cancer. Some of the more successful 




1.1.5 Chemoresistance  
Resistance to chemotherapy is a major problem in the treatment of ovarian cancer; it is a key factor 
in the high mortality rate associated with ovarian cancer. Understanding the mechanisms behind the 
development of resistance is important in combatting the low survival rate of women with ovarian 
cancer. So far it has been established that the development of chemoresistance in ovarian cancer is 
multifactorial and may involve multiple mechanisms.60 
A mainstay in chemoresistance involve alterations in the drug transport pathways, which can lead to 
a development of Multiple Drug Resistance. For example, overexpression of ATP-binding cassette 
(ABC) transporters confers resistance to many chemotherapeutic agents.61 ABC transporters are 
responsible for the efflux of endogenous and foreign substances across the cell membrane, when 
overexpressed this can lead to a reduction in accumulation of chemotherapeutic agents in cancer 
cells. Copper transporter 1 (CTR1), is the major copper influx transporter protein, it also controls the 
accumulation of platinum based drugs in tumour cells. Furthermore, CTR1 expression has been 
correlated with acquired cisplatin resistance in ovarian cancer cells.62 Alterations in detoxification 
proteins, such as Glutathione S-Transferase (GST) enzymes and metallothionein, have been shown 
to confer resistance to chemotherapy. GST’s detoxify xenobiotics by catalysing their nucleophilic 
attack by glutathione preventing interactions with nucleic acids and proteins. GST’s have also been 
shown to detoxify chemotherapeutic drugs such as alkylating agents and platinum-based drugs.63 
Metallothioneins are metal detoxifying proteins, which bind to metal ions to prevent them from 
interacting inappropriately. The expression and induction of metallothioneins, has been associated 
with protection against cell damage, apoptosis and oxidative stress.64  
Alterations in the drug targets themselves is another method of developing resistance, such as 
changes in β-tubulin, the target of the taxane class of chemotherapeutic agents. β-tubulin is 
responsible for the production of microtubules which are essential for cell division. Taxanes such as 
paclitaxel, bind to β-tubulins and inhibit microtubule function preventing cell cycle progression 




mechanism of the development of resistance to taxanes.65-66 Another target alteration include that of 
the topoisomerases. Topoisomerases regulate the under-winding or over-winding of DNA and are 
the target of many chemotherapeutic agents such as topotecan and doxorubicin, which intercalate the 
DNA-topoisomerase complex leading to cell death.66 Mutations in topoisomerase enzymes have been 
observed causing a reduction in availability of cleavable complexes leading to reduced DNA damage 
and hence less cell death.67  
In addition, another mechanism of resistance involves changes in DNA repair mechanisms. Platinum 
chemotherapeutic agents bind to and cause crosslinking of DNA preventing DNA repair. Therefore, 
the ability to repair via other mechanisms could confer resistance. A study by Masuda et al. found 
that resistance to cisplatin was related to an increase in the removal of platinum-DNA adducts.68 
Furthermore, Zhen et al. reported that acquired cell resistance to cisplatin may be associated with 
increased gene specific DNA repair efficiency of  the interstrand crosslink69 and Johnson et al. found 
that resistance to cisplatin may be associated with DNA repair and alterations in interstrand crosslink 
formation.70 Moreover, alterations in specific genes (oncogenes, tumour suppressor genes, metastasis 
suppressor genes) appear to be directly associated with the loss of chemosensitivity.60  
1.1.6 Summary 
Although advances in the treatment of ovarian cancer have been made over the past couple of decades 
due to improvements in cytoreductive surgeries, chemotherapy regimens, such as dose dense 
chemotherapy, and the use of combinational therapy there are still significant developments required 
to better treat ovarian cancer, particularly due to resistance to known drugs. More recently 
morphologic and molecular genetic studies have shown that ovarian cancer is a heterogeneous 
disease with many distinct subtypes from different origins, therefore ovarian cancer subtypes should 
be treated on an individual basis. Advances in the understanding of the biology of ovarian cancer has 
resulted in the development of more targeted therapies, these include PARP inhibitors such as the 






G. Mills et al. first discovered that patients with ovarian cancer develop an accumulation of ascites 
fluid containing factors which support the growth of epithelial cancer cells in the intraperitoneal 
cavity over two decades ago.71 Five years later Xu et al. discovered that the growth factor 
lysophosphatidic acid (LPA) is the major ovarian cancer activating agent present in ascites fluid.72 
Levels of LPA in the ascites fluid can reach concentrations up to 80 µM.73 Since this discovery, LPA 
has been implicated in a number of mechanisms involved in the pathogenesis and survival of ovarian 
cancer. However, the development of molecules designed to interfere with this major cancer 
activating agent are relatively limited. This may largely be due to the complexity of the LPA 
signalling pathways. More recently the enzymes and receptors involved in the LPA signalling 
pathway have been defined. One enzyme, autotaxin was discovered by Umezu-Goto et al. to produce 
LPA from lysophosphatidylcholine (LPC).74 Autotaxin was originally identified as an autocrine 
motility factor released by human melanoma cells.75 It was later found to have lysophospholipase D 
activity and to play a major role in the production of LPA in many biological fluids generated from 
both normal human cells and cancer cells.74 It is synthesised as a pre-proenzyme and secreted into 
the extracellular space.76   
Lysophosphatidic acid (LPA; mono-acylglycerol-3-phospate) is the simplest glycerophospholipid 
consisting of a single acyl chain, a glycerol backbone and a phosphate group, (Figure 1.1). There are 
different molecular species of LPA with varying acyl chain lengths and variants of either saturated, 
mono- and poly-unsaturated chains. There are also sn1 or sn2 regioisomers. The predominant species 
of LPA is poly-unsaturated 18:2 which accounts for approximately half the amount of LPA present 
in plasma.77-78 It plays a vital role as a precursor in phospholipid biosynthesis and also functions as 
an intercellular lipid mediator inducing many actions including cell proliferation, invasion and 
migration, inhibition of apoptosis, senescence, angiogenesis and chemoresistance. It acts via specific 






Figure 1.1: Structure of Lysophosphatidic acid.  
1.2.2 LPA synthesis 
In addition to autotaxin, there are several other enzymatic pathways by which LPA can be produced, 
(Scheme 1.1). Different species of LPA can be formed via the hydrolysis of phosphatidic acid (PA) 
by either phospholipase A1 (PLA1) or soluble phospholipase A2 (sPLA2).77, 79 sPLA2 cleaves the sn2 
positioned fatty acid chain whereas PLA1 cleaves the fatty acid chain in the sn1 position. PA itself is 
produced by hydrolysis of membrane phosphatidylcholine (PC) by phospholipase D (PLD). Another 
route to LPA formation involves catalysis by ATX/lysophospholipase D (lysoPLD).74 Autotaxin 
hydrolyses the choline from lysophosphatidylcholine (LPC) to form LPA. Initially, LPC is formed 
by hydrolysis of PC by PLA1 or sPLA2.77 Due to autotaxins association with cell motility and tumour 





Scheme 1.1: Synthetic scheme of LPA production.
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1.2.3 Structure  
Autotaxin (ATX) is a 125 kDa glycoprotein extracellular enzyme which is a member of the ecto-
nucleotide pyrophosphatase/phosphodiesterase (ENPP) family, encoded by the gene ENPP-2 on 
chromosome 8 (Figure 1.2).75 Transcription of ENPP2 is regulated by various transcription factors 
(including Hoxa13, NFAT-1 and v-jun)80-82 resulting in three different isoforms, ATXα, ATXβ and 
ATXγ.75, 83 ATXβ is the most common isoform of autotaxin; it was first identified from 
tetracarcinoma cells and is the shortest of the isoforms with 863 amino acids.84 ATXα was first 
derived from melanoma cells; it is similar to ATXβ but contains an extra 52 residue insertion in the 
catalytic domain.85 ATXγ is the least common isoform; it is a brain specific isoform and is similar in 
structure to ATXβ with an extra 24 residue insertion near the nuclease like domain.86-88 
Determination of the autotaxin crystal structure has only recently been achieved, providing a valuable 
tool in understanding the binding site of LPA and therefore aiding the development of inhibitors of 
the enzyme. So far 12 crystal structures have been defined by Nishimasu89 and Hausmann.90 Of these 
PDB entries 3NK(N-R)89 show autotaxin with LPA bound with varying lengths of acyl chains, PDB 
entries 3NKM89 and 2XR990 show autotaxin with no inhibitor bound (mouse and rat respectively). 
PDB entry 2XRG90 shows autotaxin bound with the known inhibitor HA155 and PDB entries 
3WA(V-Y) show autotaxin bound with newly developed inhibitors discovered from a large library 
of compounds.91 




Figure 1.2: Overview of autotaxin structure. 
The structure of autotaxin consists of 4 domains; two Somatomedin B like domains (SMB1 & SMB2) 
at the N-terminus, a central catalytic phosphodiesterase domain (PDE) and a nuclease like domain 
(NUC) at the C terminus. A linker region (residues 141–160) connects the SMB-like domain 2 with 
the catalytic domain, and lasso loop region (residues 540–589) connects the catalytic domain with 
the nuclease-like domain. 
The SMB1 (56-96) and SMB2 (96-140) domains are cysteine rich and involved in protein-protein 
binding. They have also been shown to bind to integrins which are possibly involved in autotaxin’s 
recruitment to the cell surface, bringing it into close proximity with the LPA receptors.92  
The PDE domain (160-539) is the site of catalysis; it is similar to the catalytic domain of alkaline 
phosphatases. It consists of a core (161-364, 471-536) and insertion (365-470) subdomain. The core 
subdomain has an α/β fold and binds to a sulphate and two Zn2+ ions. 
The NUC domain (590-862) is thought to be catalytically inert. It consists of varied α/β folds and 
binds a number of ions. It has been suggested that this domain along with the glycan chain is essential 
for maintaining the structure of the ligand binding site. Computer modelling studies suggest the 
SMB1 
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existence of an allosteric interaction pathway from the NUC domain to the Thr209 residue in the 
catalytic domain.93 
The lasso loop (540–589) wraps around the NUC domain and interacts with the rest of the protein 
via hydrogen bonds, salt bridges and a disulphide bond. Other features to note include a glycan chain 
and a cysteine bridge which are assumed to be essential for the interface between the domains, 
connecting the PDE and NUC domain. It is also thought that a hydrophobic tunnel between the SMB 
domain and the ligand binding domain may be involved in delivery of LPA to cell surface 
receptors.89-90  







Figure 1.3: Ligand binding site shown with LPA Bound; PDB entry 3NKR. 
The main features of the ligand binding site include the two Zn2+ ions, and a deep hydrophobic tunnel. 
One of the zinc ions is coordinated by Asp311, His315 and His474, and the second zinc ion is 
coordinated by Asp171, Thr209 and His359 residues, leaving one site available on each ion for 
coordination with another negatively charged molecule, in the ligand free form a sulphate or 
phosphate is bound here.89 The Zn2+ binding sites are conserved among the ENPP family members 
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Thr209 residues which provide a hydrogen bonding environment for the binding of ligands, (Figure 
1.3). 89 
When in complex with LPAs of varying chain lengths the acyl chain, glycerol and phosphate group 
are all recognised by autotaxin in a similar manner, (Figure 1.4). A slight conformational change 
occurs on binding to LPA, causing Asp358 which normally forms hydrogen bonds with the OH group 
of Thr209 to coordinate with one of the zinc2+ ions. One oxygen atom of the phosphate coordinates 
the first zinc2+ ion, whilst a second oxygen atom of the phosphate hydrogen bonds to Asn230, and 
the NH and OH groups of Thr209. The final phosphate oxygen forms a water mediated hydrogen 
bond with Lys208, Asn230 and Asp473. The glycerol moiety forms van der Waals contacts with 
Thr209 and Leu243, and its hydroxyl group forms water-mediated hydrogen bonds with Asp311 and 
Glu308. The acyl chain forms van der Waals contacts with Phe210, Leu213 and Tyr306, and an 
additional hydrogen bond between the carbonyl group and Tyr306. The lipid tail of the 14:0 LPA, 
16:0 LPA and 18:0 LPA sits in a hydrophobic pocket lined by Ile167, Leu216, Ala217, Leu259, 
Phe273, Trp275 and Met512, the structure is kinked providing specificity for unsaturated substrates. 
A slight local conformational change occurs in the complexes with Leu216 and Glu308 rotating to 
accommodate LPA. There was also an observed decrease in electron density with increasing acyl 




















Figure 1.4: Ligand binding site showing residues involve in the binding of LPA; PDB entry 
3NKR. 
The mechanism of catalysis has not been defined; however, the structural similarity between X. 
axonopodis NPP suggest the mechanism could be similar. The two Zn2+ ions, their coordinating 
residues and the highly conserved Asn230 and Tyr306 of autotaxin were shown to overlap with 
Asn111 and Tyr205 of X. axonopodis NPP, respectively. These observations substantiate that 
autotaxin hydrolyse LPC through a mechanism similar to that of X. axonopodis NPP.89, 94 
1.2.5 LPA catabolism 
There are a number of ways in which LPA can be processed, (Scheme 1.2). Two main pathways are 
by LPA-acyltransferase (LPAAT) to generate (PA), or dephosphorylation by lipid phosphate 
phosphohydrolases (LPPs) to mono-acyl glycerol (MAG).95-98 LPP expression is decreased in 
ovarian cancer and overexpression has been shown to reduce apoptosis and cell growth in ovarian 
cancer cells.95-98 This coupled with increased LPA production by ATX creates “the perfect storm” 














Scheme 1.2: LPA catabolism. 
1.2.6 LPA Receptors 
The diverse actions of LPA on cells are explained by the existence of at least six GPCRs, LPA1-6, 
(Figure 1.5) and the different signalling pathways used by each of them.99 The first LPA receptor 
was described in 1996 by Chun et al., LPA1 formerly Edg2 is part of the endothelial differentiation 
gene (Edg) family.100 A further two structurally similar LPA receptors LPA2 and LPA3101 (formerly 
Edg4 and Edg7 respectively) were found. These three receptors along with five sphingosine-1-
phosphate receptors are the EDG family of receptors. Later Noguchi et al. discovered a fourth LPA 
receptor LPA4, formerly GPR23/p2y9, which is more closely related to the purinergic receptor 
family.103 Two more LPA receptors, structurally similar to LPA4 were subsequently identified. 
GPR92/93 and p2y5 now known as LPA5 104-105 and LPA6 106-108 respectively, along with LPA4 
comprise the non-Edg family of LPA receptors. Other receptors which have been linked to 
stimulation by LPA include GPR35,109 GPR87110 and P2Y10111; however more research is needed to 
fully classify these proteins.112  
LPA1-6 are type 1 rhodopsin-like GPCRs with seven transmembrane domains. LPA receptors couple 
to one or more heterotrimeric G proteins, namely G12/13, Gq, Gi and Gs, resulting in the activation of 
many signalling pathways leading to many biological responses, (Figure 1.5); and some of which 
have been implicated in carcinogenesis. Rho and rac are GTPases which are involved in regulating 
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cell motility in cancer cells.113 The mitogen-activated protein kinase (MAPK) pathway has been 
implicated in cancer growth and the Akt pathway in cancer survival. Moreover, downstream events 
of PLC activation have been shown to promote tumour progression.  
 
 
Figure 1.5: LPA receptor signalling cascades. 
Expression of LPA receptors has been associated with the pathogenic process of cancer.  For 
example, overexpression of LPA1 in MDA-MB-231 breast cancer cells promoted skeletal tumour 
growth in a xenograft model. Also silencing or inhibition of LPA1 was found to reduce the growth 
of the tumour and metastasis bone progression.114 Contradictorily LPA1 has been found to have a 
decreased expression in ovarian cancer and when expression was induced it led to an increase in 
apoptosis independent of LPA.115 LPA2 and LPA3 overexpression has been observed in ovarian 
cancer,97,116,117 furthermore, expression was found to correlate with tumour stage.118  
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It has been demonstrated that autotaxin and LPARs can contribute to the initiation and progression 
of breast cancer.119 Transgenic mouse models driven by the mouse mammary tumour virus (MMTV) 
long terminal repeat (LTR) promotor expressing autotaxin (MMTV-ATX) or one of the three main 
LPA receptors LPA1-3 (MMTV-LPA) developed chronic mastitis, hyperplasia, mammary 
intraepithelial neoplasia and invasive metastatic tumours.119 A recent study exploring the biological 
roles of the LPA receptors LPA1-3 in the pathogenesis of tumour cells found that LPA2 and LPA3 
expression lead to an increased activity in cell motility and invasion assays, the activity was further 
increased by the addition of LPA. Conversely expression of LPA1 showed decreased intrinsic cell 
motility and invasion.120  
In addition to GPCRs LPA activates other receptors such as the peroxisome proliferator-activated 
receptor, PPARγ, which may also play a role in the carcinogenesis of LPA in ovarian cancer. PPARγ 
is a transcription factor that drives the expression of genes involved in many biological responses 
including apoptosis, Zhang et al. found that PPARγ is overexpressed in ovarian cancer.121 
Furthermore, Davidson et al. observed increased PPARγ expression had a direct correlation with a 
poor response to chemotherapy and shortened survival.122 Contradictorily, PPAR agonists inhibit the 
proliferation of ovarian cancer cells and induce apoptosis.123 Synergies between PPARγ ligands and 
platinum based drugs have also been observed.124 The contradicting evidence for PPARγ contribution 
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1.3 Physiological and pathophysiological functions 
1.3.1 Physiological role of autotaxin 
Autotaxin is essential for embryonic development. Transgenic mice lacking autotaxin die as an 
embryo at embryonic day 9.5.125-127 Lethality is due to abnormal vascular and neuronal development, 
indicating autotaxin is vital in the development of vasculature by vasculogenesis and 
angiogenesis.125-127 A recent study by Yukiura et al. found overexpression of autotaxin in transgenic 
mice also led to embryonic lethality around embryonic day 9.5 with vascular defects present.128 
Autotaxin is found in most biological fluids including plasma, serum,74 urine,129 synovial fluid,130-132 
peritoneal fluid73 and cerebrospinal fluid.133-134 High levels of autotaxin mRNA are found in the 
ovaries, brain, small intestine and placenta.84 High levels are also observed in adipose tissue135 and 
high endothelial venules (HEVs).136 HEVs enable lymphocytes to enter lymph nodes. Inactivated 
autotaxin reduced T-cell homing to the lymph nodes suggesting that autotaxin may regulate 
lymphocyte migration.136 Autotaxin may exert other roles not associated with its production of LPA, 
however most of its biological activity arises from LPA production. Autotaxin is also able to catalyse 
the production of the sphingolipid, sphingosine-1-phosphate (S1P) which potentially has 
bioactivity.137 LPA is present in most biological fluids. There have been many documented effects 
of LPA in many cell types. The major effects LPA has been associated with include cytoskeletal 
reorganisation, morphological and physiological cellular changes affecting cellular communication 
and extracellular matrix interactions.138 As autotaxin is bioactive and essential to embryonic 
development there is a possibility that inhibition of autotaxin may produce adverse effects. However, 
no adverse effects where found from long term inhibition of autotaxin with either siRNA silencing 
or an autotaxin inhibitor in a mouse model.139 
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1.3.2 Autotaxin and cancer 
1.3.2.1 Migration and invasion 
Autotaxin and LPA have been well documented in cancer cell migration and invasion. Although 
autotaxin has not been directly linked to a role in ovarian cancer metastasis and invasiveness, there 
are many examples of its role in other cancers. First and foremost, autotaxin was initially identified 
as an autocrine motility factor.75 Furthermore, expression of α6β4 integrin in advanced breast cancer 
is associated with a migratory and invasive phenotype,  and also led to an increased expression of 
autotaxin.81 This overexpression was found to be mediated by the transcription factor NFAT1.81 
Autotaxin has also been directly linked to cell motility and invasive phenotype, knockout of autotaxin 
leads to inhibition of invasion and motility140-142 in several cell lines; and over expression of autotaxin 
has been shown to increase cell invasion143 and migration.142-143 The autotaxin/LPA signalling 
pathway promotes the expression of many pro-migration and invasion factors including the ECM 
protein osteopontin, an important chemokine involved in the survival, proliferation, migration, 
invasion and metastasis of gastric cancer cells.144 Furthermore, autotaxin, through LPA production 
induces the expression of urokinase plasminogen activator (uPA) and the matrix metalloproteinase 
MMP3 via activation of the MAPK cascade, which in turn leads to increased invasiveness in human 
fibrosarcoma HT-1080 cells.145 Autotaxin activates the small G-proteins cdc42, rac and focal 
adhesion kinases all of which are key regulators of cell motility.142, 146-147 Autotaxin has been shown 
to regulate the formation of invadopodia, cell membrane protrusions involved with invasion, in a 
LPA dependent manner.142 Lastly, autotaxin expression by cancer cells also promotes bone 
metastasis.148 Thus there is a significant body of evidence linking autotaxin to invasion and 
migration.  
As might be expected from the foregoing discussion LPA has been implicated in these processes. 
LPA has been extensively studied in a variety of cancer cell migration and invasion models; in 
ovarian cancer cells an impact of LPA on many pathways has been discovered. LPA induces the 
activation of the Src family kinase, Fyn, and increases its association within adherens junction protein 
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p120-catenin, recruiting Fyn to cell-cell junctions, leading to the dispersal of in the ovarian cancer 
cell line SKOV3.149  
 
Figure 1.6: Pathways implicated in LPA induced cell migration.  
Additionally, LPA activates cytoskeletal reorganisation via the down regulation of RhoA leading to 
a loss of stress fibres and dissociation of focal adhesion components thereby promoting cell 
migration.150 Down regulation of RhoA is dependent on the activation of AMP-activated protein 
kinase (AMPK).151 RhoA down regulation has also been shown to be dependent on reorganisation of 
the cell interface with the ECM by inducing FAK auto-phosphorylation via the G12/13 –RhoA-ROCK 
signalling pathway leading to promotion of cell motility.152-153 Similarly the Gi-Ras-MEK-1 
signalling pathway has been shown to mediate LPA-stimulated ovarian cancer cell migration by 
facilitating focal adhesion kinase (FAK) redistribution to focal contacts, FAK regulates the turnover 
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of focal contacts therefore contributing to cell migration, (Figure 1.6).154 Furthermore, induction of 
the expression of several proteases in ovarian cancer cells by LPA has been observed, including 
urokinase plasminogen activator (uPA) and the matrix metalloproteinases- MMP1, MMP2, MMP7, 
and MMP9; which all contribute to the breakdown of ECM facilitating cancer cell invasion.153, 155-157 
LPA also decreases the expression of metalloprotease inhibitors increasing the effect of activation of 
the MMPs.158 uPA induction by LPA has been shown to occur in ovarian cancer cells but not in 
normal epithelial ovarian cells.159 From the body of evidence discussed in this section, it is clear that 
the autotaxin-LPA axis is linked to invasion and migration. 
1.3.2.2 Inhibition of apoptosis 
LPA and autotaxin have been associated with the inhibition of apoptosis via a variety of pathways. 
LPA induces the translocation of the pro-apoptotic receptor Fas in the extrinsic apoptotic pathway, 
from the cell surface.160 Translocation of Fas leads to a reduction in the responsiveness of the cell to 
apoptotic stimuli. In contrast, LPA also induced the expression of the Fas ligand which induces 
apoptosis. However, in ovarian cancer this LPA induced Fas Ligand has been implicated in the 
apoptosis of lymphocytes allowing the cells to avoid immune surveillance.161-162 Furthermore, LPA 
increases the expression of the caspase 8 inhibitor CFLIP, preventing caspase 8 activation leading to 
suppression of the extrinsic apoptotic pathway.160 
LPA activates the PI-3 kinase/Akt pathway.160 The PI-3 kinase/Akt pathway is a cell survival 
pathway, whose activation leads to decreased apoptosis. LPA also promotes the phosphorylation of 
the pro-apoptotic protein, BAD; unphosphorylated BAD facilitates activation of Bak and Bax to 
activate the intrinsic apoptotic pathway.160 Once phosphorylated, BAD can no longer promote 
activation of Bax and Bak leading to a reduction in apoptosis.160 LPA also increases the expression 
of the survival factor, Granulin-epithelin precursor (GEP); which has been shown to be an autocrine 
growth factor in ovarian cancer.163 Furthermore,  expression of autotaxin has been directly linked to 
cell survival in fibroblasts with suppression of apoptosis observed in response to serum starvation.164 
The implication of LPA and autotaxin in this wide variety of apoptotic suppressing 
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pathophysiological pathways together with increased expression of autotaxin and LPA in ovarian 
cancer provides validation of autotaxin as a target for the treatment of ovarian cancer.  
1.3.2.3 Proliferation and senescence 
LPA was first described as a growth factor by van Corven et al. in 1989, and has since been shown 
to increase cell growth in several types of cancer.165-166 In ovarian cancer, LPA stimulated  growth 
via several signalling pathways.167 Additionally, LPA induces the expression of the growth related 
oncogene, Groα.168 
LPA induces the production of the major angiogenic factor VEGF by ovarian cancer cells, and 
increases the expression of the VEGF receptor in endothelial cells simulating the growth of malignant 
ovarian tumours.169-170 It also promotes the expression of pro-angiogenic factor IL-8171 by ovarian 
cancer cells signifying that LPA increases the angiogenesis of ovarian cancer cells. Furthermore, 
VEGF induced expression of autotaxin has been found to increase the effects of LPA.170 
LPA has also been implicated in the suppression of senescence; LPA has been shown to reduce the 
amount of the tumour suppressor p53 in A549 lung cancer cells.172  The effect on LPA was found to 
be dependent on an increase in proteasome degradation of p53 which leads to a decrease in p53 
mediated transcription.172 It was also found that over expression of the LPA2 receptor resulted in 
suppression of the p53-dependent replicative senescence in primary mouse embryo fibroblasts, in a 
Rho GTPase-dependent manner.173 It has been suggested that this occurs through the induction of 
telomerase, allowing indefinite cell proliferation.174-175 
1.3.2.4 Chemoresistance 
LPA and autotaxin have been shown to directly confer resistance to chemotherapy in a number of 
studies. LPA has been related to the development of resistance to carboplatin in ovarian cancer 
cells,176 this has also been observed in colon cancer.177 Furthermore, expression of autotaxin delayed 
apoptosis induced by carboplatin in ovarian cancer cells.178 Apoptosis was also accelerated after 
inhibition of autotaxin by either siRNA silencing or with a small molecule inhibitor.178 In addition to 
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conferring resistance to platinum-based chemotherapy, autotaxin and LPA have been shown to 
protect breast cancer cells against paclitaxel induced cell death.179 Paclitaxel disrupts normal spindle 
function leading to mitotic arrest. LPA was found to restore normal spindle function in breast cancer 
cells exposed to paclitaxel, leading to the cells escaping mitotic arrest, preventing cell death. This 
depended on PI3K activation through LPA receptors and involved the displacement of taxol from 
tublin.179-180   
Further to autotaxin and LPA, the LPA2 receptor has been linked to chemoresistance. An increase in 
irradiation induced apoptosis was observed in LPA2 null mice.181-182 The ability of LPA2 to regulate 
the pro-apoptotic protein, SIVA1 is one potential way in which LPA is involved with the apoptotic 
pathway.183 LPA2 contains a PDZ domain, which recruit NHERF2 and TRIP6, here they form a 
complex with SIVA1.183 SIVA1 is an apoptotic regulatory protein. DNA damage leads to activation 
of the tumour suppressor p53 which in turn increases the expression of SIVA1, and this contributes 
to cisplatin induced apoptosis.184 LPA, through the receptor LPA2, contributes to the suppression of 
apoptosis via LPA-induced ubiquitination and turnover of SIVA1, therefore it may be deduced that 
LPA confers resistance to cisplatin.185 As SIVA1 inhibits the anti-apoptotic protein Bcl-XL, part of 
the Bcl-2 family, which suppresses the activation of Bak/Bax and inhibition of the Bcl-2 family has 
previously been shown to increase sensitivity to carboplatin.186-187 This may provide evidence that 
autotaxin confers resistance to carboplatin  via the intrinsic apoptotic pathway.178   
Further to autotaxin/LPA other proteins associated with LPA Signalling pathway may contribute to 
chemoresistance, for example, regulator of G protein signalling (RGS) proteins. RGS proteins reduce 
the signalling of LPA receptors by increasing the GTPase activity of G-proteins that are activated by 
LPA receptors.188 The expression of several RGS proteins is decreased in ovarian cell lines which 
are resistant to cisplatin.189 When the RGS proteins, RGS10 and RGS17, were knocked down, a 
reduction in the potency of cytotoxic chemotherapeutic agents was observed. Further to this RGS10 
and RGS17 were shown to suppress LPA-induced activation of Akt survival pathways.189 This 
suggests a LPA signalling dependent role for RGS proteins in the regulation of chemoresistance in 
ovarian cancer. 
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1.3.3 Autotaxin and inflammatory diseases 
Further to its role in cancer, the ATX/LPA signalling pathway is implicated in many inflammatory 
diseases, including cardiovascular diseases,190 obesity,191 rheumatoid arthritis,192 multiple 
sclerosis,193 pulmonary fibrosis194 and chronic hepatitis.195 Increased autotaxin expression was also 
observed in the frontal cortex of Alzheimer’s like dementia patients.196  
LPA has been implicated in the progression of rheumatoid arthritis. Genetic ablation of autotaxin 
resulted in disease attenuation in animal models of rheumatoid arthritis.192 Autotaxin expression from 
synovial fibroblasts (SF) induced by TNF, and led to increased LPA which in turn activated SF 
activation and effector functions in synergy with TNF.192 Furthermore, inhibition of autotaxin with 
BrP-LPA reduced arthritis induce by collagen.197 
In asthmatic patients Broncho alveolar lavage fluid (BALF) increased autotaxin was observed after 
allergen challenge.198  This correlated with findings in a murine model, mice which were transgenic 
for autotaxin expression had a more severe asthmatic phenotype, which was reduced upon addition 
of an autotaxin inhibitor.198 Furthermore, LPA concentrations are increased in BALF.199 Deletion of 
autotaxin from bronchiolar epithelial cells and macrophages diminishes the severity of bleomycin 
induced idiopathic pulmonary fibrosis (IPF).194 Autotaxin inhibition was also able to reduce disease 
progression in this model.  
Additionally, autotaxin’s role in obesity and related diseases is currently emerging. White adipose 
tissue produces autotaxin which produces significant levels of LPA.191 White adipose tissue with a 
null autotaxin allele present with reduced plasma autotaxin levels and improvement in glucose 
tolerance levels.191 Furthermore, autotaxin expression is increased in the adipose tissue of obese 
insulin resistant mice and humans.135 Therefore the role of autotaxin in obesity is unclear and needs 
further exploration.  
Autotaxin in liver disease is a rapidly emerging field. Autotaxin and LPA levels are increased in 
patients with chronic hepatitis C.195 Autotaxin and LPA levels were also found to be increased in 
chronic liver fibrosis model induced by carbon tetrachloride.200  
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The role of autotaxin in cancer and inflammatory diseases suggests inhibitors may be therapeutically 
useful. 
1.4 Autotaxin inhibitors 
1.4.1 Introduction 
There are three main classes of autotaxin inhibitors; metal chelators, analogues of LPA and small 
non-lipid molecules. Initially metal chelators where used due to the knowledge that the active site 
contained two Zn2+ ions which are essential to autotaxin’s function. The first molecule found to 
inhibit the activity of autotaxin was L-histidine which was chosen as a potential inhibitor due to its 
essential role in many metalloenzymatic reactions. L-histidine was found to inhibit autotaxin at 
millimolar concentrations and also inhibited ovarian cancer and melanoma cell migration.201 Other 
metal chelators such as EDTA and phenanthroline have also been shown to inhibit the activity of 
autotaxin, via the same mechanism of action.202  
1.4.2 Lipid analogues 
Several lipid analogues of LPA have been developed and shown to inhibit autotaxin. Product 
inhibition of autotaxin by LPA (1-oleoyl) has been observed (IC50 = 2.2 µM),203 this led to the 
discovery of a large number of biologically active LPA analogues which inhibit autotaxin. These 
include two fatty acid phosphate analogues of LPA, oleoyl-thiophosphate 1 and tetradecyl-
phosphonate 2, (Figure 1.7).204 Both 1 and 2 were found to inhibit autotaxin in an LPA-mimicking 
fashion, the length of the acyl chain of these compounds are consistent in length to the optimal chain 
length observed in analysis of the crystal structure in complex with LPA of varying acyl-chain 
lengths.89 Furthermore, compound 1 was found to be more potent than compound 2 and LPA at 
inhibiting autotaxin, with micromolar dose-dependent inhibition observed.204  
 
 






Figure 1.7: Structure of LPA analogues oleoyl-thiophosphate 1 and tetradecyl-phosphonate 2. 
Darmstoff 3, (Figure 1.8), is a naturally occurring molecule of similar structure to LPA, with a 
dioxolane moiety inserted before the acyl chain. Darmstoff and its analogues were tested for the 
ability to mimic LPA. They were also tested for inhibition by analysing their ability to 
agonise/antagonise of a number of LPA receptors were they showed good activity; however when 
tested for activity against autotaxin they proved to only have mild inhibitory capability.205 
Cyclic phosphatidic acid (cPA) is another naturally occurring analogue of LPA in which the sn-2 
hydroxyl group forms a 5-membered ring with the sn-3 phosphate. Some cPA’s have been shown to 
have an inhibitory effect on the migration and invasion of cancer cells in vitro206 and in vivo.207 cPA 
analogues 4-5, containing the natural 2,3-cyclic phosphate group were poor inhibitors of autotaxin, 
(Figure 1.8). However, upon stabilisation by replacement of the sn-2 oxygen with an isosteric group, 
methylene, the compounds showed high inhibition of autotaxin with 6 and 7 (Figure 1.8) achieving 
IC50s of 140 nM and 370 nM, respectively.208 Stabilisation at the sn-3 oxygen with a methylene group 
did not improve the IC50s as significantly with compound 8 and 9 (Figure 1.8) achieving 294 nM and 
620 nM potency respectively.208 Another study investigated the stereoselectivity between the sn-3 r- 
and s- stereoisomers and identified no significant difference between the two isomers’ inhibition of 
autotaxin, with binding affinities, Ki’s of 0.8 μM and 1.6 μM, respectively.209 It was also found in 
this study that the cPA’s had a mixed mechanism of inhibition.209 The effects of chirality of the sn-2 
stereoisomers was also separately studied and the stereoisomers showed no significant difference in 
1 2 
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inhibition of autotaxin.210 These studies suggest that the stereoselectivity of cPA’s does not influence 
their activity against autotaxin. 
 
 
Figure 1.8: Darmstoff scaffold and cPA scaffold. 
Compound R X Y IC50 (nM) 
4 C15H29 O O - 
5 C17H33 O O - 
6 C15H29 CH2 O 140 
7 C17H33 CH2 O 370 
8 C15H29 O CH2 294 
9 C17H33 O CH2 620 
Table 1.1: Structural variations of cPA tested. 
Another set of analogues of LPA that have been investigated are α- and β- substituted 
phosphonates.211-213 A study investigating β-keto and β-hydroxyl phosphonates, identified two β-
hydroxyl phosphonates 10 and 11, differing only in their stereochemistry at the β-hydroxy group, 
(Figure 1.9), as the most potent.211 The stereochemistry at the α-carbon atom and the 4-methoxy-3,5-
dimethyl-pyridyl moiety proved to be important to the activity.211 Further structural activity 
relationships (SAR) studies showed that the β-hydroxyl-substituted analogues had a higher potency 
than α-substituted analogues.213 Further structural optimisation of the lead compounds did not 
produce a more potent compound, nevertheless similar potencies were achieved.213 These tyrosine 
derived analogues where further analysed by East et al. who found that the electron density of the 
pyridine moiety greatly influenced the potency of these inhibitors, docking modelling found this may 
4-9 3 
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be due to an interaction between the pyridine group and Arg456; therefore it is likely that inhibitors 
must be electron rich.214 
 
 
Figure 1.9: Structure of β-hydroxyl phosphonates. 
FTY720 (finglimod) 12 (Figure 1.10), an immune-modulator, was recently found to inhibit tumour 
progression,215 and, coupled with the structural similarity to LPA, led to the hypothesis that inhibition 
of autotaxin may be involved in the drug’s mechanism of inhibition. The synthesis of FTY720 was 
established by Kim et al. 2006.216 Phosphorylated FTY720 13 (Figure 1.10) was observed to inhibit 
autotaxin by 70% at 1 µM.217 Further development of SAR based on phosphorylated FTY720 
identified FTY720-vinylphosphonate 14, (Figure 1.10) as effective inhibitors of autotaxin, they also 
study the effect of the chirality of these compound and found similar inhibition for both (S)-FTY720-
vinylphosphonate and (R)-FTY720-vinylphosphonate. However, they differed in mechanism of 
action with (R)-FTY720-vinylphosphonate inhibiting autotaxin via an uncompetitive mechanism, 
whereas (S)-FTY720-vinylphosphonate inhibited autotaxin via a competitive mechanism.218  
10 11 





Figure 1.10: Structure of FTY720 and the analogues Phosphorylated-FTY720 and Vinylphosphate-
FTY720. 
The first described nanomolar inhibitor of autotaxin was S32826, 15 (Figure 1.11) (IC50 9 nM).83 
However, when studied in cellular and in vivo models it was found to exhibit little activity and had 
poor solubility, bioavailability and a lack of stability.83 Using S32826 as a lead compound several 
studies have investigated structural variation in order to improve pharmacokinetic properties. Gupte 
et al. developed a library of analogues to try and address the lack of stability of S32826; they 
suggested this lack of stability may be due to hydrolysis of the amide bond.219 They identified many 
compounds with similar activity to S32826, a further two inhibitors, lacking the amide, 16 and 17 
(Figure 1.11) were identified as potent inhibitors and maintained stability in in vivo models.219 
S32826’s poor pharmacokinetics were also addressed by Jiang et al. they suggested the poor 
solubility may be due to the lipophilicity of the compound. And so developed a library of compounds 
decreasing the lipophilicity, via shortening the lipophilic chain and also substituting at the α position 
with either a halide or hydroxyl group. This led to the discovery of a new potential inhibitor, an α-
hydroxymethylene phosphonate analogue 18 (Figure 1.11) which retained good potency and an 









Figure 1.11: Structure of S32826, and analogues based on this scaffold which have achieved 
nanomolar activity. 
Although many of these LPA analogues are potent inhibitors of autotaxin they lack structural 
diversity and have poor pharmacokinetics. LPA analogues also have the potential to be an agonist or 
an antagonist of the multiple LPA receptors; this could lead to the development of adverse effects.  
Thus it may be preferable to develop selective autotaxin inhibitors, although there maybe benefits to 
simultaneously inhibiting certain LPA receptor subtypes. 
1.4.3 Small molecule inhibitors 
In order to improve the structural diversity and bioavailability of potential autotaxin inhibitors, Parill 
et al. set out to identify new inhibitor scaffolds utilising virtual throughput screening.221  Prior to the 
determination of the autotaxin crystal structure the structure of a bacterial NPP enzyme (which shares 
a 30% similarity with autotaxin’s catalytic domain) was used for the generation of a homology model 
for use in the structural and computational design of new autotaxin inhibitors. Preliminary docking 
studies led to the identification of a range of lead compounds based on several structural scaffolds 
including diphenyl diazerenes, thioureas, isoindoles, and xanthenes, from these a number of 
bioavailable potent inhibitors of autotaxin were identified. The most effective small molecule 
15 16 
18 17 
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inhibitor developed from this study was H2L 7905958 19 (IC50 1.6 µM), (Figure 1.12) which has a 
pipemidic acid core.222 Studies were carried out in order to improve the potency and further 
understand the SAR of this compound. Using H2L 7905958 as the lead compound, 70 potential 
pipemidic analogues where identified via computational screening. 30 of these were chosen to be 
synthesised for further investigation. Four of these analogues 20-23 (Figure 1.12), were found to 
have potency similar to H2L 7905958 with the most potent being the R2 trifluoromethyl- substituted 
compound, 20 (IC50 900 nM), (Figure 1.12).222 
 
 
Figure 1.12: Structure of H2L 7905958 and analogues based on the pipemidic acid core. 
Another study by Albers et al. discovered a range of thiazolidinediones, through the biochemical 
screening of a large chemical library.223 The most potent molecule discovered in the initial screen 
20 = R2 trifluoromethyl- 
21 = R1 & R4 dichloro- 
22 = R2 iodo- 
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was compound 24 (Figure 1.13) which had an IC50 of 56 nM. This compound was further optimised 
but no increased activity from variation of the benzyl and benzylidine groups was observed. 
However, moving the carboxylic acid group to the meta-position led to a 2.5-fold increase in potency. 
It was hypothesised that the carboxylic acid is involved in strong binding to zinc ions, in order to 
increase the strength of this interaction the carboxylic acid group was replaced with a boronic acid 
group, resulting in a 100 fold increase in potency.223,224 The boronic acid thiazolidinediones are also 
expected to improve selectivity over hydrolytic enzymes as boronic acids are often present in 
phosphate ester hydrolysing enzymes. HA130 25 (Figure 1.13), in which the carboxylic acid was 
replaced by a boronic acid group and the methoxy- substituent was removed lead to an increase in 
activity. This compound was found to reduced plasma levels of LPA when tested in vivo.223 So far 
from all of the SAR and optimisation of thiazolidinediones based inhibitors HA155 26, (Figure 1.13) 
has proven to be the most potent (IC50 6 nM), this compound has also been shown in crystal structure 
bound with autotaxin.225 This HA155 autotaxin complex confirmed the theoretical binding mode.225  
 





Figure 1.13: Structure of the thiazolidinedione core autotaxin inhibitors. 
The recent solution of the crystal structure of autotaxin has also provided a useful tool in the 
development of autotaxin inhibitors. Kawaguchi et al. have taken advantage of this recently 
describing a set of inhibitors where optimisation was based on the crystal structure of autotaxin. Their 
most potent inhibitors 3BoA 27 and 4BoA 28 (Figure 1.14), achieved respective IC50s of 13 nM and 
22 nM in a TG-mTMP assay. TG-mTMP is a specific autotaxin fluorescence probe developed by the 









Figure 1.14: Structure of 3BoA and 4BoA. 
The crystal structure of autotaxin bound with thiazolidinedione 26 shows one of the oxygens of the 
boronic acid coordinates with the zinc ions in the catalytic domain and the boron forms a covalent 
bond with the Thr209. Similarly, the boronic acid head group of both 3BoA 27 and 4BoA 28 have 
been shown to bind to autotaxin in the same manner forming the same contacts.90-91 
Two of the most recent autotaxin inhibitors described, PF-8380 and ONO-8430506, have shown 
promise for prolonged inhibition of autotaxin in vivo.226-227 
PF-8380 29 (Figure 1.15), the most potent inhibitor to date, was based on an autotaxin inhibitor hit 
identified in the Pfizer compound library and was synthesised in an efficient 3 step process. This 
compound doesn’t contain the carboxylic/boronic acid moiety important in the binding of the 
28 
27 
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previous set of inhibitors; however, this compound does contain a polar coordinating head group 
capable of binding to in the catalytic site. PF-8380 exhibited an IC50 of 2.8 nM, against isolated 
autotaxin and 101 nM in whole blood. Furthermore, the ability of this compound to inhibit LPA 
formation in vivo was measured after 4 h; 95% inhibition was observed with a dose of 100 mg/kg. 
They also demonstrated inhibition of inflammation in a rat tail model.226 
 
 
Figure 1.15: Structure of PF-8380. 
ONO-8430506 is a tetrahydrocarboline derivative, which was identified by in vitro screening and 
subsequent chemical development by ONO pharmaceutical.227 The structure of ONO-8430506 has 
not been disclosed. This compound exhibited an IC50 of approximately 10 nM against both 
recombinant autotaxin and plasma. They also investigated the effects of the inhibitor in vivo 
observing complete inhibition of LPA formation for 24 h at a dose of 30mg/kg.227 Furthermore, 
ONO-8430506 was found to inhibit autotaxin leading to a delay in breast tumour growth and lung 
metastasis in mice.228 
There have been many other autotaxin inhibitors reported, based on a variety of scaffolds. Merck has 
reported autotaxin inhibitors with nanomolar activity based on benzoxoazolone, benzotriazole and 
benzopthyridinamine cores.229-231 Pfizer has developed low nanomolar autotaxin inhibitors with 
pyridazine and tetrahydropyridopyrimidine scaffolds.232 Amira Pharmaceuticals have potent 
autotaxin inhibitors which are indole-thioether carboxylic acid derivatives.233 And Eli lilly have 
pyrido-fused pyrimidine and pyrrolo-fused pyrimidine based autotaxin inhibitors.234 There has also 
29 
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more recently been bicyclic aryl compounds described as nanomolar autotaxin inhibitors by 
Biogen.235 
1.5 Polymer therapeutics  
1.5.1 Introduction 
Autotaxin inhibitors are small molecule inhibitors which are likely to be rapidly expelled from the 
peritoneal cavity. Small molecular weight drugs (<20kDa) in the peritoneal cavity are quickly 
absorbed through the peritoneal capillaries into systemic circulation.236-237 This leads to frequent or 
continuous dosing and if drugs are delivered by the intraperitoneal route, this creates problems such 
as increased risk of infection. In contrast, polymers have a higher molecular size, and are therefore 
absorbed slowly from the peritoneal cavity mainly via lymphatic drainage. Using polymers as drug 
carriers would increase the half-life of the drugs in the peritoneal cavity and therefore allow less 
frequent dosing. Polymers have the potential to increase the half-life of autotaxin inhibitors in the 
peritoneal cavity.  
Polymers have been used in medicine for many years and have a number of biomedical applications. 
Polymer therapeutics include polymer drugs in which the polymer exhibits bioactivity, polymer-
protein conjugates in which a polymer is attached to the protein in order to improve the half-life of 
the protein, polymeric micelles which encapsulate the drug, and polymer-drug conjugates in which 
drugs are attached to polymers in order to improve their pharmacokinetics and specificity, (Figure 
1.16). Polymer therapeutics differ from conventional drug delivery systems and formulations as they 
can be chemical tailored to fit specific requirements. This can be through addition of targeting 
moieties, cleavable linkers or modification of molecular weight. 





Figure 1.16: Representation of Polymeric therapeutic agents; Polymer-drug conjugate, Polymer-
protein conjugate, Dendrimer-drug conjugate and polymeric drug micelle. 
There are many different types of polymers which can be chosen to best suit specific requirement of 
the drug product. The most common polymer currently used is N-(2-hydroxypropyl) methacrylamide 
(HMPA) a synthetic polymer.238 Other polymers currently used include synthetic polymers 
(polyethyleneglycol (PEG),239 poly(vinyl-pyrrolidone) (PVP) and poly(ethylimine) (PEI), or natural 
polymers (dextrin, dextran and chitosan) or synthetic polymers based on natural products 
(poly(glutamic acid) (PGA) and poly(malic acid). There are also new classes of polymers being 
investigated such as dendrimers. Dendrimers are versatile spherical polymers with various functional 
terminal groups providing a pathway to conjugate potential drugs or targeting molecules furthermore 
these terminal groups can be modified to control the properties of the dendrimer.240  
1.5.2 Polymeric anticancer drugs in the clinic 
There are many polymeric therapeutics currently in the clinic, the first to be approved was a polymer-
protein conjugate in the early 1990’s since then, many more polymeric therapies have been 
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investigated pre-clinically and some have gone on to be approved for clinical use. So far polymer 
anticancer therapeutics have been beneficial, improving localised bioavailability, increasing 
solubility, decreasing toxicity and delivering the therapeutic agent to the cancerous tissue. A number 
of anticancer therapeutics have progressed to routine clinical use (Table 1.2). For instance polymer-
protein conjugates have been found to improve the stability of the protein and increase the half-life 
delivery; such as Pegaspargase (Oncaspar) and Pegfilgrastim (neulasta) and the albumin bound 
paclitaxel nanoparticle (abraxane) which has been approved for the treatment of breast cancer, more 
recently this conjugate has been approved for the treatment of non-small cell lung cancer (NSCLC) 
and pancreatic cancer as a less toxic alternative, to paclitaxel alone.241 Furthermore, polymeric 
micelles can also prolong circulation time by encapsulating the drug molecule and preventing its 
uptake by the macrophage system; Genexol-PM is a polymeric micelle currently used in the clinic. 

















Metastatic breast cancer 
(intravenous), hormone 





















Metastatic breast cancer 
(Intravenous) 
Table 1.2: Polymeric therapies on the market for the treatment of cancer. 
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1.5.3 Polymer-drug conjugates 
Polymer-drug conjugates are drug molecules chemically conjugated to polymeric molecules. 
Ringsdorf first suggested the rationale for using pharmacologically active polymeric molecules in 
the 1970’s.242 Conjugation to a polymer can improve the pharmacokinetic profile of the drug. 
Polymers increase the half-life of the drug by increased molecular size leading to reduced renal 
clearing and providing a shielding effect from chemical or enzymatic degradation of the drug. 
Furthermore,  macromolecules such as polymer-drug conjugates can directly target the tumour via 
the enhanced permeability and retention effect (EPR effect); this occurs due to the increased capillary 
permeability observed in tumours.243 A polymer-drug conjugate usually consists of a linker between 
the drug and the polymer which can be bio-responsive, releasing the drug when at the target site. The 
polymer needs to be able to carry sufficient drug molecules to be efficacious and potentially also 
contain a targeting moiety for improved specificity. 
Currently, there are a number of polymer-drug conjugates in clinical development (Table 1.3) which 
are traditional chemotherapeutic agents such as platinum based compounds, paclitaxel, doxorubicin 
and captothecin conjugated to water soluble polymers in order to improve their pharmacokinetics. 
The most promising so far appears to be a paclitaxel-polyglutamate conjugate which has reached 
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Compound (name) Clinical status Indication 
Polyglumex-paclitaxel (CT-2103, Xyotax) Phase III 
Various cancers; ovarian 
cancer as single agent or 
in combination 
Polyglutamate-camptothecin (CT-2106) Phase I/II 
Colorectal and ovarian 
cancers 
HPMA copolymer doxorubicin (FCE28068) Phase II Various cancers 
HPMA copolymer-doxorubicin-
galactosamine (FCE28069) 
Phase I/II Hepatocellular carcinoma 
HPMA copolymer-paclitaxel (PNU166945) Phase I Various cancers 
HPMA copolymer-camptothecin (MAG-
CPT) 
Phase I Various cancers 
HPMA copolymer-carboplatin platinate 
(AP5280) 
Phase I/II Various cancers 
HPMA copolymer-DACH-platinate 
(AP5346, ProLindac) 
Phase II Ovarian cancers 
Dextran-doxorubicin (AD-70, DOX-OXD) Phase I Various cancers 
Modified dextran camptothecin (DE-310) Phase I Various cancers 
PEG-camptothecin (Prothecan) Phase II Various cancers 
PEG-irinitecan (NKTR-102) Phase II/III 




Phase I/II Hepatocellular carcinoma 
Polycyclodextrin-camptothecin (IT-101) Phase I Metastatic solid tumours 
Table 1.3: Polymer-drug conjugates undergoing clinical evaluation for cancer therapeutics.  
Polymer-drug conjugates have shown therapeutic benefit in both preclinical and clinical 
investigations. These benefits include improved pharmacokinetics, such as better distribution and an 
increased half-life, fewer side effects and enhanced therapeutic efficacy. This is further validated by 
the polymer based systems which have already made it to the clinic for the treatment of cancer. 









Ovarian cancer is a major disease with only a 40% survival rate; of those who initially respond to 
chemotherapy the majority relapse with a developed resistance to traditional chemotherapy. The 
development of resistance is a major downfall for the treatment of ovarian cancer and overcoming 
this problem is of huge importance for improving the survival of patients with ovarian cancer. 
Targeting the Autotaxin-LPA signalling pathway is a potential approach in treating drug resistant 
ovarian cancer because this signalling pathway has been shown to be involved in the pathogenesis 
of ovarian cancer and also to be instrumental in the development of resistance. There have been many 
autotaxin inhibitors described to date, however most of these inhibitors have shown poor efficacy in 
vivo, with poor pharmacokinetic profiles. Polymer-drug conjugates have shown therapeutic benefit 
in both preclinical and clinical investigations. These benefits include improved pharmacokinetics, 
fewer side effects and enhanced therapeutic efficacy. This is further validated by the polymer based 
systems which have already made it to the clinic for the treatment of cancer. Delivery of drugs 
directly to the peritoneal cavity is currently being investigated for the treatment of ovarian cancer, 
with cisplatin, paclitaxel, carboplatin, and docetaxel suggesting a pharmacokinetic advantage.244 
Because high levels of LPA are found in ascites fluid associated with ovarian cancer and as autotaxin 
has also been shown to be elevated in ascites fluid, and it is understood to be the main contributor to 
the production of LPA. Inhibition of autotaxin in the intraperitoneal cavity has the potential to reduce 
the pathogenic level of LPA present in ascites fluid.  
It is proposed that autotaxin inhibitors which are retained in the peritoneal cavity will improve the 
efficacy of chemotherapy particularly in drug resistant disease. 
The overall aim of this thesis was the synthesis and biological evaluation of polymer conjugates of 
autotaxin inhibitors for use in ovarian cancer treatment with intraperitoneal delivery. Medicinal 
chemistry and in vitro pharmacological studies were employed to achieve the following key 
objectives: 
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 Synthesis of polymer-autotaxin inhibitor conjugates; two autotaxin inhibitors were explored: 
an LPA analogue S32826 coupled to a dendrimer and a small molecule inhibitor with a 
thiazolidinedione core coupled to icodextrin  
 Characterisation of polymer autotaxin inhibitor conjugates; evaluation of the substitution, 
permeability and solubility of the conjugates and in vivo peritoneal retention 
 Biological evaluation of polymer autotaxin inhibitor conjugates; the activity of the 
conjugates against autotaxin in enzymatic activity assays and in cellular assay modelling 
migration and potentiation of apoptosis 
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 Reagents and solvents were obtained from commercial suppliers and were not further purified before 
use unless stated. G3 PAMAM dendrimer refers to a 3rd generation polyamidoamine (PAMAM) 
dendrimer (20 wt. % solution methanol) containing 32 surface groups, (Sigma Aldrich, cat 
no.412422). Icodextrin was obtained as EXTRANEAL™ peritoneal dialysis solution, (7.5% w/v 
icodextrin in an electrolyte solution, (Baxter)). 
2.1.2 General chemistry 
Solvents were removed under reduced pressure with a Büchi rotary evaporator. Any remaining 
solvent was removed under high vacuum. The progress of the reactions was monitored by TLC 
analysis, using aluminium pre-coated silica gel plates (Merck) visualised by UV irradiation at a 
wavelength of 254 nm. Flash column chromatography was carried out on silica gel 60 (43-60 mesh); 
columns were slurry packed in the appropriate solvent/solvent mixture and samples were added as a 
concentrated solution or pre-absorbed onto silica. Dialysis was carried out using either 8 kDa MWCO 
(Biodesign) or 20 kDa MWCO (Biotech) dialysis membrane tubing.  
2.1.3 Analytical techniques  
2.1.3.1  NMR spectroscopy 
 1H and 13C nuclear magnetic resonance (NMR) were measured on a Bruker DPX300 Fourier 
transform spectrometer, or a Jeol 400 MHz Fourier transform spectrometer using d-DMSO, CDCl3, 
D2O or MeOD solvents. Chemical shifts are quoted in ppm downfield from TMS; coupling constants 
(J) are quoted in Hertz (Hz). TMS was defined as 0 in 1H NMR and the residual chloroform triplet 
as 77.10ppm in 13C NMR. The following abbreviations were used in analysis; broad (br), singlet (s), 
doublet (d), triplet (t), quartet (q) and multiplet (m).  
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2.1.3.2 IR spectroscopy 
Infra-red (IR) spectra were recorded in their natural state on a Thermo Scientific GladiATR 
spectrometer and the vibrational frequencies were recorded in cm-1. 
2.1.3.3 Mass Spectrometry 
 Mass Spectra were obtained from the EPSRC National Mass Spectrometry Centre at the University 
of Wales, Swansea, using electron spray ionisation (ES) or atmospheric pressure chemical ionisation 
(APCI).  
2.1.3.4 Elemental analysis 
Elemental analysis was performed by MEDAC Ltd, Chobam. Where appropriate the stoichiometry 
of coupling was determined by measuring the ratio of elemental phosphorus to the elemental ratio of 
other elements in the compound.  
2.1.3.5 X-ray crystallography  
Crystallisation was performed at room temperature in ethyl acetate. Data collection and structural 
analysis was carried out by Dr. M. Elsegood at the University of Loughborough. See appendix 1 for 
details of X-ray diffraction data and collection. 
2.1.3.6 LC/MS 
Liquid chromatography mass spectrometry (LC/MS) was performed whilst at Charnwood Molecular 
Ltd. LC/MS measurements were performed on an Applied Biosystems API 150EX system, in either 
acetonitrile or methanol. The purity of all tested compounds as determined by LC/MS analyses was 
greater than 95%. 
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2.1.3.7 Thermogravimetric analysis  
Thermogravimetric analysis (TGA) was performed using a SDT Q 600 TA instrument, with a 
constant nitrogen flow of 100 mL/min, heating rate of 20 °C/min, heating was held stable at 100 °C 
for 10 min to remove any residual solvent. Results were obtained for greater than 10 mg per sample 
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2.1.4 Synthesis of dendrimer-autotaxin inhibitor conjugates 
2.1.4.1 Synthesis of [4-(12-Acetylamino-dodecanoylamino)-benzyl]-phosphonic acid 
diethyl ester (34) 
 
To a solution of [4-(12-Amino-dodecanoylamino)-benzyl]-phosphonic acid diethyl ester (2.00 g, 
4.69 mmol, 1.0 equiv.) in pyridine (10 mL) acetic anhydride (0.5 mL, 5.80 mmol, 1.2 equiv.) was 
added and the reaction mixture was stirred at room temperature for 16 h. The reaction mixture was 
added to an ice/water mixture (30 mL) and the resultant precipitate was collected via filtration to 
give [4-(12-Acetylamino-dodecananoylamino)-benzyl]-phosphonic acid diethyl ester (1.89 g, 4.03 
mmol, 85%) as a white crystalline powder. 
 δH (300 MHz d-DMSO): 7.99 (s, 1H, NH), 7.49 (d, J 6.0, 2H), 7.21 (d, J 6.0, 2H), 5.70 (s, 1H, NH), 
5.31 (dd, J 9.0, 3.0, 2H), 4.04-3.99 (m, 4H), 3.22 (dq, J 18.0, 6.0, 4H), 3.14 (s, 1H), 3.08 (s, 1H), 
2.36 (t, J 6.0, 3H), 2.00 (s, 2H), 1.72 (t, J 9.0, 2H) 1.48-1.46 (m, 2H) and 1.28-1.24 (m, 16H). 
νmax/cm -1 (solid): 3451, 3317, 2982, 2917, 2849, 1671, 1652, 1609, 1542, 1514, 1478, 1411, 1369, 
1219. 
 m/z (ES+) (Found: [M+H]+ 483.2973, C25H44O5N2P1 required, 483.2910).  
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2.1.4.2 Synthesis of [4-(12-Acetylamino-dodecanoylamino)-benzyl]-phosphonic acid (35) 
 
To a solution of [4-(12-Acetylamino-dodecanoylamino)-benzyl]-phosphonic acid diethyl ester 
(0.700 g, 1.4 mmol, 1.0 equiv.) in anhydrous dichloromethane (10 mL), under N2, trimethylsilyl 
iodide (400 µL, 2.8 mmol, 2.0 equiv.) was added via syringe. The resulting solution was stirred at 
room temperature for 8 h, evaporated to dryness and recrystallised from methanol to give [4-(12-
Acetylamino-dodecanoylamino)-benzyl]-phosphonic acid (0.581 g, 97%, 1.36 mmol) as a white 
crystalline powder. 
 δH (300 MHz d-DMSO); 9.79 (s, 1H, NH), 7.49 (d, J 6.0, 2H), 7.14 (d, J 6.0, 2H), 5.31 (dd, J 9.0, 
3.0, 2H), 4.14 (s, 1H, NH), 3.56 (s, 2H) 3.15 (s, 1H), 3.00 (s, 1H), 2.85 (t, J 6.0, 2H), 2.27 (s, 2H), 
1.76 (t, J 9.0, 2H) and 1.22-1.16 (m, 16H). 
νmax/cm -1 (solid); 3451, 3302, 2917, 2849, 2160, 1652, 1609, 1541, 1514, 1471, 1412, 1369, 1219. 
 m/z (ES+) (Found: [M+H]+ 427.2357, C21H36O5N2P1 required, 427.2356).  
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2.1.4.3 Synthesis of [4-(12-Acryloylamino-dodecanoylamino)-benzyl]-phosphonic acid 
diethyl ester (31) 
 
 To a solution of [4-(12-amino-dodecanoylamino)-benzyl]-phosphonic acid diethyl ester (1.50 g, 
3.40 mmol, 1.0 equiv.) and triethylamine (0.9 mL, 6.80 mmol, 2.0 equiv.) in anhydrous 
dichloromethane (25 mL) cooled to −20 °C, a solution of acryloyl chloride (0.340 g, 3.75 mmol, 1.1 
equiv.) in anhydrous dichloromethane (15 mL) was added dropwise. The reaction mixture was 
warmed to 0 °C and stirred for a further 4 h under N2. The reaction mixture was then washed with 
saturated aqueous NaHCO3 (3x 30 mL), water (3x 50 mL) and saturated brine (3x 30 mL), dried 
(MgSO4) and evaporated. The resultant product was stirred in ethyl acetate: petrol (3:7) for 16 h and 
collected via filtration to give [4-(12-acryloylamino-dodecanoylamino)-benzyl]-phosphonic acid 
diethyl ester (0.715 g, 1.44 mmol, 43%) as a white crystalline powder. 
δH (300 MHz d-DMSO): 8.31 (s, 1H, NH), 7.42 (d, J 6.0, 2H), 7.12 (d, J 6.0, 2H), 6.23 (m, 1H), 6.08 
(m, 1H), 5.98 (br. s, 1H, NH), 5.53 (dd, J 9.0, 3, 2H), 3.99-3.88 (m, 4H), 3.23 (q, J 18.0, 6.0, 2H), 
3.07 (s, 1H), 3.00 (s, 1H), 2.29 (t, J 6.0, 3H), 1.63 (t, J 9.0, 2H) 1.46-1.42 (m, 2H) and 1.20-1.16 (m, 
16H). 
νmax/cm -1 (solid): 3293, 2985, 2918, 2850, 1674, 1656, 1627, 1601, 1538, 1470, 1456, 1330, 1305, 
1239. 
m/z (ES+) (Found: [M+H]+, 495.2978, C26H44O5N2P1 required, 495.2982).  
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2.1.4.4 Synthesis of [4-(12-Acryloylamino-dodecanoylamino)-benzyl]-phosphonic acid 
diethyl ester dendrimer conjugate (32) 
 
A solution of G3 PAMAM dendrimer (0.250 g, 7.24x10-3 mmol, 1.0 equiv.) and [4-(12-
Acryloylamino-dodecanoylamino)-benzyl] phosphonic acid diethyl ester (0.458 g, 0.92 mmol, 128 
equiv.) in ethanol (10 mL) was heated with stirring at 100 °C for 48 h in an ACE™ pressure tube. 
The solution was then transferred to dialysis tubing (MWCO 8 kDa (Biodesign)) and dialyzed in 
methanol (500 mL), being changed 3 times per day for 3 days. The methanol was then evaporated to 
yield [4-(12-Acryloylamino-dodecanoylamino)-benzyl]-phosphonic acid diethyl ester dendrimer 
conjugate (0.200 g, 0.009 mmol, 30% based on complete substitution) as a yellow solid. 
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2.1.4.5 Synthesis of conjugate 1 (33) 
 
To a solution of [4-(12-Acryloylamino-dodecanoylamino)-benzyl]-phosphonic acid diethyl ester 
dendrimer conjugate (0.200 g, approx. 0.009 mmol, 1.0 equiv.) in anhydrous dichloromethane (5 
mL), under N2, trimethylsilyl iodide (0.28 mL, 2.00 mmol, 222 equiv.) was added via syringe. The 
resulting solution was stirred at room temperature for 8 h. The reaction mixture was then directly 
transferred into dialysis tubing (MWCO 8 kDa (Biodesign)) and dialyzed in methanol (500 mL), 
being changed 3 times per day for 3 days. The methanol was then evaporated to give conjugate 1 
(0.016 g, 7.73x10-4 mmol, 9% based on complete substitution) as an orange oil. 
νmax/cm -1 (solid): 3242, 2952, 2927, 2860, 1709, 1671, 1585, 1508, 1438, 1414, 1388, 1341, 1276.  
Elemental analysis: C718H1310N154O148P16: Theory; C 58.13%, H 8.90%, N 14.54%, P 3.34%; Found; 
C 45.65%, H 6.14%, N 8.45%, P 3.38%. 
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2.1.5 Synthesis of icodextrin-autotaxin inhibitor conjugates 
2.1.5.1 Synthesis of 3-(4-Fluorobenzyl)-thiazolane-2,4-dione (38) 
 
A solution of thiazolidine-2,4-dione (2.94 g, 25 mmol, 1.5 equiv.) in anhydrous DMF (50 mL), under 
N2, was cooled to 0 °C. Sodium hydride (60% dispersed in oil, 0.92 g, 23 mmol, 1.35 equiv.) and a 
solution of 4-fluorobenzyl chloride (2.1 mL, 17 mmol) in anhydrous DMF (10 mL) were added. The 
reaction mixture was allowed to warm to room temperature over 4 h.  The mixture was transferred 
into an ice/water mixture (100 mL) and hexane (50 mL) was added. The mixture was allowed to 
crystallise overnight at 4 °C, and collected via filtration to yield 3-(4-Fluoro-benzyl)-thiazolane-2,4-
dione (4.2 g, 19 mmol, 75%) as white crystalline needles. 
δH (300 MHz CDCl3): 7.35 (m, 2H) 6.91 (m 2H), 4.65 (s, 2H), 3.87 (s, 2H). 
δC (75 MHz CDCl3); 171.7, 171.2, 162.6 (d, 1JCF 247.5), 131.7 (d, 2JCF 8.3), 130.9 (d, 3JCF 3.3), 115.7 
(d, 4JCF 21.4)5, 44.6, 33.8. 
νmax/cm -1 (solid): 1719, 1677 (C=O), 1589, 1520, 1447, 1385, 1342. 
m/z (APCI) (Found: [M+H]+, 226.0333. C10H9O2N1F1S1 required, 226.0333).  
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2.1.5.2 Synthesis of 4-(4-Formyl-2-methoxy-phenoxymethyl)-benzoic acid (41) 
 
Vanillin (0.70 g, 4.60 mmol, 1.05 equiv.) and potassium hydroxide (0.32 g, 5.70 mmol, 1.3 equiv.) 
were suspended in anhydrous DMSO (10 mL). Methyl 4-(bromomethyl)-benzoate (1.00 g, 4.37 
mmol 1.0 equiv.) was added and the mixture was stirred at room temperature for 30 min. Water (50 
mL) was added and the solution was heated to 115 °C for 2 h. 1 M NaOH (10 mL) was added and 
the solution was refluxed for approximately 4 h until the solution became clear. The reaction mixture 
was diluted with water (100 mL) and acidified with 1 M HCl to pH 2. The product was collected via 
filtration to give 4-(4-Formyl-2-methoxy-phenoxymethyl)-benzoic acid (1.21 g, 4.20 mmol, 71%) as 
a yellow crystalline powder. 
δH (300 MHz d-DMSO): 13.03 (bs, 1H, OH), 9.84 (s, 1H), 7.99 (d, J 8.3, 2H), 7.58 (d, J 8.3, 2H), 
7.54 (dd, J 8.3, 1.9, 1H), 7.43 (d, J 1.8, 1H), 7.26 (d, J 8.3, 1H), 5.31 (s, 2H), 3.85 (s, 3H). 
δC (75 MHz d-DMSO); 191.4, 167.0, 152.8, 149.3, 141.3, 140.2, 130.3, 129.9, 129.5, 128.6, 127.6, 
125.8, 112.6, 109.7, 69.3, 55.6. 
νmax/cm -1 (solid): 3726, 2988, 2529, 1989, 1716 (C=O), 1674 (C=O), 1583, 1504, 1278, 1257. 
m/z (ES-) (Found: [M-H]-, 285.0762. C16H13O5 required, 285.0768). 
1H NMR and IR data agrees with that published in the literature.224 
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2.1.5.3 Synthesis of 4-{4-[3-(4-Fluoro-benzyl)-2,4-dioxo-thiazolidin-5-ylidenemethyl]-2-
methoxy-phenoxymethyl}-benzoic acid (24) 
 
3-(4-Fluoro-benzyl)-thiazolane-2,4-dione (0.51 g, 2.25 mmol, 1.1 equiv.) was dissolved in ethanol 
(10 mL). Piperidine (0.014 mL, 2.07 mmol, 1.0 equiv.) and 4-(4-formyl-2-methoxy-phenoxymethyl) 
benzoic acid (0.70 g, 2.25 mmol, 1.1 equiv.) was added and the solution was heated at reflux for 24 
h. The mixture was cooled to room temperature and the resulting precipitate was collected via 
filtration to yield 4-{4-[3-(4-fluoro-benzyl)-2,4-dioxo-thiazolidin-5-ylidenemethyl]-2-methoxy-
phenoxymethyl}-benzoic acid (1.03 g, 2.08 mmol, 93%) as yellow crystalline powder. 
δH (300 MHz CDCl3): 13.03 (bs, 1H, OH), 9.84 (s, 1H), 7.99 (d, J 9.0, 2H), 7.57 (d, J 6.0, 2H), 7.53-
7.23 (m, 7H), 5.31 (s, 2H), 4.82 (s, 2H), 3.85 (s, 3H). 
δC (75 MHz CDCl3); 167.8, 166.7, 166.2, 162.6 (d, 1JCF 247), 150.0, 149.8, 141.4, 134.2, 131.1 (d, 
4JCF 3.3), 130.9 (d, 3JCF 8.2), 130.0, 129.9, 126.8, 126.7, 124.4, 118.9, 115.6 (d, 2JCF 21.5), 113.6, 
112.9, 76.6, 70.2, 56.0, 44.5. 
νmax/cm-1 (solid): 3734, 2988, 2880, 2826, 2519, 2190, 2155, 1541 (C=O), 1448, 1404, 1279, 1250. 
 m/z (ES-): (Found: [M-H]-, 492.0924, C26H19O6N1F1S1 required, 492.0923). 
1H NMR and IR data agrees with that published in the literature.224 
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2.1.5.4 Synthesis of 3-Acetoxy-4-hydroxybenzaldehyde (44) 
 
3,4-Dihydroxybenzaldehyde (0.300 g, 2.20 mmol, 1.0 equiv.), was suspended in THF (3 mL) and 
cooled to 0 °C. 2 M NaOH (3 mL, 5.40 mmol, 2.5 equiv.) was added dropwise followed by dropwise 
addition of acetic anhydride (0.25 mL, 2.64 mmol, 1.2 equiv.). The solution was stirred at 0 °C for 
20 min. The solution was diluted with ethyl acetate (5 mL) and then acidified with concentrated HCl 
(0.25 mL) and pH 2.5 phosphate buffer (2 mL). THF was removed via evaporation, followed by 
filtration through a celite pad and washed with ethyl acetate. The combined organic layers were dried 
(MgSO4) and ethyl acetate was evaporated. The resulting yellow oil was purified by column 
chromatography (dichloromethane/methanol, gradient 1-10% methanol). The product 3-Acetoxy-4-
hydroxybenzaldehyde (0.247 g, 1.30 mmol, 62%) was collected as a colourless oil with 
approximately 20% 4-acetoxy-3-hydroxy-benzaldehyde impurity. 
 δH (300 MHz CDCl3): 9.77 (s, 1H), 7.61-7.58 (m, 2H), 7.20 (s, 1H), 6.74 (bs, 1H, OH), 3.68 (s, 3H). 
δC (75 MHz CDCl3): 191.5, 169.1, 153.1, 138.7, 129.7, 124.0, 123.3, 117.7, 21.0. 
No further analysis was performed.  
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2.1.5.5 Synthesis of Methyl-4-(4-formyl-2-hydroxy-phenoxymethyl)-benzoate (45) 
 
3,4-Dihydroxybenzaldehyde (0.15 g, 1.1 mmol, 1.0 equiv.) was dissolved in DMF (5 mL), sodium 
bicarbonate (0.13 g, 1.5 mmol, 1.5 equiv.), methyl-4-(bromomethyl)-benzoate (0.456 g, 2.00 mmol, 
2.0 equiv.) and sodium iodide (0.044 g, 0.30 mmol, 0.3 equiv.) was added. The reaction mixture was 
heated at 40 °C for 24 h. the reaction was quenched with 10 % aqueous HCl (10 mL) and extracted 
with ethyl acetate (3 x 10 mL), washed with brine (3 x 10 mL), dried (MgSO4) and the solvent was 
evaporated to yield the crude product as a brown oil. The resulting product was purified by column 
chromatography (ethyl acetate/hexane (1:4)). The product methyl-4-(4-formyl-2-hydroxy-
phenoxymethyl)-benzoate (0.22 g, 0.76 mmol, 70%) was collected as a colourless solid with slight 
impurities.  
δH (300 MHz d-DMSO): 9.77 (s, 1H), 8.01-7.98 (m, 2H), 7.64-7.61 (m, 2H), 7.47 (d, J 7.5, 1H), 7.23 
(s, 1H), 6.92 (d, J 7.5, 1H), 5.41 (s, 2H), 4.58 (br s, 1H), 3.83 (s, 3H). 
δC (75 MHz d-DMSO): 191.1, 166.2, 152.1, 152.0, 148.3, 147.3, 145.8, 129.3, 129.0, 128.8, 126.3, 
124.5, 115.5, 114.2, 62.3, 52.0. 
νmax/cm-1 (solid): 3672, 2988, 1713 (C=O), 1672 (C=O), 1583, 1428, 1406, 1394, 1310, 1276. 
m/z: 284.8 
The crystal structure was also determined for this compound, see section 4.2.2.3. 
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2.1.5.6 Synthesis of Methyl 4-{4-[3-(4-fluoro-benzyl)-2,4-dioxo-thiazolidin-5-
ylidenemethyl]-2-hydroxy-phenoxymethyl}-benzoate (46) 
 
3-(4-Fluoro-benzyl)-thiazolane-2,4-dione (0.390 g, 0.176 mmol 1.0 equiv.) was dissolved in ethanol 
(10 mL). Piperidine (0.017 mL, 0.176 mmol 1.0 equiv.) and methyl-4-(4-Formyl-2-hydroxy-
phenoxymethyl)-benzoate (0.504 g, 0.176 mmol 1.0 equiv.) was added and the reaction mixture was 
heated at reflux for 24 h. The mixture was cooled to room temperature resulting in precipitation. The 
precipitate was collected via filtration to yield methyl-4-{4-[3-(4-fluoro-benzyl)-2,4-dioxo-
thiazolidin-5-ylidenemethyl]-2-hydroxy-phenoxymethyl}-benzoate (0.594 g, 0.12 mmol, 69%) as 
yellow crystalline powder. 
δH (300 MHz d-DMSO): 7.99 (d, J 9.0, 2H), 7.80 (s, 1H), 7.63 (d, J 9.0, 2H), 7.35 (dd, J 9.0 2H), 
7.20 (d, J 9.0, 2H), 7.15-7.06 (m, 3H), 5.29 (s, 2H), 4.80 (s, 2H), 3.85 (s, 3H). 
νmax/cm -1 (solid): 3627, 2988, 1712 (C=O), 1672 (C=O), 1583, 1504, 1428, 1406, 1394. 
m/z (ES+) (Found: [M + NH4]+ 511.1330, C26H24O6N2F1S1 required, 511.1334). 
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2.1.5.7 Synthesis of 4-(4-Formyl-2-hydroxy-phenoxymethyl)-benzoic acid (47) 
 
Methyl-4-(4-formyl-2-hydroxyl-phenoxymethyl) benzoate (0.100 g, 0.34 mmol) was dissolved in 
DMSO (1 mL). Water (5 mL) was added and the reaction was heated to 70 °C for 2 h. 1 M NaOH (1 
mL) was added and reaction was heated at 70 °C until the solution became clear. The reaction mixture 
was diluted with water (20 mL) and acidified to pH 2 with 1 M HCl, resulting in precipitation. The 
resulting precipitate was collected via filtration to yield 4-(4-Formyl-2-hydroxy-phenoxymethyl)-
benzoic acid (0.092 g, 0.33 mmol, 98%) as a pale yellow crystalline powder.  
δH (300 MHz, d-DMSO): 9.79 (s, 1H), 8.00 (m, 2H), 7.62 (m, 2H), 7.39 (dd, J 9.0, 3, 1H), 7.33 (d, J 
3.0, 1H), 7.20 (d, J 9.0, 1H), 5.34 (2H, s). 
 δC (75 MHz, d-DMSO): 196.2, 166.9, 157.4, 155.6, 148.7, 147.2, 145.8, 131.5, 129.8, 129.7, 129.4, 
119.6, 117.5, 76.2.  
νmax/cm -1 (solid): 3726, 3705, 2988, 2529, 1674 (C=O), 1583 (C=O), 1406. 
 m/z: 270.8. 
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2.1.5.8 Synthesis of 4-{4-[3-(4-Fluoro-benzyl)-2,4-dioxo-thiazolidin-5-ylidenemethyl]-2-
hydroxy-phenoxymethyl}-benzoic acid (42) 
 
3-(4-Fluorobenzyl)-1,3-thiazolane-2,4-dione (4.00 g, 17.70 mmol, 1.0 equiv.) was dissolved in 
ethanol (100 mL). Piperidine (1.72 mL, 17.70 mmol 1.0 equiv.) and 4-(4-formyl-2-hydroxy-
phenoxymethyl)-benzoic acid (4.80 g, 17.7 mmol 1.0 equiv.) was added and the reaction mixture 
was heated at reflux for 24 h. The mixture was cooled to room temperature and acidified to pH 2 
with 1 M HCl resulting in precipitation of the product. The precipitate was collected via filtration to 
yield 4-{4-[3-(4-fluoro-benzyl)-2,4-dioxo-thiazolidin-5-ylidenemethyl]-2-hydroxy-
phenoxymethyl}-benzoic acid (6.78 g, 14.16 mmol, 80%) as a yellow crystalline powder. 
δH (400 MHz d-DMSO); 7.87 (d, J 9.0, 2H), 7.75 (s, 1H), 7.47 (d, J 9.0, 2H), 7.29-7.24 (m, 2H), 
7.12-7.06 (m, 5H), 5.19 (s, 2H), 4.75 (s, 2H). 
δC (75 MHz d-DMSO); 167.2, 165.7, 162.4 (d, 1JCF 278.0), 149.1, 147.4, 145.2, 141.8, 133.9, 131.9 
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2.1.5.9 Synthesis of tosylated icodextrin (49) 
 
Extraneal™ (30 mL) was transferred to dialysis tubing (MWCO 8 kDa (Biodesign)) and dialysed in 
water (1 L), being changed 3 times per day for 3 days. The dialysate was then added to an excess of 
acetone (100 mL) and stirred overnight. The resulting precipitate was collected via vacuum filtration, 
washed (acetone) and desiccated for 16 h over potassium pentoxide. Icodextrin (1.5 g) was added to 
anhydrous DMAc (30 mL) and was heated to 160 °C for 3 h. LiCl (anhydrous, 1.5 g, 30 mmol) was 
added and the mixture was heated at 100 °C for 16 h. the reaction was cooled to 50 °C and tosyl 
chloride (7.8 g, 40 mmol) was added and the reaction was heated for 8 h. The solution was then 
cooled to room temperature and transferred to dialysis tubing (MWCO 8 kDa (Biodesign)) and 
dialyzed in water (1 L), being changed 3 times per day for 3 days to yield tosylated icodextrin (1.15 
g, 77%) as a colourless crystalline solid. 
δH (300 MHz d-DMSO); 7.47 (d, J 6.0, 2H), 7.12 (d, J 9.0, 2H), 5.14 (br. s, 1H, anomeric proton), 
2.29 (s, 3H). Other peaks were too broad to be characterized, see NMR spectrum in section 4.2.3.2. 
νmax/cm-1 (solid): 3325, 1646, 1361, 1151. 
Elemental analysis: Found: C 38.79%, H 6.21%, S 2.23%. Theoretical: C 46.70%, H 5.43%, S 9.59%. 
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2.1.5.10 Synthesis of Methyl-4-{4-[3-(4-fluoro-benzyl)-2,4-dioxo-thiazolidin-5-
ylidenemethyl]-2-hydroxy-phenoxymethyl-} benzoate icodextrin conjugate (50) 
 
To a solution of tosylated icodextrin (0.050 g) and methyl-4-{4-[3-(4-fluoro-benzyl)-2,4-dioxo-
thiazolidin-5-ylidenemethyl]-2-hydroxy-phenoxymethyl-} benzoate (0.250 g, 0.717 mmol) in 
anhydrous DMSO (10 mL), triethylamine (0.5 mL, 3.70 mmol) was added and the solution was 
heated to 100 °C for 20 h. The solution was cooled to room temperature and transferred to dialysis 
tubing (MWCO 8 kDa (Biodesign)) and dialysed against methanol (1 L), being changed 3 times per 
day for 3 days to yield thiazolidine-2,4-dione ester conjugate (0.145 g, 48% mass recovered) as an 
orange oily solid. 
See section 4.2.4 for characterisation. 
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2.1.5.11 Synthesis of Triisopropylsilyl-4-{4-[3-(4-fluoro-benzyl)-2,4-dioxo-thiazolidin-5-
ylidenemethyl]-2-hydroxy-phenoxymethyl}-benzoate (52) 
 
To a cooled solution of 4-{4-[3-(4-fluoro-benzyl)-2,4-dioxo-thiazolidin-5-ylidenemethyl]-2-
hydroxy-phenoxymethyl-}-benzoic acid (0.100 g, 0.20 mmol, 1.0 equiv.) in anhydrous DMF (10 
mL), under N2, sodium hydride (0.005 g, 0.20 mmol, 1.0 equiv.) was added. The reaction was stirred 
and allowed to warm to room temperature over 1 h. Triisopropylsilyl chloride (0.043 g, 0.02 mL, 
0.22 mmol, 1.1 equiv.) was added and the reaction was stirred at room temperature for 4 h. The 
solution was poured into ice/water mixture and the product was extracted with ethyl acetate (3 x 20 
mL), washed with brine (3 x 20 mL) and dried (MgSO4). The solvent was evaporated to yield 
triisopropylsilyl-4-{4-[3-(4-fluoro-benzyl)-2,4-dioxo-thiazolidin-5-ylidenemethyl]-2-hydroxy-
phenoxymethyl}-benzoate (0.046 g, 0.07 mmol, 49%) as a yellow crystalline powder. 
δH (400 MHz CDCl3): 8.00 (d, J 7.4, 2H), 7.69 (s, 1H), 7.40-7.38 (m, 4H), 7.01 (s, 1H), 6.95-6.81 
(m, 4H), 5.84 (s, 1H), 5.15 (s, 2H), 4.75 (s, 2H), 1.35 (m, 3H), 1.04 (m, 18H). 
δC (75 MHz CDCl3): 173.6, 164.1, 151.9, 148.7, 147.3, 146.2, 135.9, 134.1, 130.7, 130.0, 127.4, 
116.1, 115.5, 112.2, 107.8, 98.4, 87.4, 70.5, 59.1, 46.5, 44.4, 43.0, 32.7, 28.3, 26.8, 23.2, 17.9, 12.0. 
m/z: 635.0. 
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2.1.5.12 Synthesis of Triisopropylsilyl-4-{4-[3-(4-fluoro-benzyl)-2,4-dioxo-thiazolidin-5-
ylidenemethyl]-2-hydroxy-phenoxymethyl}-benzoate icodextrin conjugate  
 
Triisopropylsilyl-4-{4-[3-(4-fluoro-benzyl)-2,4-dioxo-thiazolidin-5-ylidenemethyl]-2-hydroxy-
phenoxymethyl}-benzoate (0.050 g, 0.078 mmol), was stirred in anhydrous DMSO (10 mL). 
Triethylamine (0.5 mL, 3.70 mmol) and tosylated icodextrin (0.010 g, >8 kDa), were added and the 
solution was heated at 100 °C for 16 h. The solution was cooled to room temperature and transferred 
to dialysis tubing (MWCO 8 kDa (Biodesign)) and dialyzed against methanol (1 L), being changed 
3 times per day for 3 days to yield triisopropylsilyl-4-{4-[3-(4-fluoro-benzyl)-2,4-dioxo-thiazolidin-
5-ylidenemethyl]-2-hydroxy-phenoxymethyl}-benzoate icodextrin conjugate (0.020 g, 33% mass 
recovered) as an orange oily solid. 
Used directly in next step. 
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2.1.5.13 Synthesis of conjugate 2 
 
To a solution of triisopropylsilyl-4-{4-[3-(4-fluoro-benzyl)-2,4-dioxo-thiazolidin-5-ylidenemethyl]-
2-hydroxy-phenoxymethyl}-benzoate icodextrin conjugate (0.020 g) in methanol (10 mL) tetra-n-
butyl ammonium fluoride (0.050 g, 0.19 mmol) was added and the solution was stirred at room 
temperature for 3 h. The solution was transferred to dialysis tubing (MWCO 8 kDa (Biodesign)) and 
dialyzed against methanol (1 L), being changed 3 times per day for 3 days to yield conjugate 2 (0.018 
g, 22% mass recovered) as a brown oil. 
νmax/cm-1 (solid): 3325, 2922, 2853, 1700 (C=O), 1673, 1601, 1551, 1456, 1434. 
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2.1.5.14 Synthesis of 2-(2-Bromo-ethoxy)-ethanol (54) 
 
To a solution of ethylene glycol (1.79 mL, 18.85 mmol, 1.0 equiv.) in MeCN (30 mL), carbon 
tetrabromide (6.88 g, 20.74 mmol, 1.1 equiv.) and triphenylphosphine (4.90 g, 18.85 mmol, 1.0 
equiv.) were added sequentially and the mixture was stirred at room temperature for 16 h. 1 M NaOH 
(25 mL) was added and the solvent was removed via evaporation. The aqueous residue was extracted 
with ethyl acetate (3 x 30 mL), washed with brine (2 x 30 mL), dried (MgSO4), and concentrated via 
rotary evaporation, to yield the crude product (6.9 g). The crude residue was purified by column 
chromatography (hexane/ethyl acetate (1:3)) to yield 2-(2-Bromo-ethoxy)-ethanol (1.57 g, 9.3 mmol, 
49%) as a yellow oil. 
δH (300 MHz d-DMSO); 3.60 (m, 4H), 3.40 (m, 4H), 2.41 (s, OH). 
No further analysis was performed. 
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2.1.5.15 Synthesis of Methyl-4-{4-[3-(4-fluoro-benzyl)-2,4-dioxo-thiazolidin-5-
ylidenemethyl]-2-[2-(2-hydroxy-ethoxy)-ethoxy]-phenoxymethyl}-benzoate (55) 
 
To a solution of methyl-4-{4-[3-(4-fluoro-benzyl)-2,4-dioxo-thiazolidin-5-ylidenemethyl]-2-
hydroxy-phenoxymethyl}-benzoate (0.465 g, 0.94 mmol 1.0 equiv.) in MeCN (5 mL), potassium 
hydroxide (0.112 g, 1.86 mmol, 2.0 equiv.) was added and the reaction mixture was heated at 60 °C 
for 2 h.  Potassium iodide (0.155 g, 0.94 mmol, 1.0 equiv.) and 2-(2-bromo-ethoxy)-ethanol (0.315 
g, 1.86 mmol, 2.0 equiv.) was added and the reaction mixture was stirred for 16 h. The mixture was 
diluted with water, extracted with ethyl acetate (3 x 20 mL), washed with brine (3x 20 mL) dried 
(MgSO4) and concentrated via evaporation to yield the crude product. The crude product was purified 
via column chromatography (petroleum ether/ethyl acetate gradient 40-100% ethyl acetate) to yield 
methyl-4-{4-[3-(4-fluoro-benzyl)-2,4-dioxo-thiazolidin-5-ylidenemethyl]-2-[2-(2-hydroxy-ethoxy)-
ethoxy]-phenoxymethy}-benzoate (0.366 g, 0.64 mmol, 68%) as a yellow crystalline powder. 
δH (400 MHz d-DMSO); 7.98 (d, J 8.0, 2H), 7.75 (s, 1H), 7.45 (d, J 7.0, 2H), 7.19 (dd, J 8.0, 3.0, 
2H), 6.99-6.96 (m, 2H), 6.94 (d, J 7.0, 1H), 5.17 (s, 2H), 4.75 (s, 2H), 4.28 (d, J 6.0, 1H), 4.16 (d, J 
6, 2H), 3.85-3.83 (m, 5H), 3.73-3.55 (m, 6H). 
m/z: 580.7. 
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phenoxymethyl}-benzoate (0.310 g, 0.627 mmol, 1.0 equiv.) was stirred in DMF (5 mL). Potassium 
carbonate (0.173 g, 1.25 mmol, 2.0 equiv.), potassium iodide (0.110 g, 0.627 mmol, 1.0 equiv.) and 
2-(2-chloro-ethoxy)-ethanol (0.2 mL, 1.88 mmol, 2.9 equiv.) was added and the reaction was heated 
to 70 °C for 18 h. The next day the solution was diluted with water (50 mL) and extracted with ethyl 
acetate (3 x 20 mL), washed with water (3 x 20 mL) and brine (3 x 20 mL). The solvent was removed 
by evaporation to yield the crude product. The crude product was purified via column 
chromatography (hexane/ethyl acetate (1:3)) to yield methyl-4-{4-formyl-2-[2-(2-hydroxy-ethoxy)-
ethoxy]-phenoxymethyl}-benzoate (0.239 g, 0.41 mmol, 58%) as a pale yellow crystalline powder. 
δH (400 MHz CDCl3): 9.82 (s, 1H), 8.04 (d, J 7.0, 2H), 7.51-7.48 (m, 3H), 7.40 (d, J 7.0, 1H), 6.96 
(d, J 7.0, 1H), 5.27 (s, 2H), 4.25 (d, J 7.0, 2H), 3.94-3.90 (m, 5H), 3.69-3.65 (m, 4H). 
 δc (75 MHz, d-DMSO): 201.0, 188.1, 184.9, 151.2, 144.7, 134.7, 134.0, 127.3, 118.9, 118.0, 102.9, 
96.7, 96.0, 79.2, 72.5, 60.7, 60.2, 44.8.  
m/z: 375.0. 
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2.1.5.17 Synthesis of 4-(4-Formyl-2-[2-(2-hydroxy-ethoxy)-ethoxy]-phenoxymethyl}-
benzoic acid (57) 
 
Methyl-4-(4-formyl-2-[2-(2-hydroxy-ethoxy)-ethoxy]-phenoxymethyl}-benzoate (0.100 g, 0.34 
mmol) was dissolved in DMSO (1 mL), water (5 mL) was added and the reaction was heated to 70 
°C for 2 h. 1 M NaOH (1 mL) was added and reaction was heated at 70 °C until the solution became 
clear. The reaction mixture was diluted with water (10 mL) and acidified to pH 2 with 1 M HCl, the 
resulting precipitate was collected via filtration to yield 4-(4-formyl-2-[2-(2-hydroxy-ethoxy)-
ethoxy]-phenoxymethyl}-benzoic acid (0.092 g, 0.33 mmol, 98%) as a pale yellow crystalline 
powder.  
δH (300 MHz CDCl3): 9.83 (s, 1H), 7.98 (d, J 9.0, 2H), 7.60, (d, J 9.0, 2H), 7.51 (dd J 9.0, 3, 1H), 
7.46-7.45 (m, 1H), 7.22 (d, J 9.0, 1H), 5.34 (s, 2H), 4.40 (br s, 1H, OH), 4.20 (m, 2H), 3.85 (m, 2H), 
3.80 (m, 4H), 3.41 (br s, 1H OH). 
δC (75 MHz, CDCl3): 200.1, 167.1, 159.7, 155.1, 135.5, 131.5, 130.6, 129.9, 127.2, 123.9, 115.6, 
115.3, 103.1, 72.5, 68.7, 66.9, 61.2, 60.2.  
m/z: 358.9 
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2.1.5.18 Synthesis of 4-{4-[3-(4-Fluoro-benzyl)-2,4-dioxo-thiazolidin-5-ylidenemethyl]-2-
[2-(2-hydroxy-ethoxy)-ethoxy]-phenoxymethyl}-benzoic acid (58) 
 
3-(4-Fluorobenzyl)-1,3-thiazolane-2,4-dione (0.51 g, 2.25 mmol, 1.0 equiv.) was dissolved in 
ethanol (10 mL). Piperidine (0.014 mL, 2.25 mmol, 1.0 equiv.) and 4-[(4-formyl-2-
methoxyphenoxy)methyl] benzoic acid (0.70 g, 2.24 mmol, 1.0 equiv.) was added and the solution 
was heated at reflux for 24 h. The mixture was cooled to room temperature and the resulting 
precipitate was collected via filtration to yield 4-[(4-{[3-(4-fluorobenzyl)-2,4-dioxo-1,3-thiazolan-5-
yliden]-methyl-2-methoxyphenoxy)methyl] benzoic acid (1.03 g, 2.08 mmol, 93%) as a yellow 
crystalline powder. 
δH (400 MHz d-DMSO); 7.98 (d, J 8.3, 2H), 7.75 (s, 1H), 7.45 (d, J 7.0, 2H), 7.19 (dd, J 8.3, 3.0, 
2H), 6.99-6.96 (m, 3H), 6.94 (d, J 7.0, 1H), 5.17 (s, 2H), 4.75 (s, 2H), 4.70 (s, 1H, OH), 4.28 (d, J 
6.0, 1H), 4.16 (d, J 6.0, 2H), 3.93-3.90 (m, 2H), 3.73-3.55 (m, 6H), 3.44 (br. s, 1H, OH). 
 
m/z: 565.8. 
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ethoxy]-phenoxymethyl}-benzoic acid (6.00 g, 10.5 mmol, 1.0 equiv.) and triisopropylsilyl chloride 
(3.4 mL, 15 mmol, 1.42 equiv.) were stirred in anhydrous THF (200 mL). Triethylamine (1.6 mL, 
11.55 mmol, 1.1 equiv.) was added and the reaction mixture was stirred for 15 min at room 
temperature. The resulting mixture was diluted with diethyl ether (200 mL) and the solvent was 
removed by rotary evaporation to yield the crude product 9.00 g as an oily yellow solid. The crude 
material was purified by column chromatography (hexane/ethyl acetate (1:1)) to yield triisopropyl-
4-{4-[3-(4-fluoro-benzyl)-2,4-dioxo-thiazolidin-5-ylidenemethyl]-2-[2-(2-hydroxy-ethoxy)-
ethoxy]-phenoxymethyl}-benzoate (5.78 g, 8.00 mmol, 76%) as a bright yellow crystalline powder. 
δH (400 MHz CDCl3): 8.06-8.04 (m, 2H), 7.78 (s, 1H), 7.49 (d, J 8.3, 2H), 7.39-7.35 (m, 2H), 7.00-
6.96 (m, 4H), 6.92-6.90 (m, 1H), 5.23 (s, 2H), 4.82 (s, 2H), 4.21-4.18 (m, 2H), 3.93-3.90 (m, 2H), 
3.68-3.65 (m, 4H), 1.40 (q, J 7.2, 3 H), 1.12 (d, J 7.6, 18H).  
δC (75 MHz CDCl3): 174.2, 167.8, 166.5, 155.1, 151.8, 149.0, 141.3, 134.0, 130.6, 126.8, 125.1, 
120.9, 115.8, 115.5, 112.2, 105.0, 102.8, 88.9, 82.1, 76.5, 69.4, 63.0, 61.8, 58.3, 44.5, 39.8, 39.0, 
20.5, 17.9, 12.0. 
m/z: 724.7. 
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Tosylated icodextrin was dialysed against water (1 L) using a 20 kDa MWCO (biotech) dialysis 
membrane, being changed 3 times a day for 3 days, 4-{4-[3-(4-fluoro-benzyl)-2,4-dioxo-thiazolidin-
5-ylidenemethyl]-2-hydroxy-phenoxymethyl-triisopropylsilyl-benzoate (0.05 g, 0.057 mmol), was 
stirred in DMSO (10 mL). Triethylamine (0.5 mL, 3.7 mmol) and tosylated icodextrin (0.01 g, 20 
kDa MWCO) was added and the solution was heated at 100 °C for 16 h. The solution was then cooled 
to room temperature and transferred to dialysis tubing (MWCO 8 kDa (Biodesign)) and dialysed in 
methanol (1 L), being changed 3 times per day for 3 days to yield triisopropyl-4-{4-[3-(4-fluoro-
benzyl)-2,4-dioxo-thiazolidin-5-ylidenemethyl]-2-[2-(2-hydroxy-ethoxy)-ethoxy]-
phenoxymethyl}-benzoate icodextrin conjugate (0.018 g, 30% mass recovered) as a brown oil. 
Used directly in next step. 
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2.1.5.21  Synthesis of conjugate 3 
 
To a solution of triisopropyl-4-{4-[3-(4-fluoro-benzyl)-2,4-dioxo-thiazolidin-5-ylidenemethyl]-2-
[2-(2-hydroxy-ethoxy)-ethoxy]-phenoxymethyl}-benzoate icodextrin conjugate (0.02 g) in methanol 
(10 mL), tetra-n-butyl ammonium fluoride (0.05 g, 0.19 mmol) was added and the solution was 
stirred at room temperature for 3 h. The solution was transferred to dialysis tubing (MWCO 20 kDa 
(Biotech)) and dialyzed against methanol (1 L), being changed 3 times per day for 3 days to yield 4-
{4-[3-(4-fluoro-benzyl)-2,4-dioxo-thiazolidin-5-ylidenemethyl]-2-[2-(2-hydroxy-ethoxy)-ethoxy]-
phenoxymethyl}-benzoic acid icodextrin conjugate (0.018 g, 30%, mass recovered) as a colourless 
oil. 
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ethoxy)-ethoxy]-phenoxymethyl}-benzoate (0.200 g, 0.343 mmol, 1.0 equiv.) was stirred in 
dichloromethane (5 mL) in a reaction vial. Triethylamine (0.095 mL, 0.686 mmol, 2.0 equiv.) and 
tosyl chloride (0.065 g, 0.343 mmol, 2.0 equiv.) were added and the reaction was stirred at room 
temperature and monitored via LC/MS; for 20 h. The reaction mixture was washed with water (3 x 
2 mL), followed by drying (NaSO4), the solvent was removed via evaporation to yield methyl-4-(4-
[3-(fluoro-benzyl)-2,4-dioxo-thiazolidin-5ylidenemethyl]-2-{2-[2-(toluene-4-sulfonyloxy)-ethoxy]-
ethoxy}-phenoxymethyl)-benzoate (0.145 g, 57%, 0.197 mmol) as a yellow oil.  
δH (400 MHz CDCl3): 7.97 (d, J 8.3, 2H), 7.75 (s, 1H), 7.73-7.69 (m, 2H), 7.42 (d, J 7.0, 2H), 7.35 
(m, 2H), 7.19 (dd, J 8.0, 3.0, 2H), 6.94-6.86 (m, 5H), 5.22 (s, 2H), 4.77 (s, 2H), 4.25 (d, J 6.0, 1H), 
4.06 -4.03 (m, 4H), 3.85-3.82 (m, 3H), 3.75-3.71 (m, 2H), 3.69-3.65 (m, 2H). 
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ethoxy)-ethoxy]-phenoxymethyl}-benzoate (2.02 g, 2.75 mmol, 1.0 equiv.), was stirred in 
dichloromethane (40 mL). Tosyl chloride (0.58 g, 3.00 mmol, 1.1 equiv.) and triethylamine (0.383 
mL, 2.75 mmol, 1.0 equiv.) were added and the reaction mixture was stirred at room temperature for 
20 h. The crude product was collected via evaporation of the solvent and the residue was purified by 
column chromatography (ethyl acetate/hexane (1:1) with 1% triethylamine). Triisopropylsilyl-4-(4-
[3-(fluoro-benzyl)-2,4-dioxo-thiazolidin-5ylidenemethyl]-2-{2-[2-(toluene-4-sulfonyloxy)-ethoxy]-
ethoxy}-phenoxymethyl)-benzoate (1.20 g, 1.4 mmol, 50%) was collected as a waxy yellow solid. 
δH (400 MHz CDCl3): 8.03 (d, J 8, 2H), 7.77 (s, 1H), 7.74 (d, J 8.0, 2H), 7.45 (d, J 8.0, 2H), 7.40-
7.37 (m, 2H), 7.25 (d, J 8.0, 2H), 7.02-6.96 (m, 4H), 6.90 (d, J 8.0, 1H), 5.21 (s, 2H), 4.83 (s, 2H), 
4.14-4.06 (m, 4H), 3.82 (t, J 6.0, 2H), 3.76-3.73 (m, 2H), 2.36 (s, 3H), 1.39 (q, J 6.0, 3H), 1.11 (d, J 
8.0, 18H).  
δC (100 MHz CDCl3): 167.8, 166.2, 165.9, 162.8 (d 1JCF 250), 150.8, 149.3, 146.8, 144.8, 141.6, 
134.0, 133.2,131.4, 131.2, 131.2, 131.0, 130.9, 130.6, 130.3, 129.8, 128.0, 127.1, 126.9, 126.9, 125.2, 
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2.1.5.24 Synthesis of 4-(4-[3-(4-Fluoro-benzyl)-2,4-dioxo-thiazolidin-5-ylidenemethyl]-2-
{2-[2-(3,4,5-tris-benzyloxy-6-methoxy-tetrahydro-pyran-2-ylmethoxy)-ethoxy]-
ethoxy}-phenoxymethyl)-benzoic acid (62) 
 
Methyl-2,3,4-tri-o-benzyl-α-D-glucopyranoside (0.100 g, 0.22 mmol, 1.1 equiv.) was stirred in 
anhydrous DMF (5 mL) and cooled to 0 °C. Sodium hydride (0.040 g, 0.22 mmol, 1.1 equiv.) was 
added and the reaction mixture was allowed to warm to room temperature. After 2 h triisopropylsilyl-
4-(4-[3-(fluoro-benzyl)-2,4-dioxo-thiazolidin-5-ylidenemethyl]-2-{2-[2-(toluene-4-sulfonyloxy)-
ethoxy]-ethoxy}-phenoxymethyl)-benzoate (0.19 g, 0.215 mmol, 1.0 equiv.) was added and the 
reaction mixture was stirred for 6 h. The reaction was quenched with NH4Cl (sat.) (0.5 mL) and the 
solvent was removed via evaporation to yield a brown oil. The crude product was dissolved in 
dichloromethane (5 mL), washed with NaHCO3 (3x 5 mL), brine (3x 5 mL), the organic layer was 
collected and the solvent was removed via rotary evaporation. The crude product was purified by 
column chromatography (methanol/dichloromethane (1:20)). 4-(4-[3-(4-Fluoro-benzyl)-2,4-dioxo-
thiazolidin-5-ylidenemethyl]-2-{2-[2-(3,4,5-tris-benzyloxy-6-methoxy-tetrahydro-pyran-2-
ylmethoxy)-ethoxy]-ethoxy}-phenoxymethyl)-benzoic acid (0.100 g, 0.09 mmol, 46%) was 
collected as a colourless oil. 
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δH (400 MHz CDCl3): 9.24 (s, 1H), 8.06 (d, J 8.3, 2H), 7.96 (s, 1H), 7.48 (d, J 8.3, 2H),7.32-7.18 (m, 
18H), 6.82 (d, J 8.3, 1H), 6.75 (d, J 8.3, 1H), 5.23 (s, 2H), 4.91 (d, 1H), 4.78 (d, 1H), 4.75-4.72 (m, 
2H), 4.61-4.45 (m, 6H), 4.40 (d, J 6.0, 1H), 4.29 (d, J 6.0, 1H), 3.97-3.94 (m, 1H), 3.88-3.83 (m, 
1H), 3.49-3.47 (m, 3H), 3.31 (s, 3H), 2.86-2.83 (m, 3H). 
δC (100 MHz CDCl3): 167.1, 150.5, 148.4, 146.3, 142.7, 138.7, 138.2, 138.0, 130.6, 128.6, 128.5, 
128.4, 128.2, 128.2, 128.1, 128.0, 128.0, 127.8, 127.7, 127.0, 122.1, 117.3, 113.2, 98.1, 82.2, 80.2, 
78.0, 77.4, 76.8, 76.0, 75.2, 73.5, 70.3, 70.2, 70.4, 69.2, 68.9, 65.9, 64.5, 55.3, 53.5, 36.4, 29.8, 15.3. 
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2.1.5.25 Synthesis of conjugate 4 
 
Icodextrin (0.325 g, approx. 0.016 mmol) was suspended in DMAc (10 mL) and heated to 100 °C 
with stirring until dissolved. The solution was then cooled to room temperature and sodium hydride 
(0.036 g, 0.89 mmol) was added and stirred under N2 for 2 h. Triisopropylsilyl-4-(4-[3-(fluoro-
benzyl)-2,4-dioxo-thiazolidin-5-ylidenemethyl]-2-{2-[2-(toluene-4-sulfonyloxy)-ethoxy]-ethoxy}-
phenoxymethyl)-benzoate (0.784 g, 0.89 mmol) was dissolved in DMAc (1 mL) and added to the 
reaction mixture dropwise. The reaction was monitored by TLC (hexane/ethyl acetate (4:2)) and 
stirred at room temperature for 20 h. The reaction mixture was transferred into a dialysis membrane 
and dialysed against methanol (1 L) being changed 3 times per day for 3 days to yield conjugate 4 
(0. 504 g, 42%). 
See section 4.2.7 for characterisation. 
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2.1.5.26 Synthesis of conjugate 5 
 
Icodextrin (0.25 g, approx. 0.016 mmol) was suspended in DMAc (5 mL) and heated to 100 °C with 
stirring until dissolved. The solution was then cooled to room temperature and sodium hydride (0.040 
g, 1 mmol) was added and stirred under N2 for 2 h. Triisopropylsilyl-4-(4-[3-(fluoro-benzyl)-2,4-
dioxo-thiazolidin-5-ylidenemethyl]-2-{2-[2-(toluene-4-sulfonyloxy)-ethoxy]-ethoxy}-
phenoxymethyl)-benzoate (0.220 g, 0.25 mmol) was dissolved in DMAc (1 mL) and added to the 
reaction mixture dropwise. The reaction was monitored by TLC (hexane/ethyl acetate (4:2)) and was 
stirred at room temp for 4 h. the reaction mixture was transferred into a dialysis membrane and 
dialysed against methanol (1 L) being changed 3 times per day for 3 days to yield conjugate 4 (0. 
407 g, 56%). 
νmax/cm-1 (solid): 3362, 2361, 2342, 1557, 1155. 
 
See section 4.2.7 for characterisation. 
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2.1.5.27 Synthesis conjugate 6 
 
Icodextrin (0.25 g, approx. 0.016 mmol) was suspended in DMAc (5 mL) and heated to 100 °C with 
stirring until dissolved. The solution was then cooled to room temperature and sodium hydride (0.040 
g, 1.00 mmol) was added and stirred under N2 for 4 h. Triisopropylsilyl-4-(4-[3-(fluoro-benzyl)-2,4-
dioxo-thiazolidin-5-ylidenemethyl]-2-{2-[2-(toluene-4-sulfonyloxy)-ethoxy]-ethoxy}-
phenoxymethyl)-benzoate (0.449 g, 0.57 mmol) was dissolved in DMAc (1 mL) and added to the 
reaction mixture dropwise. The reaction was monitored by TLC (hexane/ethyl acetate (4:2)) and 
stirred at room temperature for 4 h. The reaction mixture was transferred into a dialysis membrane 
and dialysed against methanol (1 L) being changed 3 times per day for 3 days to yield conjugate 6 
(0. 401 g, 43%). 
νmax/cm-1 (solid): 3362, 1507, 1146, 2361, 2342, 1078, 1019. 
The 1H NMR spectrum is shown in section 4.2.6.3. 
 
 
  Chapter 2 
   83 
 
2.1.6 Degree of substitution 
The degree of substitution of icodextrin-drug conjugates was determined by measuring the inherent 
fluorescence of the inhibitor molecule, (Ex = 360 nm, Em = 440 nm) using a Synergy 2 microplate 
reader (BioTek instruments, Inc.). A calibration curve for fluorescence against concentration was 
generated by dissolving a known concentration of the molecule in DMSO and creating a dilution 
series with PBS (pH 7.4). Fluorescence was then measured for the test compound and compared to 
the standard curve and the inhibitor. The amount of inhibitor present could then be determined as a 
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2.2 Biological evaluation 
2.2.1 Cell lines and culture 
3E3 and 3V5 cell lines were obtained from CRUK, Clare Hall, South Mimms. 3E3 ovarian cancer 
cells have previously been engineered from Ovcar-3 cells to express autotaxin178 whereas 3V5 cells 
were transfected with the empty vector. 3E3 and 3V5 cells were maintained in either RPMI growth 
medium (RPMI 1640, Lonza) supplemented with 10% fetal bovine serum (FBS, Lonza), 
Penicillin/Streptomycin (50 µg/mL, Lonza) and glutamine (2 mM, Lonza). Caco2 cells were 
obtained from Sigma Aldrich and maintained in Eagle’s Minimum Essential medium (EMEM, 
Lonza) supplemented with 10% fetal bovine serum (FBS, Lonza), Penicillin/Streptomycin (50 U/mL, 
Lonza) and glutamine (2 mM, Lonza), HEPES (1% v/v, Lonza), MEM non-essential amino acid 
solution (1% v/v, Sigma). Cells were grown at 37 °C in 5% CO2 in a NAPCO heater jacket incubator 
(Precision Scientific).  
2.2.2 Cell passage and counting 
To passage cells, the growth medium was removed and cells were washed with phosphate buffered 
saline (PBS, 2 mL, Lonza). To detach the cells, trypsin (1 mL, Lonza) was added and the cells were 
incubated at 37 °C for up to 10 min until cells were detached. The trypsin was quenched with 
appropriate growth medium (1 mL) and the cells were transferred into a sterile 15 mL tube (Sarstedt). 
The cells were centrifuged (150 g, 3 min, room temperature, Thermo Scientific Heraeus Megafuge 
8), the supernatant was aspirated and the cell pellet re-suspended in the appropriate growth medium 
before adding to a new flask containing fresh medium (sterile T25 or T75 cell culture flask, Sarstedt). 
When the cells were prepared for an experiment the re-suspended cells were counted using a 
Neubauer haemocytometer (Reichert Brightline), and the appropriate amount of cells were seeded 
into cell culture plates (96-well, 6-well, Sarstedt). 
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2.2.3 Cell freezing and recovery 
Cells of a low passage number, 50% confluent in a T75 cell culture flask were detached from the 
plastic with trypsin (2 mL) and the trypsin was quenched with growth medium (2 mL). The cells 
were collected by centrifugation (150 g, 3 min, room temperature), the supernatant was aspirated and 
the cells re-suspended in 1 mL freezing medium (growth medium supplemented with FBS (10%) 
and DMSO (8%, (Sigma Aldrich)). Re-suspended cells were then dispensed into cryovials (0.2 mL, 
Triple Red) and stored in liquid nitrogen after an initial 24 h at -80 °C in an ultralow freezer (Nuaire).  
For cell recovery from liquid nitrogen storage, cells were quickly thawed in a water bath (37 °C, 
Grant instruments), suspended in growth medium (5 mL), collected by centrifugation (150 g, 3 min, 
room temperature), the medium was aspirated and the cells were suspended in growth media (1 mL) 
before adding to a T25 cell culture flask containing growth medium (7 mL). The cells were then 
maintained as described in section 2.2.2. 
2.2.4 Cell proliferation assay 
Cells were prepared as described in section 2.2.2. 5,000 cells were seeded per well in 80 µL growth 
medium in a 96-well plate and incubated for 24 h. The growth medium was removed and the cells 
were washed with PBS (100 µL). Serum free growth medium containing the desired drug treatment 
(final volume 100 µL) was then added to the cells which were incubated for 16-72 h. The relative 
cell number was determined by sulforhodamine B (SRB, Sigma Aldrich) assay. The growth medium 
was removed from the cells and 100 µL trichloroacetic acid (10%, TCA, Sigma Aldrich) and the 
cells were incubated on ice for 30 min. The TCA was removed and the plate washed 3 times by 
immersion in water and dried at room temperature. Once dry, SRB (0.4% in 1% acetic acid, Sigma 
Aldrich) was added to stain the cells (30 min, room temperature). Excess SRB was removed by 
washing with acetic acid ((1%) 3 x 100 µL) and the plate was dried at room temperature. The bound 
stain was solubilized (100 µL, 10 mM Tris (pH 10, Sigma Aldrich)) and absorbance was measured 
using a Synergy 2 microplate reader (BioTek instruments, Inc.) (λ = 570 nm). 
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2.2.5 Protein extraction and quantification 
Cells were lysed in (100 µl per 10 cm2) radio-immunoprecipitation buffer (RIPA) containing Hepes 
(20 mM, CalbioChem), sodium chloride (150 mM, Sigma-Aldrich), ethylene-diamino-tetraacetic 
acid (2 mM EDTA, Sigma Aldrich), sodium deoxycholate (0.5%, Sigma Aldrich), NP40 (1%, Sigma 
Aldrich), Leupeptin (120 µM, Sigma Aldrich), Pepstatin (10 µM, Sigma Aldrich) and 
phenylmethanesulfonyl fluoride (PMSF, 1 mM, Sigma Aldrich). The cell lysate was cleared by 
centrifugation (2500 g, 4 °C, 10 min) and the supernatant was transferred into new microcentrifuge 
tubes and stored at -80°C. 
Protein concentration was determined using a Bicinchonic acid (BCA) assay. Bovine serum albumin 
(BSA, Sigma Aldrich) solution was prepared containing 0.1, 0.25, 0.5, 0.75, 1.0, 1.5 and 2.0 mg/mL 
BSA to create a standard curve for the assay. BCA reagent was prepared by adding 1:50 copper (II) 
sulphate solution (Sigma Aldrich) to Bicinchonic acid solution (Sigma Aldrich). The samples or 
standards (10 µL of sample appropriately diluted with RIPA buffer or BSA standards (10 µL)) were 
treated with 100 µL of the BCA reagent. After incubation (37°C, 30 min), absorbance was measured 
using a Synergy 2 multimode microplate reader (BioTek instruments, Inc.) (λ=570 nm). The protein 
concentration of the lysate was calculated from a calibration curve constructed using the protein 
standard by linear regression. 
2.2.6 Western blotting 
The cell lysates were prepared as described above and diluted 1:4 with NuSep sample buffer 
((Invitrogen), containing 5% v/v 2-mercaptoethanol, (Sigma Aldrich)) and mixed. The samples were 
denatured by heating (15 min, 70 °C) and collected by brief centrifugation (10,000 g, 30 secs, room 
temperature). The appropriate volume of sample (10 µg protein) was loaded on a 4-20% Tris-Glycine 
gel (NuSep) and run in an electrophoresis module (XCell SureLock Mini Cell, Invitrogen), at 75 V 
for 1 h 15 min in hepes running buffer (100 mM hepes, 100 mM Tris and 1% sodium dodecyl sulphate 
(SDS, Sigma Aldrich), a PageRuler protein Ladder (Thermo Scientific) was loaded onto each gel to 
estimate protein size. Protein was then transferred to polyvinylidene difluoride (PVDF) membranes 
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(GE healthcare Life Sciences) at 25 V for 2 h in NuSep transfer buffer (25 mM Tris HCl (pH 7.5, 
Sigma Aldrich), 200 mM glycine (Sigma Aldrich), 0.075% SDS and 10% methanol (Sigma 
Aldrich)). The membrane was blocked using Tris-buffered saline with Tween (TBST, (50 mM Tris 
HCl, 150 mM NaCl and 1% Tween) containing 5% w/v low-fat dry milk powder) for 1 h at room 
temperature with shaking (Stuart Scientific Platform Shaker STR6). The blocking solution was 
removed and the primary antibody, diluted to the appropriate concentration in TBST containing 5% 
w/v low-fat dry milk powder (see Table 2.1), was added and incubated for 16 h at 5 °C with shaking. 
The membrane was washed (TBST, 3x 5 min) and the secondary antibody, diluted to the appropriate 
concentration in TBST containing 5% w/v low-fat dry milk powder (see Table 2.1), was then added 
and the membrane was incubated for 1 h at room temperature with shaking. The membrane was 
washed (TBST 5x 5 min) and then incubated with the chemiluminescent substrate (uptilight HS HRP, 
Uptima) and visualised using FluorChem M imager (Protein Simple). 
Antibody Dilution factor Source 
GAPDH 1:5000 Millipore 
Anti-mouse 1:2000 Cell Signaling Technology 
Anti-rabbit 1:2000 Cell Signaling Technology 
Autotaxin 1:500 Santa Cruz Biotechnology 
Table 2.1: Antibodies used for protein immunodection. 
2.2.7 Purification of autotaxin 
In order to efficiently test compounds for activity against autotaxin, a suitable assay was required. 
The cell line 3E3 has previously been derived from OVCAR-3 to ectopically express autotaxin.178 
And this was used as one source of autotaxin. The cell line 3V5 which had been transfected with the 
empty vector was used as a control.  
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Purification of autotaxin from 3E3 cell supernatant was achieved with Concanavalin A (Con A) 
affinity chromatography. Con A is a protein which specifically binds to carbohydrate molecules, 
allowing the separation of glycoproteins. Autotaxin is a glycoprotein and so is retained by the Con 
A on the column. Autotaxin can be eluted with α-methylmannoside which has a high affinity for Con 
A.  
To purify autotaxin, 3E3 cells were seeded in a T75 flask and when 50% confluent the medium was 
replaced with serum free medium (10 mL) and incubated overnight. The next day the supernatant 
was collected and cleared by centrifugation (2600 g, 4 °C, 15 min). The supernatant was loaded onto 
a HiTrap Con A sepharose column (GE healthcare) and recirculated for 1 h at 4 °C. 20 mL Tris 
buffered saline (TBS; 20 mM Tris, 0.5 M NaCl, pH 7.4) was passed through the column and autotaxin 
was eluted with 2 mL α-methylmannoside (0.5 M, (Sigma Aldrich)) in TBS at 4 °C for 24 h. The 
next day, a 2 mL fraction was collected, and dialysed against TBS (1 L) with a dialysis membrane 
(MWCO 8 KDa, Biodesign) at 4 °C. The retentate was then used directly as the source of autotaxin 
for the bis-pNPP assay. 
2.2.8 Bis-pNPP Assay 
In order to quantify autotaxin activity the previously described bis-pNPP assay was employed.203 
Bis-para-nitrophenylphosphate (bis-pNPP) also contains a phosphodiester moiety and so can be 
considered an analogue of the autotaxin substrate LPC. Autotaxin hydrolyses bis-pNPP to form the 
chromophore p-nitrophenol, whose concentration is then measured by absorbance (λ = 405 nm), 
(Figure 2.1).  
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Figure 2.1: Bis-pNPP assay reaction; Autotaxin hydrolyses bis-pNPP to the chromophore p-
nitrophenol. 
 
In a 96-well plate, 20 µL 5X reaction buffer (250 mM Tris HCl, 25 mM KCl, 5 mM CaCl2, 5 mM 
MgCl2.6H2O, NaCl 700 mM, pH 7.8), 10 µL bis-pNPP (1 mM prepared in dH2O), and 20 µL of the 
test compound were added to each well, followed by the addition of recombinant autotaxin (50 µL 
per well), purified as described in section 2.2.7. After incubation (37°C, 4 h) absorbance was 
measured using a Synergy 2 multimode microplate reader (BioTek instruments, Inc.) (λ = 405 nm). 
Data was analysed using GraphPad Prism software (GraphPad Software, Inc.). Non-linear regression 
was used to fit a 4 parameter (Hill equation) sigmoidal dose-response curve to determine the IC50. 
2.2.9 FS-3 assay 
Inhibition of autotaxin activity was also evaluated using a commercially available assay to measure 
the hydrolysis of FS-3, a fluorescence-quenched analogue of LPC (Echelon Biosciences, Inc. Salt 
Lake City, UT), (Figure 2.2).246  
 
Figure 2.2: FS-3 assay reaction; Autotaxin hydrolyses FS-3 which releases the fluorescent molecule 
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Reaction buffer containing autotaxin (80 µL per well, made as specified in the autotaxin inhibition 
kit protocol) and sample compounds (10 μL per well) appropriately diluted, were mixed in a white 
96 well plate using a rocker for 1 min and then pre-incubated for 10 min at 37 °C. Subsequently, FS-
3 substrate ((10 μL per well), 10 µM stock solution in dH2O) was added and mixed for 3 minutes on 
a rocker. The final concentration of autotaxin and FS-3 substrate per well was 2 nM and 1 µM, 
respectively. The Synergy 2 multimode microplate reader (BioTek instruments, Inc.) was used to 
maintain the samples (Ex = 485 nm, Em = 528 nm) at 37 °C and fluorescence was measured every 
two minutes for 30 min. The rate of hydrolysis was determined using linear regression for the data 
from the period over which the fluorescence increased linearly with time. The reaction rates for each 
sample were analysed using GraphPad Prism software. Non-linear regression was used to fit a 4 
parameter (Hill equation) sigmoidal dose-response to determine the IC50. A control using BrP-LPA 
standards was performed with each screen. A secondary screen was performed to ensure the inhibitor 
activity identified in the initial screen was not due to interference with the fluorescence of hydrolysed 
FS-3. In the second screen the fluorescence of fluorescein was measured in the presence of the 
compounds. Fluorescein buffer ((90 µL per well) made as specified in autotaxin inhibition kit 
protocol) and either dH2O, BrP-LPA or sample compound (10 µL per well) were added per well and 
the plate was incubated at 37°C for 10 mins. Fluorescence was then measured (Ex = 485 nm, Em = 
528 nm). The data was then averaged and the background fluorescence was subtracted.  The 
percentage inhibition of fluorescein fluorescence was calculated using the following equation:  
𝑃𝑒𝑟𝑐𝑒𝑛𝑡 𝑖𝑛ℎ𝑖𝑏𝑖𝑡𝑖𝑜𝑛 𝑆𝑎𝑚𝑝𝑙𝑒
=  [1 − ((
(𝐶1 +  𝐶2)
2
) – (
(𝐴1 +  𝐴2)
2
)) / ((
(𝐵1 +  𝐵2)
2
) – (
(𝐴1 +  𝐴2)
2
))]
∗  100 
Equation 2.1: Percentage sample inhibition; Where A represents the background fluorescence in the 
absence of inhibitor and fluorescein, B represents fluorescence in the absence of the inhibitor and C 
represents fluorescent in the presence of the inhibitor; “1” and “2” represent duplicate readings. 
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2.2.10 Wound healing assay 
Cells were plated at a density of 200,000 cells/mL in 6-well plates using growth medium. When the 
cells had reached confluence the medium was removed and a P200 plastic pipette tip was drawn 
across the centre of the plate to produce a clean wound area. The wells were washed gently twice 
with PBS to remove any debris and remaining FBS. The medium was then replaced with serum free 
medium supplemented with lysophosphatidyl choline (0.5 μM), and the compound to be tested. 
DMSO was added to each well as necessary to normalise the DMSO concentration to 0.5%. The cells 
were viewed and photographed by phase contrast microscopy immediately after wounding. After 
incubation at 37 °C for 16 h the cells were stained and fixed with methylene blue (200 μL, 30 min, 
room temperature, (Sigma Aldrich); 0.5% w/v in 50% H2O, 50% EtOH) and photographed by phase 
contrast microscopy. The wound closure was measured using imageJ software. A calibration image 
was used to determine distance (µm). The area of a section of the wound pre- and post-migration was 
then measured and the percentage wound closure was calculated as; 
𝑃𝑒𝑟𝑐𝑒𝑛𝑡𝑎𝑔𝑒 𝑤𝑜𝑢𝑛𝑑 𝑐𝑙𝑜𝑠𝑢𝑟𝑒 = (
(𝑎𝑏 − 𝑎𝑎)
𝑎𝑏
) ∗ 100 
Equation 2.2: Calculation of percentage wound closure; Where ab represents the area of the wound 
immediately after wounding and aa represents the area of the wound after migration.  
2.2.11 Caspase 3/7 activity assay 
3E3 and 3V5 cells were plated at a density of 5,000 cells per well in a 96-well plate in 80 µL of 
growth medium and incubated for 24 h.  The medium was removed and the cells were washed with 
PBS. 100 μL of serum free medium supplemented with LPC (0.5 μM, Sigma Aldrich) and the 
indicated combinations of carboplatin (300 µM), and compound to be tested were then added and the 
cells were incubated for 18 h. The cells were centrifuged (1000 g, 2 min), the supernatant was 
removed and 30 μL PBS and 30 µL of Caspase-Glo 3/7 reagent (Promega) were added and cells were 
incubated for 30 minutes at room temperature in the dark. Luminescence was then measured using 
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Synergy 2 multimode microplate reader. To normalise for cell number, identical samples were 
prepared in parallel and stained with SRB as described in section 2.2.4.247  
2.2.12 Parallel Artificial Membrane Permeation Assay (PAMPA) 
MultiScreen Filter Plates (Millipore) were used for PAMPA. Test compounds were dissolved in 
DMSO and diluted with PBS (pH 7.4) to a final 2% DMSO concentration. Propranolol (highly 
permeable) and furosemide (poorly permeable) were used as a controls for permeability alongside 
each assay; solutions of these (100 µM) were made in PBS (containing 2% DMSO). The limit of 
quantification (LOQ) by UV/Vis spectroscopy and fluorescence spectroscopy of each compound was 
determined before each experiment. A 2-fold serial dilution for each compound in PBS (2% DSMO) 
starting at 100 µM was performed and the absorption or fluorescence measured and a peak maximum 
was plotted for each compound against concentration. The LOQ was defined as the concentration of 
compound whose absorbance/emission background + 5 S.D.  A 1% solution (w/v) of Lecithin (Sigma 
Aldrich) in dodecane (Sigma Aldrich) was prepared and sonicated for 30 mins until complete 
dissolution. 5 µL per well of the lecithin mixture was pipetted onto each well of the donor plate 
(MAIPN4510, Millipore), directly followed by the addition of 150 µL of the test compound solution. 
The donor plate top compartment was then placed in the PTFE acceptor plate (MSSACCEPTOR, 
Millipore), each well of the acceptor plate contained 300 µL of PBS (2% DMSO). The plates were 
incubated in a moist environment, to avoid evaporation, at room temperature for 48 h. After 
incubation, UV/Vis absorption from 250 nm to 500 nm or the fluorescence emission (Ex = 485 nm, 
Em = 528 nm), was measured using 100 µL per well of the donor solution and 100 µL per well of 
the acceptor solution. Compound solutions were also made up at the theoretical equilibrium 
concentration and the fluorescence emission or UV/Vis absorption was measured sing 100 µL per 
compound. The analysis was performed in triplicate. The following equation was used to calculate 
Log Pe. 
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Equation 2.3: Calculation of Log Pe; Where VD is the volume of the donor solution in cm3 and VA 
is the volume of the acceptor solution in cm3. Area is the Surface area of the membrane in cm2 and 
time is the length of incubation in seconds. 
2.2.13 Caco-2 permeability 
Caco-2 cells were maintained as described in section 2.2.2. 100,000 cell/cm2 were plated in 
transwells (surface area 0.33 cm2, 0.4 µm pore size, Greiner Bio-One) which were placed in 24-well 
plates containing 500 µL medium per well and cultures for 28 days changing the medium every three 
days. On the day of the experiment the Trans Epithelial Electrical Resistance (TEER) was measured 
using a Millicell® ERS-2 Voltohmmeter (MerkMilipore) a TEER value threshold of 200 Ω.cm2 was 
used to confirm an intact monolayer. Medium was changed to serum free medium in both the apical 
and basolateral side. After 3 h, the medium was removed, the cells were washed twice with Hank’s 
Balance Salt Solution (HBSS, Lonza). 500 µL of HBSS was placed in the basolateral side and 500 
µL of HBSS containing the test compound was added to the apical side. 200 µL was immediately 
removed from the apical side for a T0 reading. The cells were incubated for 2 h at 37 °C, after which 
the supernatant was collected from both the apical and basolateral side. The fluorescence (Ex. = 360 
nm, Em. = 440 nm) of 100 µL of each sample was measured using a Synergy 2 multimode microplate 
reader. The concentration of the compounds was calculated from a standard curve of fluorescence 




) . 𝑆𝐴. [𝑑𝑟𝑢𝑔] 
Equation 2.4: Calculation of Papp; Where DQ is the molar concentration Dt is the time in seconds, 
SA is the surface area of the membrane in cm2.  
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2.2.14 Solubility 
2.2.14.1 Kinetic solubility  
The compound was diluted in Tris HCl buffer from a 1 mM stock in DMSO. The solution was shaken 
on a rocker for 2 h to dissolve followed by centrifugation at 10, 000 g for 20 min. The absorbance 
was measure using a NanoDrop 2000 spectrophotometer (ThermoScientific). The analysis was 
performed in duplicate. The concentration of the sample was calculated from a standard absorbance 
curve of the test compound in Tris buffer containing DMSO, utilising the beer-lambert law. 
𝐴 = 𝜀𝑐𝑙 
Equation 2.5: Beer-Lambert law. 
 
2.2.14.2 Thermodynamic solubility 
The miniaturised shake flask method was used to measure the thermodynamic solubility of the 
compounds. An excess of the compound to be tested was placed into a 1.5 mL microcentrifuge tube 
and to this 200 µL of PBS was added. Compounds were shaken for 24 h at room temperature in order 
to achieve equilibrium. After equilibration, the tubes were centrifuged at 10000 g for 20 min. The 
fluorescence, (Ex. = 360 nm, Em. = 440 nm) of 100 µL of the supernatant was measured using a 
Synergy 2 multimode microplate reader. The concentration of the solution was determined according 
to a calibration curve of test compound. The calibration curve was generated by linear regression 
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3.1 Introduction 
As previously discussed, autotaxin is the main enzyme which catalyses the production of LPA, and 
consequently stimulates cell migration, proliferation and survival in many cancer types including 
ovarian cancer. There are currently many autotaxin inhibitors in development due to autotaxin’s 
emerging role in the pathogenesis of cancer and other diseases.  Some of the first autotaxin inhibitors 
were analogues of LPA, based on observed product inhibition.203 Analogues of LPA which function 
as competitive autotaxin inhibitors are lipophilic due to the extended alkyl chain and therefore have 
poor bioavailability and poor solubility; they may also be susceptible to degradation by endogenous 
hydrolytic pathways. One of the most potent LPA analogues described to date is S32826, 15, as 
shown in Figure 3.1.83 This compound exhibited nanomolar inhibition of autotaxin in vitro and 
reduced the amount of LPA present in plasma and ascites ex vivo.83 However, when tested in vivo no 
inhibition of LPA production in plasma was observed a few minutes after administration.83 This may 
be due to the poor pharmacokinetic profile associated with LPA analogues. 
 
Figure 3.1: Structure of S32826. 
 Dendrimers are highly branched macromolecules of low poly-dispersity with a multifunctional 
central core molecule, and branches of various lengths, as shown in Figure 3.2.240, 248 In general 
dendrimers are spherical with small molecular size but high molecular weights. The multiple surface 
groups of dendrimers offer the opportunity to covalently attach multiple drug molecules per 
dendrimer.249-250 The larger hydrodynamic volume of polymers has the potential to increase the half-
15 
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life of a drug molecule in plasma and ascites, increasing the probability of tumour accumulation.251-
252 A larger hydrodynamic volume leads to reduced renal clearing and can also provide a shielding 
effect from chemical or enzymatic degradation of the drug. Macromolecules such as dendrimers can 
directly target the tumour via the EPR effect; this occurs due to the increased capillary permeability 
observed in tumours.243 Furthermore, the multiple surface groups of dendrimers also allow the 
possibility of attaching targeting agents such as folic acid which has a high affinity for the folate 
receptor that is overexpressed in many epithelial cancers including ovarian cancer.253 The 
conjugation of drug molecules to dendrimers can also increase their metabolic stability.240, 254 An 
example of improved pharmacokinetics due to conjugation to a dendrimer is a PAMAM-cisplatin 
conjugate. Cisplatin is poorly soluble in aqueous solution and associated with significant toxicity. 
Upon conjugation, increased solubility and a decrease in systemic toxicity was observed.255  
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Figure 3.2: Structure of G3 PAMAM dendrimer. The Core is shown in red and successive 
generations are shown in blue, green and orange, respectively. 
Attaching the lipophilic autotaxin inhibitor S32826 15 to a G3 PAMAM dendrimer has the potential 
to prolong the retention of the inhibitor in circulation and in the peritoneal cavity. When designing 
the dendrimer-S32826 conjugate the crystal structure of autotaxin had not yet been determined. It 
was theorised that the alkyl chain of LPC would be buried in the plasma membrane and therefore be 
free from the enzyme. It was also hypothesised that the alkyl chain of S32826 would behave similarly 
to the alkyl chain of LPC leaving the alkyl chain free from the active site and so a suitable place to 
attach to the dendrimer.  
In this chapter the conjugation of S32826 to a dendrimer was evaluated. However, this necessitated 
confirmation that conjugation of the autotaxin inhibitor to a dendrimer would not impair its ability 
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to inhibit autotaxin.  Firstly, the synthesis of a novel drug conjugate of the potent autotaxin inhibitor, 
S32826 with a 3rd generation (G3) PAMAM dendrimer is described. Then the conjugate’s ability to 
inhibit autotaxin in vitro, was assessed using two autotaxin inhibitor assays. Two assays were used 
to confirm the conjugate retained biological activity. The role of autotaxin and LPA in cell migration 
is well documented, with inhibition of autotaxin previously shown to decrease migration. The 
conjugate was assessed for activity in an ovarian cancer cell migration model. Due to autotaxin 
previously being shown to delay apoptosis induced by carboplatin;178 the conjugate’s ability to 
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3.2 Materials and methods 
3.2.1 Solubility 
Solubility was measured as described in section 2.2.14.1 and adapted as follows. A solution of 
conjugate 1 in DMSO (1 mM) was diluted in Tris HCl buffer increasing the concentration of the 
conjugate until the conjugate began to precipitate. The saturated solution was shaken on a rocker for 
2 h to equilibrate followed by centrifugation at 10000 g for 20 min. Absorbance (λ 277) of the 
solution was measured. The concentration of the solution was determined using a standard curve of 
absorbance.  
3.2.2 FS-3 assay 
Compounds were tested for autotaxin inhibition using the FS-3 assay as described in section 2.2.11 
and adapted as follows. Conjugate 1 (10 μM) was prepared as a stock solution in DMSO, and the G3 
PAMAM dendrimer (1 mM) in Tris HCl buffer. A range of concentrations were prepared with a 3-
fold serial dilution in Tris buffer. 80 μL reaction buffer, containing autotaxin, and 10 μL of standard, 
compound or vehicle were pre-incubated for 10 min at 37 °C. 10 μL FS-3 substrate was added and 
fluorescence was measured at 37 °C every two minutes for 30 min. 
3.2.3 Bis-pNPP Assay 
Compounds were further tested for their ability to inhibit autotaxin in the bis-pNPP assay as 
described in section 2.2.10 and adapted as follows. S32826 (1 mM), S32826-acetamide (10 µM) and 
conjugate 1 (10 μM) were prepared as a stock solution in DMSO, and the G3 PAMAM dendrimer (1 
mM) in Tris HCl buffer. S32826-acetamide, conjugate 1 and G3 PAMAM dendrimer were diluted 
2-fold in Tris HCl buffer to yield a range of concentrations. 5X Bis-pNPP assay reaction buffer 20 
µL, 10 μL bis-pNPP (1 mM) and 20 μL of compound dilution or solvent was added to each well, 
followed by the addition of 50 μL autotaxin solution. Absorbance was measured after 4 h incubation.  
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3.2.4 Wound healing assay 
The ability of the compound to inhibit migration was tested in the wound healing assay as described 
in section 2.2.12 and adapted as follows. Serum free growth medium was supplemented with LPC 
(0.5 μM), DMSO (normalised to 0.5%) and either no inhibitor, S32826 (30 nM) or conjugate 1 (1.3 
μM or 2.6 μM) and 1 mL of the medium mixture was added per well. The percentage wound closure 
was measured after 16 h.  
3.2.5 Caspase 3/7 activity assay 
The ability of the compounds to potentiate apoptosis induced by carboplatin was tested using the 
Caspase 3/7 assay as described in section 2.2.13 and adapted as follows. The cells were incubated 
with serum free medium supplemented with LPC (0.5 μM) and the indicated combinations of 
carboplatin (300 µM), S32826 (300 nM) or Conjugate 1 (10 µM) for 18 h. After 30 min incubation 
with the Caspase-Glo 3/7 reagent, the fluorescence was measured. 
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3.3 Results 
3.3.1 Synthesis of Conjugate 1 
To couple S32826 to the PAMAM dendrimer, a reactive moiety was required. The commercially 
available [4-(12-amino-dodecanoylamino) benzyl] phosphonic acid diethyl ester 30 was converted 
to the intermediate acrylamide phosphonate 31 via a nucleophilic addition-elimination with acryloyl 
chloride. This reaction was performed at 0 °C with triethylamine in dichloromethane to yield the 
desired intermediate 31 (43%), as shown in Scheme 3.1. 
 
Scheme 3.1: Synthesis of S32826-acrylamide. 
Intermediate 31 was then conjugated to the G3 PAMAM dendrimer through a conjugate addition 
reaction. The intermediate (128 equiv.) and G3 PAMAM dendrimer were dissolved in ethanol and 
heated to 100°C in a sealed reaction tube for 48 h. The reaction mixture was then dialysed in methanol 
30 
31 
Acryloyl chloride,  
TEA, CH2Cl2, 
0 °C, 4 h 
43% 
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to remove any unreacted acrylamide, yielding the desired dendrimer S32826-ester conjugate 32 
(30%) based on the dendrimer used, as shown in Scheme 3.2. 
 
Scheme 3.2: Conjugation to the dendrimer. 
Removal of the ethyl protecting groups to reveal the phosphonic acid necessary for binding to the 
zinc ions in the catalytic site of autotaxin was achieved by treating compound 31 with an excess of 
trimethylsilyl iodide in methanol to yield the final dendrimer-autotaxin inhibitor conjugate, conjugate 





100 °C, 48 h          
30% 
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Scheme 3.3: Phosphonate deprotection of the conjugate. 
The mechanism for cleavage of phosphonate esters with TMS-I proceeds via a two-step reaction the 
lone pair of the phosphoryl oxygen attacks the partially positive silicon of TMS-I, the displaced 
halide ion then attacks one of the alkoxy groups of the phosphonate forming the trimethylsilyl 
phosphonate, the process is then repeated with the other alkoxy group. This is followed by hydrolysis 





rt, 8 h 
9% 
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Scheme 3.4: Mechanism of hydrolysis of dialkylphosphonate with trimethylsilyl iodide. 
3.3.2 Derivatisation of the terminal amine of S32826 
A further analogue of S32826 was prepared in which the terminal amine was converted to an 
acetamide moiety. This compound mimics the inhibitor coupled to the amine (in particular, lacking 
the positive charge that the free amine would endow) but lacks the steric bulk of the dendrimer. It 
provides a useful control to help understand the effect of modifying the inhibitor on the inhibitor’s 
activity. The terminal amine of [4-(12-amino-dodecanoylamino) benzyl] phosphonic acid diethyl 
ester 30 was converted to the amide with acetic anhydride, in pyridine to yield the acrylamide 
phosphonic diethyl ester 34 (85%), The resulting acetamide 34 was deprotected as before utilising 
TMS-I to yield the acetamide phosphonic acid 35 (97%), as shown in Scheme 3.5. 
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Scheme 3.5: Synthesis of S32826-acetamide. 
3.3.3 Structural analysis of Conjugate 1 
The structure of conjugate 1 was supported by 1H NMR, IR spectroscopy and elemental analysis. 
The 1H NMR spectrum showed evidence that conjugation has occurred  





pyridine, rt, 16 h 
85% 
TMS-I, CH2Cl2, 
rt, 8 h 
97% 
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Figure 3.3: 1H NMR spectrum for conjugate 1.Comparison of the 1H NMR spectrum for acrylamide 
intermediate, G3 PAMAM dendrimer and conjugate 1. 
The structure of conjugate 1 was further confirmed by IR analysis. Analysis shows the presence of a 
peak at 1709 cm-1 which may correspond to the amide formed when conjugated, not present in either 
the S32826-acrylamide or the G3 PAMAM dendrimer, as shown in Figure 3.4. 
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Figure 3.4: IR spectra of conjugate 1; Dendrimer (Bottom), S32826-acrylamide (Middle), Conjugate 
1 (Top). 
3.3.4 Determination of degree of substitution 
The success of coupling the inhibitor to the G3 PAMAM dendrimer was established by measuring 
the elemental ratio of the phosphorus (only present in the inhibitor molecule) compared to nitrogen 
in conjugate 1. The elemental analysis suggested essentially complete coupling to the 32 terminal 
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corresponds favourably to the theoretical ratio for maximum conjugation, 0.43. The elemental ratio 
of the phosphorous was also compared to carbon and hydrogen. The ratio of phosphorus to carbon 
and hydrogen also gave similar ratios to that expected of maximum conjugation, as shown in Table 
3.1. 
 Percentage (%) Ratio compared to P 
Element Theoretical Found Theoretical Found 
C 56.92 45.65 0.0834 0.0740 
H 8.47 6.14 0.207 0.550 
N 12.68 8.45 0.380 0.400 
O 17.11 - - - 
P 4.82 3.38 - - 
Table 3.1: Elemental analysis of conjugate 1; Comparison to theoretical fully substituted G3 
PAMAM dendrimer of the elemental analysis results of conjugate 1. 
3.3.5 Solubility 
The kinetic solubility of conjugate 1 was measured. Solubility was determined by measuring 
absorbance of a 2mg/mL solution of conjugate 1 in Tris HCl buffer. The concentration was calculated 
using a standard curve of absorbance versus concentration. The concentration of conjugate 1 in 
solution was found to be 91 µM. 
3.3.6 Inhibition of autotaxin activity 
The ability of conjugate 1 to inhibit autotaxin was evaluated in two autotaxin enzyme assays 
measuring hydrolysis of either FS-3 246 or bis-pNPP 203 substrates. 
3.3.6.1 FS-3 assay 
Conjugate 1 demonstrated only a moderate decrease in apparent potency after coupling to the 
dendrimer with an IC50 of 160 nM (Figure 3.5), compared to the literature value for the free 
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compound, S32826 with an IC50 of 9 nM.220 The unconjugated dendrimer had no measureable effect 
in this assay. A secondary screen was also undertaken to ensure the compounds did not interfere with 
the fluorescence of the FS-3 substrate. None of the compounds tested interfered with substrate 
fluorescence.  
 
Figure 3.5: Inhibition of autotaxin enzymatic activity by conjugate 1, tested in FS-3 assay; The 
results are expressed as a fraction (mean ±S.D. n=2) of the activity measured in the absence of the 
inhibitor. IC50 values were calculated as means of IC50s from separate experiments.  
3.3.6.2 Bis-pNPP assay 
The supernatant from 3E3 cells was used as a source of autotaxin for this assay. To confirm the level 
of expression of autotaxin the supernatant was analysed in the FS-3 autotaxin inhibitor assay for 
activity and by western blotting as described in sections 2.2.9 and 2.2.6, respectively. The 3E3 cell 
supernatant showed sufficient activity in the FS-3 assay and the western blot indicated the presence 
of autotaxin, (Figure 3.6). 
 
 
Figure 3.6: 3E3 western blot for autotaxin presence. Conjugate 1 was tested for activity using bis-
pNPP as the substrate. Autotaxin was purified from 3E3 cells as described in section 2.2.7. A 
comparable potency was measured using this substrate. Conjugate 1 exhibited an IC50 of 1.7 μM, 
 3V5      3E3 
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whereas S32826 had an IC50 of 30 nM, (Figure 3.7). The unconjugated dendrimer had no 
measurable effect on autotaxin activity in this assay. 
 
Figure 3.7: Inhibition of autotaxin activity by conjugate 1 and S32826, tested in bis-pNPP assay; 
The results are expressed as a fraction (mean ±S.D. n=3) of the activity measured in the absence of 
the inhibitor. IC50 values were calculated as means of IC50s from separate experiments. 
Furthermore, derivatisation of S32826 terminal amine group to an acetamide had no significant effect 
on autotaxin inhibition, with the compound demonstrating an IC50 of 50 nM using bis-pNPP as the 
substrate, (Figure 3.8).  
 
Figure 3.8: Inhibition of autotaxin activity by S32826-acetamide, tested in bis-pNPP assay; The 
results are expressed as a fraction (mean ±S.D. n=2) of the activity measured in the absence of the 
inhibitor. IC50 values were calculated as means of IC50s from separate experiments. 
3.3.7 Inhibition of migration 
LPA and autotaxin have been shown to regulate cell migration in many cancer cell types including 
ovarian carcinomas.141, 256-257 To ensure conjugate 1 retained the ability to inhibit autotaxin in a 
biological assay, the effect of conjugate 1 on wound healing was evaluated using 3E3 ovarian cancer 
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cells. 3E3 cells, derived from Ovcar-3 cells and previously engineered to over express autotaxin,178 
were grown to a confluent monolayer. Once an even monolayer had formed a wound was inflicted 
and the migration of the cells was measured as percentage wound closure, in serum free medium, 
supplemented with LPC (0.5 µM), containing the autotaxin inhibitor S32826 (30 nM) or conjugate 
1 (0.65 μM or 1.3 μM). Both autotaxin inhibitors reduced would closure almost two-fold compared 
to the wound closure measured with cells exposed to vehicle alone, as shown in Figure 3.9. The 
dendrimer alone was also tested in the wound healing experiment at a concentration comparable to 
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Figure 3.9: Effect of autotaxin inhibition with conjugate 1 on wound closure, in 3E3 cells. A. 
Inhibition of autotaxin with S32826 and conjugate 1. 3E3 cells were grown to confluence, a wound 
was created and serum free media containing 30 nM S32826, 0.65 μM conjugate 1 or 1.3 μM 
conjugate 1 was added and wound closure was measured after 16 h. B. The percentage wound closure 
was measured, wound closure = ((pre-migration area – post-migration area)/pre-migration area) 
*100. (Bars show mean +S.D., n=3–5, S32826 n=5, 0.65 µM n=3, 1.3 µM n=5). Control cells were 
treated with vehicle (0.5% DMSO). * P < 0.05, ** P < 0.01, *** P <0.001 vs. control (paired t-test 
comparing treatment to corresponding control within experiment). 
The effect of the inhibitors on the migration of 3V5 cells, which were transfected with the empty 
vector, and do not over express autotaxin was measured concurrently, as shown in Figure 3.10. Both 
the free inhibitor and the inhibitor bound to the G3 PAMAM dendrimer had no measurable effect on 
the percentage wound closure. 
B 
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Figure 3.10: Effect of autotaxin inhibition with conjugate 1 on wound closure, in 3V5 cells. 
Inhibition of autotaxin with S32826 and conjugate 1. 3V5 cells were grown to confluence, a wound 
was created and serum free media containing 30 nM S32826, 0.65 μM conjugate 1 or 1.3 μM 
conjugate 1 was added and wound closure was measured after 16 h. B. The percentage wound closure 
was measured, wound closure = ((pre-migration area – post-migration area)/pre-migration area) 
*100. (Bars show mean +S.D., n=3). Control cells were treated with vehicle (0.5% DMSO). 
3.3.8 Potentiation of apoptosis induced by carboplatin 
Previous work has shown that expression of autotaxin delays apoptosis induced by carboplatin, while 
apoptosis was accelerated after inhibition of autotaxin by either siRNA or with a small molecule 
inhibitor.178 To investigate the ability of conjugate 1 to potentiate apoptosis induced by carboplatin, 
caspase 3/7 activity was measured in 3E3 and 3V5 cells. The cells were treated with either 
carboplatin (300 μM), in the presence or absence of LPC (0.5 µM), and either vehicle, S32826 (300 
nM) or conjugate 1 (10 μM). After 18 h, cell death was assessed by measuring caspase 3/7 activity. 
Carboplatin increases caspase 3/7 activity in 3E3 cells, and this could be substantially repressed by 
the addition of the substrate of autotaxin, LPC. However, the inclusion of the autotaxin inhibitors, 
S32826 or conjugate 1 prevented the suppression of caspase activity induced by LPC, as shown in 
Figure 3.11. On otherwise untreated cells, the autotaxin inhibitors had no measurable effect on 
caspase activity.  
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Figure 3.11: Caspase 3/7 activity measured in the presence of carboplatin and conjugate 1 in 3E3 
cells. Ovarian cancer cells (3E3) engineered to overexpress autotaxin were treated and caspase 3/7 
activity was measured following incubation with 10 μM conjugate 1, 300 nM S32826 with or without 
300 μM carboplatin for 18 h. Caspase 3/7 activity was normalised for cell death (SRB assay). (Bars 
show mean + S.D., n = 3–5). * P < 0.05, ** P < 0.01, *** P <0.001 vs. LPC + carboplatin only (one-
way anova, post-hoc Tukey test). 
In contrast, in 3V5 cells, which were transfected with the empty vector and which do not ectopically 
expressed autotaxin, addition of LPC was unable to supress the increase in caspase activity induced 
by carboplatin, as shown in Figure 3.12. Addition of the autotaxin inhibitors S32826 or conjugate 1 
with carboplatin did not significantly alter the caspase 3/7 activity from that measured in the presence 
of carboplatin alone. The effect of the G3 PAMAM dendrimer on caspase activity in the presence of 
carboplatin was also measured, no significant difference between the carboplatin treated and the 
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Figure 3.12: Caspase 3/7 activity measured in the presence of carboplatin and conjugate 1 in 3V5 
cells ; Ovarian cancer cells (3V5) transferred with the vector were treated and caspase 3/7 activity 
was measured following incubation with 10 μM conjugate 1, 300 nM S32826 with or without 
300 μM carboplatin for 18 h. Caspase 3/7 activity was normalised for cell death (SRB assay). (Bars 
show mean + S.D., n = 3–5). * P < 0.05, ** P < 0.01, *** P <0.001 vs. LPC + carboplatin only (one-
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3.4 Discussion 
Inhibition of autotaxin has the potential to decrease the survival, migration and proliferation of 
cancerous cells. Attaching an autotaxin inhibitor to a dendrimer has the potential to improve the 
pharmaceutical properties of the inhibitor and also increase the retention of the inhibitor in the 
intraperitoneal cavity. In the work described in this chapter the autotaxin inhibitor S32826 has been 
attached to a dendrimer and the effect of this conjugation on the biological activity of the inhibitor 
has been investigated. 
The LPA analogue S32826 was chosen as unlike many other autotaxin inhibitors, S32826 has been 
described as having a low potency for LPA receptors.83 Due to the similarity of structure of LPA 
analogues they have the potential to be an agonist or antagonist of the multiple LPA receptors, 
alongside their potent inhibition of autotaxin. The effects of LPA analogues on LPA receptors is not 
well established and therefore it was considered appropriate to use a drug which inhibits autotaxin 
without agonistic/antagonistic effects on LPA inhibitors. This was considered particularly important 
because the LPA receptors LPA2 and LPA3 have been shown to promote ovarian cancer 
tumorigenesis.97, 118, 258 In contrast, LPA1 expression is decreased in ovarian cancer cells and it has 
been shown to promote apoptosis.115 Thus, the agonist/antagonist profile of autotaxin inhibitors at 
LPA receptors may influence their clinical efficacy. S32826 has no affinity for the LPA1 receptor up 
to concentrations of 10 µM.83 This study also showed S32826 had no affinity for a panel of other 
receptors.  
Initial work had attempted to derivatise the G3 PAMAM dendrimer using ester groups as 
electrophiles. The aim was to react the ester groups with the terminal amine of the inhibitor to provide 
an amide linkage with the dendrimer, followed by deprotection of the phosphonate esters to give the 
desired phosphonic acid terminus, which is known to be important in binding to autotaxin.  
Although initial attempts to functionalise the G3 PAMAM dendrimer in this way were unsuccessful, 
this was easily resolved by switching to a conjugate addition reaction to provide an amide linkage. 
Conjugate 1 was synthesised in an effective three step process involving acyl derivatisation of the 
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drug molecule to form the acrylamide, conjugate addition to the terminal amines of G3 PAMAM 
dendrimer and finally phosphonate ester deprotection.  
The structure of conjugate 1 was confirmed through standard 1H NMR and IR studies, and the degree 
of substitution was determined via elemental analysis. Elemental analysis suggested almost complete 
coupling of the inhibitor to each of the 32 terminal amines of the G3 PAMAM dendrimer was 
achieved. Although complete substitution was achieved it is unlikely that each inhibitor molecule 
can bind to autotaxin simultaneously due to steric constraints. While the primary objective of this 
study was to determine if conjugating autotaxin to a dendrimer would impair its activity, and several 
lines of evidence have shown retention of activity, different degrees of substitution could be 
investigated in the future to establish the effect this has on the potency of autotaxin inhibition and 
the physicochemical properties expressed by conjugate 1. Gas Phase chromatography (GPC) could 
be used to determine the polydispersity onto the dendrimer.  
Conjugate 1 was initially evaluated for biological activity, by assessing its ability to inhibit autotaxin 
obtained from two different sources (commercial kit or purified from 3E3 cells) and measured using 
two different substrates. Conjugate 1 showed an approximate 10-60-fold reduction in potency 
compared to unconjugated S32826. This suggests that conjugation to the dendrimer has notably 
impaired the inhibitor’s ability to bind to autotaxin, however conjugate 1 has retained some 
pharmacological activity. This reduction in activity may be due to the way in which the inhibitor 
binds to the ligand binding site of autotaxin. When this conjugate was designed the crystal structure 
of autotaxin had not been determined. In 2011 the crystal structure of LPA bound to autotaxin was 
elucidated and this showed the lipophilic chain of LPA sitting within a hydrophobic pocket.89-90 As 
the dendrimer is attached to the end of the lipophilic chain of the drug molecule; this chain is unlikely 
to be able to sit in this pocket anymore, forcing an alternative binding conformation which might 
explain the observed reduction in potency.  
Consistent with this interpretation, the S32826 analogue in which the terminal amine was converted 
to an acetamide retained potency comparable to the parent compound. Thus derivatisation of the 
inhibitor at the terminal end did not have a significant effect on the pharmacological activity of 
S32826 per se, rather the steric bulk of the dendrimer is likely to have prevented the drug molecule 
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binding with high affinity to the enzyme. It is possible that this prevents the alkyl group entering the 
hydrophobic pocket, causing a substantial reduction in the binding interactions that drive high 
affinity binding of S32826. 
The Autotaxin/LPA pathway is known to regulate cell migration, in many cancer cell types, including 
ovarian cancer. Inhibition of autotaxin has been shown to reduce cancer cell migration. A monolayer 
wound healing experiment was used to confirm S32826 inhibits migration in ovarian cancer cells 
overexpressing autotaxin.  The same assay was used to confirm conjugate 1 retained its biological 
activity, conjugate 1, at a concentration relative to potency, explain inhibited wound healing in this 
assay. 
Autotaxin is over-expressed in tumours that are relatively resistant to chemotherapy259 and autotaxin 
can contribute to resistance to carboplatin.178 Thus, autotaxin inhibitors may be useful in the 
treatment of ovarian cancer as agents to overcome the resistance to chemotherapy. LPA has 
previously been shown to inhibit cell death induced by cisplatin in ovarian cancer cells.176 
Furthermore autotaxin inhibited apoptosis induced by paclitaxel in breast cancer and melanoma 
cells.179 Previous work in cells engineered to over-express autotaxin, has shown that inhibition of 
autotaxin with the inhibitor ccPA 16:1 potentiates cell death induced by carboplatin.178 Based on this 
previous work, the ability of conjugate 1 to potentiate apoptosis induced by carboplatin was evaluated 
by measuring caspase 3/7 activity. LPC was shown to protect cells from carboplatin induced caspase 
3/7 activity in 3E3 cells, engineered to overexpress autotaxin, whereas no protective effect was 
observed in 3V5 cells which were transfected with the empty vector. Addition of the LPC provides 
autotaxin with the substrate to synthesise LPA which in turn promotes cell survival, as the cells 
transfected with the vector do not express autotaxin this protection is not observed. The addition of 
the free inhibitor S32826 or conjugate 1 was able to supress the decreased activation of caspase 3/7, 
producing caspase activity similar to that induced by carboplatin in the absence of LPC. The free 
inhibitor did not induce caspase 3/7 activity on its own. Lack of protection in 3V5 cells gives 
confidence the conjugate is biologically active through inhibition of autotaxin.  
The primary aim of attaching an autotaxin inhibitor to a polymer, such as a dendrimer, was to increase 
the retention of the drug molecule in the intraperitoneal cavity. Providing continual and prolonged 
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inhibition of autotaxin may reduce the production of LPA and potentially prevent metastasis and 
reduce chemoresistance. However, although dendrimers were initially thought to be a good choice 
for this purpose due to their large hydrodynamic volume; there is evidence that dendrimers are 
rapidly cleared from the intraperitoneal cavity. Intraperitoneal injection of 125I-labelled PAMAM 
dendrimers were found to be rapidly expelled from the intraperitoneal cavity.248 A similar study 
investigating the bio-distribution of 125I-labelled biotinylated-PAMAM dendrimers after 
intravenously administration and obtained similar results260 with most of the dendrimers 
accumulating in the kidneys after 4 h. Furthermore, attaching the drug to a dendrimer resulted in 
reduced potency. This led to different drugs and different polymers being investigated. The 
elucidation of the crystal structure of autotaxin bound to LPA and also to a small molecule inhibitor 
allowed the design of more structured polymer-autotaxin inhibitor conjugates as described in the 
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3.5 Conclusion 
 The results from this study suggest that in principle autotaxin inhibitors may be conjugated to 
dendrimers and retain their pharmacologic activity. While dendrimers are rapidly cleared from the 
intraperitoneal cavity, limiting their use for prolonging intraperitoneal retention of autotaxin 
inhibitors, they may still be of use for improving the physicochemical properties of the highly 
lipophilic class of autotaxin inhibitors based on LPA. Attaching the autotaxin inhibitor S32826 to a 
dendrimer has the potential to improve the pharmacokinetic profile, reducing the rapid clearance 
observed when tested with in vivo models.83 Although the focus of the studies described here are to 
evaluate autotaxin inhibitors for the treatment of ovarian cancer, autotaxin inhibitors have potential 
in other cancers and other diseases. A dendrimer-autotaxin inhibitor may be therapeutically 
beneficial for retaining autotaxin in other cavities such as joints, autotaxin expression has been shown 
to be increased in rheumatoid arthritis. It would be useful to evaluate this conjugate in a rheumatoid 
arthritis model. It will also be useful to evaluate this approach using other autotaxin inhibitors and to 
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4.1 Introduction 
As discussed in chapter 1, there are many potent autotaxin inhibitors currently in development. 
Albers et al. discovered a series of inhibitors based on a thiazolidinedione core, this series produced 
several inhibitors with nanomolar potency.224 Additionally, Hausmann et al. determined the crystal 
structure of autotaxin in complex with one of the series a boronic acid inhibitor, HA155, as shown 









Figure 4.1: Ligand binding site with HA155 bound, PDB entry 2XRG. 
The availability of the crystal structure of this compound in complex with autotaxin enables structure 
based design of polymer inhibitor conjugates based on this scaffold. Comparing the crystal structure 
of autotaxin in complex with LPA obtained by Nishimasu et al. it can be deduced that the inhibitor 
shares the same binding pocket as LPA.89  The inhibitor binds to autotaxin in the catalytic domain, 
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groups is stabilised by the two zinc ions.90 The four membered hydrophobic ring system forms a 
network of van der Waal interactions and the 4-fluorobenzyl moiety binds with the hydrophobic 
pocket which is also the site of binding of the acyl chain of LPA.90 The thiazolidine-2,4-dione and 
its conjugated ring lie between the hydrophobic pocket and catalytic site, similar to the glycerol 
moiety of LPA,90 as shown in Figure 4.1, circled in black. 
The design of a conjugate was based upon a comparison of the structure of compound 24 and the 
crystal structure of the similar boronic acid. Compound 24 was the first potent autotaxin inhibitor 
discovered in this thiazolidine-2,4-dione series and had an IC50 of 56 nM in the Bis-pNPP assay, 
(Figure 4.2).224 This compound was chosen for attachment to a polymer due to the potential of the 
methoxy group to serve as a point of conjugation. Analysis of the conformation of the similar boronic 
acid inhibitor in complex with autotaxin suggests this methoxy group sits in an accessible position. 
 
 
Figure 4.2:  Structure of 2,4-thiazolidinedione autotaxin inhibitor. 
As dendrimers are rapidly cleared from the intraperitoneal cavity, a polymer was required possessing 
features which would enable long-term retention. Icodextrin, is the main constituent of Extraneal™, 
a peritoneal dialysis solution, already established for clinical use. Icodextrin is a water soluble 
glucose polymer derived from maltodextrin with α 1-4 glyosidic bonds and approximately 10% α 1-
6 glyosidic bonds. It has a weigh average molecular weight between 13 and 19 kDa. The retention 
24 
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of icodextrin in the intraperitoneal cavity has been studied, with approximately sixty per cent 
remaining in the intraperitoneal cavity after 12 hours.261  
 
Figure 4.3: Structure of icodextrin. 
This chapter will discuss the synthetic approach for both the autotaxin inhibitor and the conjugation 
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4.2 Results 
4.2.1 Synthesis of thiazolidine-2,4-dione autotaxin inhibitor  
Initially, synthesis of the autotaxin inhibitor 24 was employed as a starting point to develop a novel 
compound which could be conjugated to Icodextrin. This was achieved utilising the previously 
described synthetic method used by Albers and co-workers, as shown in Scheme 4.1.224  
Firstly, intermediate 38 was prepared by N-benzylating thiazolidine-2,4-dione 36 with 4-
fluorobenzyl chloride 37, following deprotonation with sodium hydride, in anhydrous DMF, (75%). 
The second intermediate 41 was prepared by O-benzylating vanillin 39 with methyl-4-
(bromomethyl)-benzoate 40 in the presence of potassium hydroxide. The ester functionality in this 
compound was then hydrolysed in situ with sodium hydroxide to give the benzoic acid 41, (71%). 
Finally, both intermediates, thiazolane-2,4-dione 38 and aldehyde 41, were combined via a 
Knoevenagel condensation mediated by piperidine in ethanol to yield the previously described 
autotaxin inhibitor 24, (93%). The identity of the product was secured from the 1H-NMR with the 





Scheme 4.1: Synthesis of thiazolidine-2,4-dione autotaxin inhibitor.
40 
i) KOH, DMSO,  
rt, 30 min 
NaH, DMF,  
0 °C to rt, 22 h 
75% 
 
piperidine, EtOH  




 reflux, 4 h 
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Scheme 4.2: Mechanism of Knoevenagel condensation. 
The Knoevenagel condensation begins by deprotonation of the activated methylene by piperidine to 
give a resonance stabilised enolate. Piperidine also reacts with the aldehyde to form an iminium ion 
intermediate, which is then attacked by the enolate. The intermediate compound formed is then 
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deprotonated by piperidine to give another enolate while the amine of the intermediate is protonated. 
A rearrangement releases the piperidine to yield the final olefin product, as shown in Scheme 4.2.  
4.2.2 Exposing the hydroxyl group 
4.2.2.1 Demethylation of the aryl methyl ether 
Demethylation of the aryl methyl ether of compound 24 to expose the phenolic hydroxyl group was 
required to create a reactive moiety for future attachment to icodextrin.  Demethylation was initially 
attempted using the Lewis acid boron tribromide at room temperature; as described by McOmie et 
al.262  
 
Scheme 4.3: Attempted demethylation of thiazolidine-2,4-dione. 
This reaction failed under a variety of conditions, resulting in either the removal of both the methyl 
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both milder Lewis acids, were also attempted. However, both were unsuccessful resulting in recovery 
of the starting material. Conditions attempted are shown in Table 4.1.  
Reducing agent Equivalents  Time (h) Temperature (°C) Outcome 
BBr3 2 2 0 No reaction 
BBr3 2 16 0 No reaction 
BBr3 2 4 23 No reaction 
BBr3 10 16 23 
Demethylation and 
debenzylation 
BBr3 10 2 23 
Demethylation and 
debenzylation 
BBr3 5 16 23 No reaction 
CeCl3 1.5 16 reflux No Reaction 
TMS-I 10 8 reflux No reaction 
Table 4.1: Conditions attempted for demethylation of the phenolic methyl ether. 
4.2.2.2 Acetylation of 3,4-dihydroxy-benzaldehyde 
Selective acetylation of the 3-hydroxyl group of 3,4-dihydroxy-benzaldehyde 43 was attempted to 
create a more labile protecting group. Synthesis was achieved with acetic anhydride in the presence 
of sodium hydroxide and subsequent acidification with hydrochloric acid and phosphate buffer, to 
yield compound 44 in an impure state in approximately 62%, as shown in Scheme 4.4.  
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Scheme 4.4: Acetylation of 3,4-dihydroxy-benzaldehyde. 
TLC and 1H NMR analysis showed by-products 3,4-diacetoxy-benzaldehyde and 4-acetoxy-3-
hydroxy-benzaldehyde were present. These by-products were separated from the desired 3-
monosubstituted isomer 44 via column chromatography. 1H NMR analysis showed the 4-
monosubstituted product was still present in a ratio of approximately 1:6, indicating that further 
purification would be required. No further action was taken with this route. 
4.2.2.3 Selective benzylation of 3,4-dihydroxy-benzaldehyde 
A method by Plourde et al. for the selective benzylation of the 4-hydroxyl position of 3,4-dihydroxy-
benzaldehyde was investigated.263 This method utilising the mild base sodium bicarbonate (1.5 
equiv.) resulted in the 4-mono-substituted benzaldehyde 45, with small 3-mono-subsituted and di-
substituted impurities. Impurities were removed via column chromatography and recrystallization to 
yield compound 45, (70%), as shown in Scheme 4.5. 
43 44 
Acetic anhydride, 
THF, NaOH, 0 °C,  
20 min 
63% 
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Scheme 4.5: Selective benzylation of 3,4-dihyroxy-benzaldehyde. 
Since sodium bicarbonate is not basic enough to deprotonate the phenol the mechanism for this 
reaction could either progress through SN2 followed by deprotonation or deprotonation followed by 
SN2. 
The regiochemistry was confirmed by Nuclear Overhauser Effect (nOe) NMR analysis and X-ray 
crystallography. nOe NMR analysis showed a correlation between the 5-position hydrogen of the 
aromatic ring and the CH2 of the ether linkage, which would not be present if the 3-hydroxyl group 
had been benzylated. Single crystal X-ray diffraction confirmed the structure as shown in Figure 4.4. 
 





DMF, 40 °C,  
24 h 
70% 
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4.2.2.4 Synthesis of thiazolidine-2,4-dione with exposed hydroxyl group 
Aldehyde 45, which possessed the desired hydroxyl functional group, then underwent piperidine 
mediated Knoevenagel condensation, as described in section 4.2.1, with thiazolidine-2,4-dione 38, 
to yield the desired compound 46, (69%), as shown in Scheme 4.6. 
.  
 
Scheme 4.6: Synthesis of thiazolidine-2,4-dione with free hydroxyl group. 
 The methyl ester was not converted to the carboxylic acid. The methyl ester would act as a protecting 
group to prevent any unwanted reactions during future conjugation to icodextrin. 
4.2.2.5 Synthesis of thiazolidine-2,4-dione carboxylic acid 
The carboxylic acid 42 was also synthesised to investigate the effect of changing the methoxy 





Reflux, 16 h 
69% 
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carboxylic acid, benzaldehyde 45 underwent saponification with NaOH and heating to yield 
intermediate, 47 (98%), as shown in Scheme 4.7. 
 
 
Scheme 4.7: Saponification of benzaldehyde benzoate. 
Compound 47, was condensed with thiazolidine-2,4-dione 38 as described in section 4.2.1 to yield 
the desire compound 42, (80%), as shown in Figure 4.5. 
 
 






70 °C, 4 h 
98% 
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4.2.3 Activation of icodextrin 
Icodextrin was tosylated to provide a suitable leaving group for conjugation to the inhibitor molecule. 
It was assumed that the sterically most accessible C6-position hydroxyl group would be tosylated 
selectively given the precedent for D-glucose.264 
4.2.3.1 Dissolution of icodextrin 
Icodextrin is insoluble in most organic solvents. After much experimentation and a screen of potential 
solvents, icodextrin was solubilised based upon a method utilised by Liu et al. to solubilise 
cellulose.265 Icodextrin was suspended in a DMAc-LiCl co-solvent system and heated to 160 °C for 
8 h until completely dissolved. LiCl is used to disrupt the strong hydrogen bonding formed within 
icodextrin due to the formation of hydrogen bonds between the hydroxyl groups of icodextrin and 
chloride ions. Once in solution cooling to room temperature was possible without precipitation of 
icodextrin.  
4.2.3.2 Tosylation of icodextrin 
Tosylation was performed in DMAc-LiCl with 5 w/w equivalents of tosyl chloride in the presence 
of pyridine. The reaction was heated for 16 h, cooled and dialysed against deionised water to yield 
icodextrin-tosylate 49, (50% mass recovery), as shown in Scheme 4.8. 
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Scheme 4.8: Synthetic route to icodextrin tosylate.  
Tosylation of icodextrin was determined via 1H NMR and IR analysis. 1H NMR analysis showed the 
presence of two aromatic peaks at 7.47 ppm and 7.12 ppm, most likely corresponding to the AA′BB′ 
aromatic ring protons of the tosyl group. The degree of tosylation can be approximated from the ratio 
of the signal from the aromatic tosyl peaks which each correspond to two hydrogens and the anomeric 
hydrogen of icodextrin, as shown in Figure 4.6. This suggests a ratio of 1 in 9 icodextrin monomers 
have been tosylated. The NMR spectrum peaks of the tosylated icodextrin are much broader than 
that of the icodextrin alone, this may be due to a higher water content possible cause by more water 




ii) TsCl, 100°C 16h 
        50% 
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Figure 4.6: 1H NMR of icodextrin tosylate. 
4.2.4 Synthesis of conjugate 2 
Conjugation of the inhibitor to icodextrin was achieved via ether formation between icodextrin-
tosylate and the inhibitor (5 mass equiv.) in DMSO in the presence of pyridine, heated for 24 h. The 
cooled reaction mixture was then dialysed against deionised water, yielding compound 50 (22% mass 
recovery), as shown in Scheme 4.9.  
3-10-09-MGE.010.001.1r.esp
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Scheme 4.9: Synthetic route for conjugation to icodextrin. 
The conversion of the ester of compound 50 to expose the essential carboxylic acid of the inhibitor 
was attempted via saponification. However, these conditions appeared too harsh for the compound 





100 °C, 24 h 
22% 
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Scheme 4.10: Attempted deprotection of compound 50. 
4.2.4.1 Silyl protection of carboxylic acid 
The carboxylic acid protecting group was replaced with a silyl group. Silyl protecting groups can be 
selectively removed using fluoride ions. The carboxylic acid was protected with a triisopropylsilyl 
group because this is sufficiently stable to the mildly basic conditions used in the other synthetic 
steps. Protection was achieved with triisopropylsilyl chloride in anhydrous DMF in the presence of 





100 °C, 8 h 
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Scheme 4.11: Silyl protection of carboxylic acid. 
4.2.4.2 Conjugation to icodextrin 
The newly protected inhibitor 52 was conjugated to tosylated icodextrin according to the method 
described in section 4.2.4. The conjugate was then treated with tetrabutylammonium fluoride (TBAF) 
in methanol to expose the essential carboxylic acid, yielding conjugate 2, (22% mass recovery) as 
shown in Scheme 4.12. 
42 
52 
TIPS-Cl, NaH,  
DMF, rt, 4 h 
72% 
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Scheme 4.12: Synthesis of Conjugate 2. 
This compound had a molecular weight greater than 8 kDa, as per the MWCO of dialysis membrane. 
In order to improve retention time in the intraperitoneal cavity a larger molecular weight was desired. 
The synthesis was attempted again using icodextrin which had been dialysed using a membrane with 
a molecular mass cut off of 20 kDa. 
4.2.5 Synthesis of conjugate 3 
Synthesis of the conjugate with icodextrin with a larger molecular mass was required. The synthesis 
of Conjugate 3 was initially attempted according to the previously employed method, described in 
section 4.2.4., using tosylated icodextrin >20 kDa. However, no conjugation was observed, resulting 
in recovery of icodextrin. This was postulated to be due to steric interactions, possibly caused by 
secondary interactions with the longer icodextrin; which make the alkylation reaction which couples 
52 
Conjugate 2 
i) Ts-icodextrin,  
DMSO, pyridine, 100°C, 16 h 
ii) TBAF, MeOH 
rt, 3 h 
22% 
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the drug to the icodextrin more difficult; the yield for the first attempt of this reaction was already 
low. 
4.2.5.1 Addition of a linker moiety 
A linker moiety was added to the inhibitor molecule to increase the distance between the two 
molecules. A diethylene glycol linker was chosen due to its stability and to retain the oxidation level 
of the functionality and method of attachment from the initial synthesis. The diethylene glycol linker 
was added by Williamson synthesis.245 
 Firstly, diethylene glycol was converted to 2-(2-bromo-ethoxy)-ethanol via the Appel reaction with 




Scheme 4.13: Synthesis of 2-(2-bromoethoxy)-ethanol. 
 





 rt, 16 h 
49% 
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Compound 46 was alkylated with 2-(2-bromoethoxy)-ethanol in the presence of potassium 
hydroxide. Potassium iodide was added to further activate the alkyl bromide with an in situ 
Finkelstein reaction, substituting the bromide for the more reactive iodide group. This yielded 
compound 55, (68%), as shown in Scheme 4.15. 
 
Scheme 4.15: Alkylation of thiazolidine-2,4-dione methyl ester. 
The alkylation of compound 52 with 2-(2-bromo-ethoxy)-ethanol, was attempted according to the 








i) KOH, KI, MeCN,  
60 °C, 2h 
ii) Compound 54, 60 °C, 
16 h 
68% 
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Base Equivalents Solvent Time (h) Temperature (°C) Outcome 
KOH 1.1 MeCN 2 21 to 70 Removal of TIPS 
Na2CO3 1.1 DMF 4 21 to 70 Removal of TIPS 
K2CO3 1.1 MeCN 4 21 to 70 
TIPS removal and 
undesired alkylation 
Na2CO3 1.1 MeCN 20 21 to 70 No change 
NaH 1.1 DMF 4 0 to 21  Removal of TIPS 
Table 4.2: Conditions for alkylation. 
 
Scheme 4.16: Attempted alkylation of thiazolidine-2,4-dione TIPS ester. 
The synthesis of the inhibitor molecule with linker, compound 56 was changed to incorporate the 
linker at an earlier stage. At this point commercially available 2-(2-chloroethoxy)-ethanol was 
substituted for the 2-(2-bromoethoxy)-ethanol reducing the amount of required synthetic steps. 
Alkylation of compound 45 was achieved with 2-(2-chloroethoxy)-ethanol in anhydrous DMF in the 





  Chapter 4 
   145 
 
This was followed by saponification with sodium hydroxide, to yield compound 57, (91%), as shown 
in Scheme 4.17. 
.  
Scheme 4.17: Alkylation of benzaldehyde. 
Compound 57 underwent Knoevenagel condensation with compound 41 according to the standard 







K2CO3, KI,  
70 °C, 18 h 
ii) NaOH, DMSO/H2O 70 °C, 2 h 
91% 
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Scheme 4.18: Synthesis of thiazolidine-2,4-dione with linker. 
 The carboxylic acid of compound 58 was then protected using triisopropylsilyl chloride according 
to a method described by Smith et al. for selective ester formation.266 The selectivity of this reaction 
is based on the pKa, although triethylamine is a weak based it is able to deprotonate the acid and 
therefore make the acid more reactive than the primary alcohol. This was achieved in anhydrous 












reflux, 16 h 
54% 
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TIPS-Cl, TEA,  
THF, rt, 15 min 
76% 
  Chapter 4 
   148 
 
4.2.5.2 Conjugation to icodextrin 
Compound 59 was conjugated to 20 kDa icodextrin as previously described in section 4.2.4.2. 
resulting in desired Conjugate 3, (30% mass recovered), as shown in Scheme 4.20. 
 









100°C, 16 h 
30% 
  Chapter 4 
   149 
 
4.2.6 Alternative route to conjugation 
Tosyl groups have the potential to act as alkylating agents in vivo, therefore the synthetic route was 
altered to guarantee no tosyl groups were present in the final conjugate. This was achieved by 
reversing the reactivity, tosylating the inhibitor-linker molecule. 
4.2.6.1 Tosylation of the inhibitor 
Tosylation of compound 55 was investigated as a model reaction. This was achieved with tosyl 
chloride in dichloromethane with 1 equivalent of triethylamine. The product was purified by column 
chromatography to yield compound 60, (57%). 
 





TsCl, CH2Cl2,  
TEA, rt, 20 h 
57% 
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Tosylation of compound 59, was achieved according to the previously described method yielding 
compound 61, (50%), as shown in Scheme 4.22. 
 
Scheme 4.22: Tosylation of thiazolidine-2,4-dione TIPS ester linker. 
4.2.6.2 Gluco model study 
A model study using the commercially available 2-methyl-3,4,5-pyranoside was performed to enable 
better structural analysis. The pyranoside was solubilised in anhydrous dimethyl-acetamide (DMAc) 
and sodium hydride was applied to deprotonate. The tosylate was added and the reaction was 
monitored by LC/MS. The resulting product was purified via column chromatography, to yield the 





TsCl, CH2Cl2,  
TEA, rt, 20 h 
50% 
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Scheme 4.23: Synthesis of model conjugate.  
The structure of the conjugate was determined via NMR studies. 1H NMR and 13C NMR suggest that 
the coupling was complete, with the presence of all expected protons. It was also apparent that the 
triisopropylsilyl ester had been cleaved either during conjugation or work-up. Mass spectrometry 







DMAc, rt, 30 min 
46% 
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4.2.6.3 Synthesis of conjugates 4, 5 and 6 
This approach was then attempted with icodextrin. Icodextrin was solubilised as described in section 
4.2.3.1. Sodium hydride was used to deprotonate icodextrin, followed by addition of tosylate 61. The 
reaction was stirred at room temperature and followed by TLC, to yield conjugates 4, 5 and 6.  
 
 









 rt, 4 h 
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A series of compounds were synthesised using different amounts of tosylate as shown in Table 4.3.  
Conjugate Equivalents Yield (g) Yield (%) 
4 50 0.504  42 
5 30 0.407 56 
6 10 0.401 43 
Table 4.3: Different equivalents of inhibitor molecule added. 
4.2.7 Structural analysis 
The structure of the conjugates was analysed via 1H and 13C NMR studies, IR spectroscopy and TGA 
analysis. Conjugate 4 was insoluble in several different solvents and therefore further 
characterisation was not possible.  
1H NMR analysis shows the presence of proton peaks representative of the inhibitor molecule, for 
example those in the aromatic region and the characteristic peaks of icodextrin, as shown in Figure 
4.7. 
 
Figure 4.7: Representative 1H NMR analysis of conjugate; Spectra of conjugate 6 shown.  
 
56-20-07-MGE-TP.010.001.1r.esp
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The IR spectra of the conjugates when compared to icodextrin alone show peaks at 2852 and 1704 
cm-1 which most likely correspond to the carboxylic acid of the inhibitor and a peak at 3386 cm-1 
corresponding to the icodextrin OH peaks, as shown in Figure 4.8. 
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TGA analysis was also performed. This showed conjugation to the inhibitor created a different profile 
to that of the inhibitor and the icodextrin, as shown in Figure 4.9. Weight loss below 100 °C was due 
to water evaporation, the weight loss above 100 °C is the thermal decomposition of the compound. 
Both icodextrin and the inhibitor have a single weight loss peak around 310 °C. Whereas the 
conjugate shows an earlier and more gradual decomposition starting at approximately 230 °C. The 
shallower decomposition pattern of the conjugate may be due to moisture escaping upon melting. 
 
Figure 4.9: TGA analysis of conjugate 6. 
The inhibitor inherent fluorescence was utilised to establish the degree of substitution of the 
conjugate. The fluorescence of a known amount of conjugate was measured and the fluorescence 
was compared to a standard curve of inhibitor fluorescence to calculate how much inhibitor was 
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2 43 0.0043 0.00212 0.07 
3 15 0.0026 0.00129 0.04 
5 95 0.095 0.0468 1.46 
6 109 0.184 0.091 2.90 


















  Chapter 4 
   157 
 
4.3 Discussion  
The initial strategy was to synthesise the lead compound and then expose the required hydroxyl 
group, utilising a mild base such as boron tribromide. However, selective removal of the aryl methyl 
ether was unsuccessful with the benzylic group also being cleaved. It was therefore attempted to 
substitute the methyl for a more selective leaving group. Derivitisation of this functional group with 
an acetyl group was attempted, however the selectivity for the 3-position was relatively low resulting 
in a mixture of compounds. Concurrently a method for selective substitution of the 4-hydroxyl group 
of 3,4-dihydroxy-benzaldehyde was investigated. This method proved successful with the mono-4-
hydroxyl group being benzylated. The structure of this compound was confirmed by NMR studies 
and X-ray crystallography. This compound was condensed with the thiazolidinedione as previously 
described to yield the desired inhibitor with a functional group in the correct position to attach to 
icodextrin. The carboxylic acid moiety was left as an ester in order to act as a protecting group during 
conjugation to icodextrin.  
Icodextrin was purchased as Extraneal™ peritoneal dialysis solution. This was an aqueous solution 
containing electrolytes and small organic molecules which required removal. This was achieved via 
dialysis against water. Icodextrin as a solid was then isolated utilising its poor solubility in organic 
solvents or were possible via freeze-drying to remove the water present. Solubilisation of icodextrin 
in an organic solvent was achieved utilising a DMAc/LiCl co-solvent system. The mechanism of 
dissolution is via disruption of hydrogen bonds between the OH of the polymer and chloride ions.267 
In order to conjugate to the inhibitor molecule icodextrin a good leaving group was required. This 
was achieved via the addition of a tosyl group, substitution at the C-6 OH was anticipated due to the 
increased reactivity of this primary position. 
The next step was to conjugate the inhibitor molecule with the icodextrin tosylate. This was achieved 
under mild basic conditions with heat. The conjugation was determined via NMR analysis. However, 
after this, upon attempting to remove the methyl protecting group to expose the carboxylic acid which 
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is essential for autotaxin inhibition, the stronger basic conditions required for this saponification 
appeared too harsh, as evident by NMR analysis. Possible reason for this are interactions with the 
allyl group present in the drug molecule. Saponification of the drug molecule not conjugate to 
icodextrin also proved unsuccessful. It was therefore decided that a more liable protecting group was 
required for the carboxylic acid. A silyl group was chosen due to the selective cleavage of silyl groups 
using fluoride ions. Conjugation and subsequent deprotection utilising fluoride ions proved 
successful generating the desired thiazolidine-2,4-dione autotaxin inhibitor icodextrin conjugate. 
As one of the primary aims of the conjugation to icodextrin is to increase the retention time of the 
autotaxin inhibitor in the intraperitoneal cavity; a larger icodextrin was desired in order to increase 
retention due to a larger hydrostatic volume. However, the previously employed synthetic route was 
unsuccessful. It was hypothesised this may be due to an increase in steric hindrance created by the 
larger chain of icodextrin present. Inclusion of a PEG linker was explored to act as a spacer between 
the icodextrin and the inhibitor molecule. This linker was chosen due to its stability and the retention 
of the terminal functional group to attach to icodextrin.  This required a new synthetic route to the 
inhibitor molecule with linker attached which was successfully achieved in an eight step convergent 
synthetic route. Silyl esters were found to be very liable to cleavage and therefore chemistry was 
performed before the addition of this protecting group. In the future it may be beneficial to explore 
different carboxylic acid protecting groups. The new inhibitor molecule was conjugated to the larger 
icodextrin successfully and the degree of substitution was determined using the intrinsic fluorescence 
of the inhibitor molecule.  
Tosyl groups have the potential to act as alkylating agents in vivo. To guarantee no tosyl groups were 
present after conjugation the reactivity was reversed, tosylating the inhibitor molecule. The 
potentially hazardous tosyl groups would therefore be removed during the dialysis step. This required 
synthesis of the inhibitor tosylate. This was achieved via selective tosylation of the terminal hydroxyl 
group of the inhibitor molecule. The inhibitor tosylate was then conjugated to icodextrin which had 
been deprotonated with sodium hydride. This was performed with multiple equivalents of the 
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inhibitor tosylate to further explore the effect the degree of substitution had on the physicochemical 
properties of the conjugate. Again the degree of substitution of these conjugates was determined via 
measurement of fluorescence.  
4.4 Conclusion 
A synthetic procedure to yield an icodextrin conjugate has been described. This synthetic route has 
the potential to be exploited for conjugation of many molecules to icodextrin. The conjugates 










Biological evaluation of icodextrin 
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5.1 Introduction  
The autotaxin/LPA pathway has been shown to promote migration and resistance to chemotherapy 
in ovarian cancer. Inhibition of this pathway has the potential to reduce these effects. In ovarian 
cancer LPA is present in ascites in concentrations up to 80 µM.73 Autotaxin has also been shown to 
be elevated in the ascites of ovarian cancer patients. It is thought this contributes to chemoresistance 
and metastasis often associated with late stage ovarian cancer. Inhibition of autotaxin has been shown 
to increase the sensitivity of ovarian cancer cells to carboplatin178 and breast cancer cells to 
paclitaxel.179  
 
Figure 5.1: Structure of Icodextrin-autotaxin inhibitor, conjugate 2. 
Reducing these high levels of LPA present in ascites has the potential to prolong the time until relapse 
after chemotherapy and reduce drug resistance. Autotaxin inhibitors are small molecules which are 
likely rapidly cleared from the peritoneal cavity. Attaching autotaxin inhibitors to polymers has the 
potential increase the half-life of the inhibitor in the peritoneal cavity. Icodextrin is a polymer which 
is already established in the clinic for peritoneal dialysis. The intraperitoneal pharmacokinetics of 
icodextrin have been defined and icodextrin is eliminated from the peritoneal cavity slowly (t½ > 12 
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hr).261 Higher molecular weight icodextrin fractions are anticipated to be eliminated even more 
slowly. Icodextrin is therefore an ideal candidate for conjugation with autotaxin inhibitors.  
 
Figure 5.2: Structure of Icodextrin-autotaxin inhibitor conjugates 3-6. 
Chapter 4 discussed the synthesis of icodextrin-autotaxin inhibitor conjugates, (Figure 5.2). This 
chapter will focus on the biological evaluation of these described conjugates. The conjugates were 
tested for in vitro activity employing the methods described in chapter 3. Firstly, the ability of these 
conjugates to inhibit recombinant autotaxin was evaluated using autotaxin from two sources. The 
effect on the autotaxin inhibitors’ biological activity was assessed with a wound healing assay. The 
solubility and permeability of the conjugates was also characterised, this was achieved using the 
miniaturized shake flask method and a PAMPA assay for transport across an artificial bilayer, and a 
Caco-2 cell permeability assay. Preliminary studies were also carried out for in vivo compatibility 
and determination of the pharmacokinetic profile, achieved in a murine model.  
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The solubility was measured as described in section 2.2.14.2 using the miniaturized shake flask 
method and adapted as follows. An excess of the test compound was suspended in 200 µL PBS (pH 
7.4) and shaken for 24 h at room temperature, followed by centrifugation. Fluorescence of the 
supernatant was measured and the concentration of the solution was determined according to a 
standard curve. 
5.2.2 FS-3 assay 
Compounds were tested for autotaxin inhibition using the FS-3 assay as described in section 2.2.9 
and adapted as follows. The free inhibitor (1 mM), conjugate 3 (6 mg/mL), conjugate 5 (10 mg/mL) 
and conjugate 6 (10 mg/mL) were prepared as a stock solution in DMSO, icodextrin (10 mg/mL) in 
water. The compounds were diluted 2-fold in PBS (pH 7.4). 80 µL of reaction buffer containing 
autotaxin and 10 µL of standard, compound dilution or solvent were pre-incubated for 10 min at 37 
°C. 10 µL of FS-3 substrate were added and the rate of FS-3 hydrolysis was measured at 37 °C every 
two minutes for 30 min. 
5.2.3 Bis-pNPP Assay 
Compounds were also tested for their ability to inhibit autotaxin in the bis-pNPP assay as described 
in section 2.2.8 and adapted as follows. The free inhibitor (1 mM), conjugate 3 (6 mg/mL), conjugate 
5 (10 mg/mL) and conjugate 6 (10 mg/mL) were prepared as a stock solution in DMSO and 
icodextrin (10 mg/mL) in water. Compounds were diluted 2-fold in PBS (pH 7.4). 20 µL of 5X 
reaction buffer, 10 µL bis-pNPP (1 mM) and 20 µL of compound dilution or solvent was added to 
each well, followed by the addition of 50 µL autotaxin solution. Absorbance was measured after 4 h 
incubation.  
  Chapter 5 
   164 
 
5.2.4 PAMPA 
Permeability across an artificial bilayer was tested as described in section 2.2.12 and adapted as 
follows. The free inhibitor (1 mM), conjugate 3 (6 mg/mL), conjugate 5 (10 mg/mL) and conjugate 
6 (10 mg/mL) were prepared as a stock solution in DMSO, icodextrin (10 mg/mL) in water and 
diluted with PBS (pH 7.4) to a final 2% DMSO. Membranes were wet with dodecane containing PC 
(5 mg/mL) 5 µL per well. Immediately after wetting 150 µL of either furosemide (10 µM), 
propranolol (10 µM), free inhibitor (10 µM), conjugate 2, (100 µg/mL), conjugate 3 (100 µg/mL), 
conjugate 5 (100 µg/mL) and conjugate 6 (100 µg/mL) was added to the appropriate donor well, and 
the donor compartment was placed in the acceptor plate, each acceptor well containing 300 µL of 
PBS (2% DMSO). The plates were incubated in a moist environment at room temperature for 48 h. 
The amount of compound present in the donor and acceptor compartments was measured by UV/VIS 
or fluorescence spectroscopy.  
5.2.5 Caco-2 permeability assay 
Permeability was further assessed in a cell based permeability assay as described in section 2.2.13 
and adapted as follows. After incubation with serum free medium for 3 h, two HBSS washes were 
performed. 500 µL of HBSS was placed in the basolateral side and 500 µL of HBSS containing either 
paracetamol (10µg/mL), the free inhibitor (10 µg/mL) or conjugate 6 (100 µg/mL) was added to the 
apical side. 200 µL was immediately removed from the apical side for a T0 reading. The cells were 
incubated for 2 h, after which the supernatant was collected from both the apical and basolateral side. 
The concentration of the compounds was calculated from a standard curve of fluorescence. 
5.2.6 Wound healing assay 
The ability of the compound to inhibit migration was tested in the wound healing assay as described 
in section 2.2.10 and adapted as follows. Serum free growth medium was supplemented with LPC 
(0.5 µM), DMSO (normalised to 0.4%) and either no inhibitor, icodextrin (50 µg/mL), the free 
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inhibitor (500 nM), conjugate 3 (50 µg/mL), or conjugate 6 (50 µg/mL), 1 mL was added per well. 
The percentage wound closure was measured after 16 h.  
5.2.7 In vivo experiments 
Animal experiments were performed under the guidelines of UK Home office regulations under the 
Animals (Scientific Procedures) Act 1986 and UKCCR guidelines for animal experimentation and 
were approved by the animal welfare commission of Keele University. Female NCR Nu/Nu mice 
between 5 and 7 weeks were used and allowed to acclimatise for 1 week after arrival. 
5.2.7.1 Sterilisation of compound NF440 
Before use, the compound was sterilised by suspending a known amount in 70% ethanol followed 
by freeze-drying (Edwards Modulyo), for 4 h to remove all traces of solvent. The compound was 
then dissolved in sterile PBS and diluted to concentrations of 0.22 mg/mL, 0.1 mg/mL and 0.03 
mg/mL. 
5.2.7.2 In vivo toxicity study 
Mice were weighed and received intraperitoneal injection of 0.4 mL of either 0.03 mg/mL, 0.1 
mg/mL or 0.22 mg/mL NF440 in sterile PBS using a 26G syringe in the lower left quadrant. The 
mice where monitored over 24 h for adverse effects. After 24 h the mice were weighed and 
euthanized by cervical dislocation. Ventral skin was removed and 0.5 mL sterile PBS was added to 
the peritoneal cavity, the wash was collected after gentle massage with the blunt end of forceps. An 
autopsy was then performed to check for signs of toxicity or adverse effects.  
5.2.7.3 In vivo peritoneal retention 
Mice were injected with 0.4 mL of 0.22 mg/mL NF440 into the peritoneum with a 26G syringe in 
the lower left quadrant. 3 mice per time point were euthanized by cervical dislocation at 1 min, 30 
min, 60 min, 3 h, 6 h and 24 h after injection. 0.4 mL PBS was used as a control for background 
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fluorescence (see below) and mice in this group were euthanized after 1 min by cervical dislocation. 
Ventral skin was removed and 0.5 mL sterile PBS was added to the peritoneal cavity, the wash was 
collected after gentle massage with the blunt end of forceps. The washes were immediately 
centrifuged (5, 000 g 10 min) and the supernatant was transferred to a new microcentrifuge tube. The 
volume collected was measured and the fluorescence, (Ex. = 360 nm, Em. = 440 nm) of 100 µL of 
each wash was measured using a Synergy 2 multimode microplate reader. The amount of compound 
present was calculated from the standard curve to determine drug concentration and from the sample 
volume. The data was analysed using GraphPad software to fit an exponential decay to calculate the 
half-life. The drug recovery by peritoneal lavage was estimated by comparison of the mass of drug 
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5.3 Results 
5.3.1 Inhibition of autotaxin 
The ability of the conjugates to inhibit autotaxin was measured in two autotaxin inhibition assays, 
using two sources of autotaxin and two substrates, FS-3 and bis-pNPP.  
5.3.1.1 FS-3 assay  
The ability of the conjugates to inhibit autotaxin was tested using FS-3 as the substrate. The 
conjugates demonstrated IC50 values ranging from 0.85 µg/mL to 6.7 µg/mL. The IC50 of the 
conjugates are between 2 and 20 fold higher than that of the free inhibitor when expressed in terms 
of the concentration of pharmacophore attached to the polymer, with IC50s of 76-640 nM compared 
to 35 nM of the free inhibitor, (Figure 5.3 and Table 1.1). The reduction in potency was more 
pronounced in the conjugates with the higher amounts of pharmacophore attached. The unconjugated 
icodextrin had no measureable effect in this assay. A secondary screen was also performed to ensure 
the compounds did not interfere with the fluorescence of the assay substrate, FS-3. None of the 
compounds tested in this assay interfered with fluorescence.  
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Figure 5.3: Inhibition of autotaxin enzymatic activity by conjugates, 3, 5 and 6, tested in 
FS-3 assay; A. inhibition with conjugate 3; B. with icodextrin; C. inhibition with conjugate 5; D. 
inhibition with conjugate 6. The results are expressed as a fraction (mean ±S.D. n=2) of the activity 






Free inhibitor 35 - 
Conjugate 3 76 1.3, 0.87 
Conjugate 5 189, 125 6.4, 7.3 
Conjugate 6 699, 611 1.0, 0.68 
Table 5.1: Inhibition of autotaxin enzymatic activity by the free inhibitor, conjugates 3, 5 and 6, 
tested FS-3 assay; IC50s are shown as either the concentration of conjugate (µg/mL) or the 
concentration of pharmacophore present in the conjugate (nM). (IC50 values of the conjugates are 
given as µg/mL because the MW of icodextrin is varied about 20 kDa). Both the mean average and 
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5.3.1.2 Bis-pNPP assay 
The ability of compounds to inhibit autotaxin was also investigated using bis-pNPP as the substrate. 
Autotaxin was purified from 3E3 cells as described in section 2.2.7. The conjugates had a comparable 
IC50 to that obtained in the FS-3 assay, with IC50s ranging from 90 nM to 640 nM, (Figure 5.4).  This 
was similarly comparable to the amount of pharmacophore present. Maximal inhibition varied with 
conjugate 2 and 3 unable to completely inhibit autotaxin, this may be due to lower solubility of these 
conjugates. As these compounds have different maximal inhibitions comparing IC50 values is limited. 
Unconjugated icodextrin (100 µg/mL) had no measureable effect in this assay. The results are 
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Figure 5.4: Inhibition of autotaxin enzymatic activity by conjugates 2, 3, 5 and 6, tested in bis-pNPP 
assay; A. inhibition with conjugate 2; B. inhibition with conjugate 3; C. inhibition with conjugate 5; 
D. inhibition with conjugate 6. The results are expressed as a fraction (mean ±S.D. n = 2-3) of the 






Free inhibitor 56 - 
Conjugate 2 120 2.9 ± 2.2 
Conjugate 3 99 ± 45 2.2 ± 1.9 
Conjugate 5 495 ± 448 6.2 ± 6.7 
Conjugate 6 392 ± 527 2.1 ± 2.9 
Table 5.2: Inhibition of autotaxin enzymatic activity by the free inhibitor conjugates 2, 3, 5 and 6, 
tested in Bis-pNPP assay; IC50s are shown as either the concentration of conjugate (µg/mL) or as a 
relative concentration to the amount of pharmacophore present in the conjugate (nM). (Results are 
expressed as mean ± S.D. n=3). Both the mean average and standard deviation were calculated using 
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5.3.2 Solubility 
The aqueous solubility of the compounds in PBS (pH 7.4) was tested using a miniaturised shake flask 
method. Conjugation to icodextrin increased the solubility of the pharmacophore compared to the 
free inhibitor, compound 24. (Table 1.3) The solubility of the conjugate 6 is less than conjugate 5, 




Degree of substitution 
Inhibitor/icodextrin (g/g)  
Free inhibitor 0.08 ± 0.015 - 
Conjugate 5 1.52 ± 0.263 0.0468 
Conjugate 6 0.22 ± 0.015 0.091 
Table 5.3: Solubility of conjugates; measured using a miniaturised shake flask method. (Results are 
expressed as mean ± S.D. n=3). 
 
5.3.3 Permeability  
 The autotaxin inhibitor was attached to icodextrin in order to increase retention of the inhibitor in 
the intraperitoneal cavity. The effect of conjugation on the permeability of the compound was tested 
in two assays, across an artificial bilayer and across an epithelial cell layer. 
5.3.3.1 PAMPA 
The ability of icodextrin to decrease the permeability of the pharmacophore across an artificial 
bilayer was measured using PAMPA assay. Furosemide and propranolol were used as a control for 
low and high permeability, respectively. These compounds showed the anticipated differences in 
permeability. The free inhibitor was moderately permeable across the membrane, but all the 
icodextrin conjugates showed substantially less permeability than the free inhibitor and were in some 
cases less permeable than furosemide, Figure 5.5. 
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Figure 5.5: Permeability of conjugates measured in PAMPA assay; Permeability of the free inhibitor 
and conjugates 2, 3, 5 and 6, Furosemide and Propranolol are shown as a control for low and high 
permeable drugs respectively. Furosemide (100 µM), Propranolol (100 µM), Free inhibitor 
(100 µM), Conjugate 2 (100 µg/mL), Conjugate 3 (100 µg/mL), Conjugate 5 (100 µg/mL) or 
Conjugate 6 (100 µg/mL) were applied to the artificial bilayer. After 48 h Log Pe was calculated. 
(Bars show mean +S.D., n=2–3). Control cells were treated with vehicle (0.4% DMSO). * P < 0.05, 
** P < 0.01, *** P < 0.001, vs. control (paired t-test). 
To further confirm a decrease in permeability when conjugated to icodextrin conjugate 6 was tested 
in a Caco-2 cell permeability assay. The effect of the conjugate on the trans epithelial electrical 
resistance (TEER) of Caco-2 cells was measured over 2 h, this determined the compound had no 
effect on the cell monolayer. The permeability of the conjugate was approximately 9 fold less than 
the free inhibitor, as shown in Table 5.4. 
Compound 
Permeability 
(Papp x 10-6) 
Paracetamol 38 
Free inhibitor 65.6 
Conjugate 6 7.4 
Table 5.4: Permeability of the free inhibitor and conjugate 6 measured in Caco-2 assay; Paracetamol 
was used as a control. Paracetamol (10 µg/mL) or Conjugate 6 (100 µg/mL) were applied to the 




Furosemide -6.4 ± 0.3 
Propranolol -5.3 ± 0.1 
Free inhibitor -5.5 ± 0.2 
Conjugate 2 -6.5 ± 0.01 
Conjugate 3 -6.9 ± 0.3 
Conjugate 4 -6.3 ± 0.3 
Conjugate 5 -6.4 ± 0.01 
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5.3.4 Inhibition of migration 
LPA and autotaxin have been shown to regulate cell migration. To confirm the biological activity of 
the conjugates their effect on wound healing was evaluated using 3E3 ovarian cancer cells; these 
cells were previously engineered to overexpress autotaxin.178 The cells transfected with the vector, 
3V5, were used as a control. Once an even monolayer had formed a wound was inflicted and the 
migration of the cells was measured.  The free autotaxin inhibitor reduced wound closure by 
approximately 50% compared to the wound closure measured with cells exposed to vehicle alone. 
The conjugates at a comparable concentration in terms of the amount of pharmacophores present, 
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Figure 5.6: Effect of autotaxin inhibition with the free inhibitor, conjugates, 3 and 6 on wound 
closure; A. Inhibition of autotaxin with the free inhibitor and conjugate. 3E3 cells were grown to 
confluence, a wound was created and serum free media containing the free inhibitor (100 nM), 
conjugate 3 (5 µg/mL), or conjugate 6 (10 µg/mL) was added and wound closure was measured after 
16 h. B. The percentage wound closure was measured, wound closure = ((pre-migration area – post-
migration area)/pre-migration area) *100. (Bars show mean +S.D., n=2–5, compound 24 n=5, 
conjugate 3 n=3, conjugate 6 n=2). Control cells were treated with vehicle (0.4% DMSO). * P < 0.05, 
** P < 0.01, *** P < 0.001, vs. control (paired t-test, compared to corresponding control). 
A 
B 
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Icodextrin alone was also tested in the wound healing experiment at a concentration comparable to 
that of conjugate used, this was found to have no significant effect on wound closure, (Figure 5.7). 
The effect of the inhibitors on the migration of 3V5 cells, which were transfected with the empty 
vector, and do not over express autotaxin was measured concurrently. Both the free autotaxin 
inhibitor and conjugates had no significant effect on the percentage wound closure. 
 
Figure 5.7: Effect of autotaxin inhibition with the free inhibitor, conjugates, 3, and 6 on wound 
closure in 3V5 cells, transfected with the vector; 3V5 cells were grown to confluence, a wound was 
created and serum free media containing the free inhibitor (100 nM), conjugate 3 (5 µg/mL), or 
conjugate 6 (10 µg/mL) was added and wound closure was measured after 16 h. The percentage 
wound closure was measured, wound closure = ((pre-migration area – post-migration area)/pre-
migration area) *100. (Bars show mean +S.D., n=2–5, compound 24 n=5, conjugate 3 n=3, conjugate 
6 n=2). Control cells were treated with vehicle (0.4% DMSO). 
5.3.5 In vivo pharmacokinetics 
5.3.5.1 Toxicity 
Before initiating in vivo experiments to assess the pharmacokinetics of the conjugates, the effect of 
intraperitoneal administration of the conjugate was evaluated for acute overt toxicity and to establish 
a safe dose for subsequent experiments. Conjugate 6 was formulated in sterile PBS at concentrations 
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of 0.03 mg/mL, 0.1 mg/mL and 0.22 mg/mL. nu/nu mice at 6-7 weeks were injected with 400 µL of 
the formulation into the peritoneal cavity. Mice were monitored for adverse effects for 24 h but no 
overt toxicity was seen. Furthermore, there was no significant difference in the weight of the mice 
before administration and after 24 h. After sacrificing the mice, autopsies did not reveal any gross 
pathological effects. 
 
Figure 5.8: Weight difference in mice treated with conjugate 6 at varying concentrations over 24 h 
(Results are express as a mean ± S.D. of n=2).  
  
5.3.5.2 Peritoneal retention 
To assess whether intraperitoneal administration of the conjugates could allow prolonged inhibition 
of autotaxin, the retention of conjugate 6 in the intraperitoneal cavity of nu/nu mice was evaluated 
over 24 h. 0.4 mL of conjugate 6 (0.22 mg/mL) was administered i.p. and mice were sacrificed 1 
min, 30 min, 60 min, 3 h, 6 h, and 24 h after administration. The peritoneal cavity was washed and 
the amount of conjugate present in the wash was measured. The half-life of the conjugate in the 
peritoneal cavity was found to be 0.59 h, as shown in Figure 5.9. Notably, however, 30% of the drug 
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elimination does not follow monophasic kinetics although insufficient data points were obtained to 
conduct a robust analysis. 
 
Figure 5.9: Conjugate 6 peritoneal retention; Conjugate 6 recovered from intraperitoneal washes 
versus time in the peritoneal cavity is plotted. (Results are express as a mean ± S.D. of n=3).  
The percentage recovery from the peritoneal cavity was calculated. The intercept of a linear 
regression of natural log of retention plotted against time was used to estimate the amount of drug 
present at time zero (from the y intercept). This value did not differ substantially from the mass of 
drug measured in the peritoneal cavity immediately after drug administration. The estimated amount 
present from linear regression analysis suggests that approximately 40% of the conjugate was 
recovered from the peritoneal cavity at time 0h.  
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Figure 5.10: Linear regression to calculate recovery from intraperitoneal cavity; Ln(recovery(µg)) 
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5.4 Discussion 
Autotaxin catalyses the production of LPA which is present at high concentrations in the peritoneal 
cavity of ovarian cancer patients. Inhibition of autotaxin has the potential to decrease the survival, 
migration and proliferation of cancerous cells. Maintaining a high local drug concentration within 
the peritoneal cavity is important to provide sufficient prolonged inhibition of autotaxin.  
The major processes for eliminating drugs from the peritoneal cavity are either via the blood and 
lymphatic system or diffusion across the peritoneal membrane.236, 268 The peritoneal membrane is 
thin and highly permeable to molecules with molecular weights of less than 20 kDa. Transfer into 
the blood vessels is limited by transfer across the capillary membrane and blood flow. The lymphatic 
system absorbs compounds with a molecular weight greater than 500 Da. Therefore, the residence 
time of small molecular weight drugs in the peritoneal cavity may not be adequate because they are 
quickly absorbed through the peritoneal capillaries into the systemic circulation, or they are lost by 
diffusion across the peritoneum. Attaching an autotaxin inhibitor to icodextrin has the potential to 
increase the retention of the inhibitor in the intraperitoneal cavity, by preventing diffusion of the 
compounds across the peritoneal membrane. In the previous chapter the synthesis of an icodextrin-
autotaxin inhibitor conjugate was described. The work described in this chapter explores the effect 
conjugation has on the pharmacokinetics and the biological activity of the inhibitor. 
The autotaxin inhibitor chosen to attach to icodextrin was a potent inhibitor with a thiazolidinedione 
core previously described by Albers et al.224  This compound had a terminal carboxylic acid but, a 
relative of this inhibitor, a boronic acid based inhibitor, has been shown to reduce plasma LPA levels 
in vivo. Although this reduction was short lived it shows promise as a candidate to target autotaxin.223  
The conjugates were initially investigated for retained activity by assessing their ability to inhibit 
autotaxin obtained from two different sources (commercial kit or purified from 3E3 cells) and 
measured using two different substrates. The conjugate retained activity in both assays giving 
confidence the drug is active. The degree of substitution appeared to have an effect on the ability of 
the conjugate to inhibit autotaxin. Having more inhibitor conjugated led to a decrease in potency 
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when expressed in terms of the pharmacophore present.  This may be due to steric hindrance caused 
by having too much drug attached to icodextrin, preventing more autotaxin from binding and 
therefore some of the drug becomes redundant.  
Conjugation to icodextrin increased the aqueous solubility of the inhibitor. However, similar to the 
observed reduction in potency with increased substitution, the aqueous solubility decreased as the 
amount of inhibitor attached was increased. This is not surprising considering that the 
pharmacophore is significantly more hydrophobic than icodextrin. It may be appropriate to optimise 
the substitution ratio to optimize the solubility/potency profile, in order to maximize the therapeutic 
benefit of the drug. 
The Autotaxin/LPA pathway is known to regulate cell migration, in many cancer cell types, including 
ovarian cancer.141, 256-257 Inhibition of autotaxin has been shown to reduce cancer cell migration. A 
monolayer wound healing experiment was used to confirm the free drug inhibits migration in ovarian 
cancer cells overexpressing autotaxin. The same assay was used to confirm the conjugates retained 
biological activity. Neither the free inhibitor nor the conjugate reduced migration in 3V5 cells, which 
were transfected with the vector and do not overexpress autotaxin. This suggests that the compounds 
are inhibiting migration by reducing the activity of autotaxin rather than as a result of activity at some 
other target. The activity of this conjugate as an inhibitor of migration suggests that the conjugate 
could be used to inhibit metastasis.  
Once the conjugates had demonstrated retained pharmacological activity, conjugate 6 was taken 
forward for in vivo pharmacokinetic analysis. Initially the toxicity of the conjugates was investigated 
to establish a safe dosage. The conjugate was found to have no evident adverse effects on the health 
of the mice. It is not surprising that the conjugate showed no toxicity because icodextrin is already 
established clinically and the drug is quickly metabolised. The pharmacophore itself has previously 
been reported to undergo rapid metabolism. This may be advantageous because once the drug 
becomes systemically available, its rapid metabolism is likely to reduce the chance of toxicity. It is 
possible, however, that the drug metabolites could be toxic. Thus, the studies here were only 
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preliminary tolerability tests to allow further in vivo testing and formal toxicological evaluation will 
still be necessary.  
A key factor for conjugation was to increase the retention time in the peritoneal cavity, the effect of 
conjugation on permeability was assessed using two in vitro assays. In a PAMPA artificial bilayer 
assay the conjugates were found to have low permeability this was consistent with the low 
permeability found in Caco-2 epithelial cell permeability assay. However, the half-life of the 
conjugate in the peritoneal cavity was less than 1 hour. This figure was calculated assuming 
monophasic drug elimination. Notably, however, 30% of the drug remained after 24 hours, 
suggesting that the drug elimination may be more complex.  One possibility is that the injection fluid 
is rapidly removed from the peritoneal cavity, and the reduced fluid volume reduces the efficiency 
of elimination. This may be therapeutically important, because it may allow the drug to accumulate 
at relatively high concentrations. The relatively short half-life may also be explained by the 
observation that rodents have an increased amount of α-amylase in the peritoneal cavity compared 
to humans.269 The half-life of icodextrin in rodents is known to be significantly less than that in 
humans due to this increased amount of α-amylase.269 This may account for the short half-life 
observed in the murine model. Retention of icodextrin is longer in humans, with a dwell time of more 
than 12 h.261 The higher molecular weight fractions, as used in these studies, are anticipated to be 
eliminated even more slowly. Coupled with the low permeability the conjugate exhibited in in vitro 
models, this suggests that the conjugate could be expected to be retained significantly longer in 
humans. This is important because it suggests that once daily dosing (or even less frequently) may 
be possible. 
Recovery of the conjugate from the peritoneal cavity was approximately 30% after time 0h of the 
drug injected. This low recovery was likely to be due to the difficulty in washing out drug from the 
peritoneal cavity. Therefore, it can be expected that the amount of drug in the peritoneal cavity is 
higher than the observable concentrations.  
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5.5 Conclusion 
The results from this study suggest that in principle autotaxin inhibitors may be conjugated to 
icodextrin and retain their pharmacological activity. Conjugation has the potential to improve the 
pharmacokinetics of the autotaxin inhibitor. The conjugate demonstrated an improved 
pharmacokinetic profile compared to the free inhibitor. This suggests that conjugation of autotaxin 
inhibitors to icodextrin has the potential to reduce autotaxin inhibitor clearance from the peritoneal 
cavity. It will be useful to evaluate the conjugate in an ovarian cancer intraperitoneal xenograft 
model. Although the focus of the studies described here are to evaluate autotaxin inhibitors for the 
treatment of ovarian cancer, autotaxin inhibitors have potential in other cancers and other diseases. 
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6.1 Introduction 
Autotaxin is an extracellular phospholipase D that catalyses the hydrolysis of lysophosphatidyl 
choline (LPC) to bioactive lipid lysophosphatidic acid (LPA). LPA has been implicated in many 
pathological processes relevant to cancer, including cell migration and invasion, proliferation, and 
survival. It has also been shown to be relevant to other pathological diseases such as inflammatory 
conditions. Autotaxin inhibition is a rapidly expanding field with many potential therapeutic uses. 
Although autotaxin inhibitors are still in the pre-clinical phase of development, the evidence for 
therapeutic benefit is mounting.   
6.2 Autotaxin as a therapeutic target in cancer 
Although there is substantial evidence of in vitro autotaxin inhibition with small molecule inhibitors, 
so far the evaluation of autotaxin inhibitors in vivo is limited. The first autotaxin inhibitor to 
demonstrate in vivo activity was BrP-LPA, this was found to reduce tumour burden in an orthotropic 
breast cancer xenograft model, however BrP-LPA shows activity against LPA receptors, therefore 
the in vivo effects cannot be attributed to autotaxin inhibition alone.256 Inhibition of autotaxin by a 
boronic acid based molecule resulted in reduction of LPA in vivo,223 but this reduction was short-
lived. The autotaxin inhibitor BoA-3 was shown to reduce levels of LPA in circulation in a murine 
model.91 Reduction in circulating LPA levels has also been shown to be reduced with the recently 
described autotaxin inhibitors PF-8380226 and ONO-8430506.228 These inhibitors are the most 
successful described autotaxin inhibitors to date. The time is ripe to evaluate these molecules in 
ovarian cancer. It may be worth testing these compounds per oral in an ovarian cancer model. The 
inhibitor described in this thesis has the advantage of direct delivery to the site of cancer and potential 
increased retention at this site. However, the use of literature inhibitors, which have been 
demonstrated to be active with oral administration may overcome the issues associated with 
intraperitoneal delivery. PF-8380 exhibited a half-life of 1.2 h after intravenous injection and a few 
hours with oral delivery, this may not provide sufficient autotaxin inhibition. ONO-8430506 was still 
measurable 24 h after oral administration at levels greater than IC90 suggesting this may be long 
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enough to sufficiently inhibit autotaxin. This requires further investigation in an in vivo ovarian 
cancer model. 
6.2.1 Autotaxin and chemoresistance  
There is limited evidence showing that inhibition of autotaxin, on its own, promotes cell death. 
However, autotaxin is over-expressed in ovarian cancer tumours that are resistant to chemotherapy. 
LPA and autotaxin have been shown to directly confer resistance to chemotherapy in a number of 
studies. LPA has been associated with the development of resistance to carboplatin in ovarian cancer 
cells,176 and colon cancer.177 Expression of autotaxin delays apoptosis induced by carboplatin in 
ovarian cancer cells.178 Additionally apoptosis was accelerated after inhibition of autotaxin by either 
siRNA silencing or with a small molecule inhibitor.178 In addition to conferring resistance to 
platinum-based chemotherapy, LPA and autotaxin also confer resistance to paclitaxel in breast and 
melanoma cancers.179,180  In chapter 3, addition of LPC, the substrate of autotaxin, was shown to 
protect ovarian cancer cells which were engineered to over-express autotaxin, from cell death 
induced by carboplatin. Treatment with either the autotaxin inhibitor S32826 or conjugate 1 resulted 
in elimination of this protection. This provides evidence that autotaxin inhibition could be used in 
combination with chemotherapy in order to overcome chemoresistance. Autotaxin inhibition could 
be used alongside frontline therapy to improve response or once patients have become resistant to 
ovarian cancer. The data suggests addition to frontline chemotherapy, this may be the most sensible 
way it could be tested in clinical trials. 
6.2.2 Autotaxin and ovarian cancer  
This thesis has focused on the development of novel polymer-autotaxin inhibitor conjugates for the 
treatment of ovarian cancer. Ovarian cancer is a particular problem as it is often diagnosed at a late 
stage and although most patients respond to first line chemotherapy they go on to develop resistance. 
Therefore, the need for new methods for treating ovarian cancer is urgently required.  
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Patients with ovarian cancer often present with an accumulation of ascites fluid in the intraperitoneal 
cavity which contains LPA at concentrations up to 80 micromolar.73 Autotaxin is also found at 
increased levels in the ascites fluid of patients with ovarian cancer.270 As autotaxin is the main 
contributor to the production of LPA, autotaxin inhibitors have the potential to reduce the potentially 
pathogenic levels of LPA observed in ovarian cancer patient ascites. As discussed, the evidence for 
a role in cell migration and invasion is extensive. Inhibitors of autotaxin have been shown to reduce 
lung metastasis and breast metastasis in animal models.228, 256 Both the polymer-autotaxin inhibitor 
conjugates described in this thesis were found to inhibit ovarian cancer cell migration in a wound 
healing assay. Hence autotaxin inhibition has the potential to reduce metastasis in the clinic. However 
most ovarian cancer patients present with disseminated disease and therefore inhibition of metastasis 
may be futile. Although it may be beneficial to prevent further metastasis; evaluating the ability of 
autotaxin inhibitors in the clinic will be challenging. In metastasised disease the major issue is the 
destruction of the metastasis, however it is possible that reducing further metastasis is therapeutically 
beneficial. One potential way to examine this would be to administer autotaxin inhibitors after a 
patient has received chemotherapy.  
6.3 Autotaxin as a therapeutic target in other diseases 
The potential benefit for autotaxin inhibitors for other indications is also evident. The ATX/LPA 
signalling pathway has been implicated various other pathophysiological processes. Autotaxin 
expression is increased in many inflammatory diseases, including in the cerebrospinal fluid of 
multiple sclerosis patients,134 the frontal cortex of Alzheimer’s like dementia patients,196 pulmonary 
fibrosis194  and in patients with rheumatoid arthritis.192 Inhibition of autotaxin has already been shown 
to be therapeutically beneficial in a rat air pouch model of inflammation, the autotaxin inhibitor PF-
8380 was able to reduce hyperalgesia with the same efficacy as the non-steroidal anti-inflammatory 
drug (NSAID), naproxen.226 Autotaxin inhibition has also been shown to reduce smooth muscle 
contraction, which is known to be promoted by lysophosphatidic acid. Treating rats with the 
autotaxin inhibitor ONO-8430506 decreased intraurethral pressure accompanied by urethral 
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relaxation.227 The BrP-LPA autotaxin inhibitor was found to attenuate collagen induced arthritis, 
however as previously discussed BrP-LPA also antagonises LPA receptors and therefore it cannot 
be concluded that this activity is due to inhibition of autotaxin.197 
6.4 Icodextrin as a drug carrier 
In this thesis the synthesis of a novel icodextrin-autotaxin inhibitor conjugate has been described. 
Further to its potential to increase autotaxin inhibitor retention in the peritoneal cavity, icodextrin 
drug carriers also have the potential improve the retention of other drugs in the peritoneal cavity. 
This may be desirable to ensure a high local drug concentration in the peritoneal cavity that promotes 
efficacy, but reduced exposure to the drug in plasma may limit systemic toxicity. The residence time 
of small molecular weight drugs (<20kDa) in the peritoneal cavity may not be adequate because they 
are quickly absorbed through the peritoneal capillaries into systemic circulation.236-237 This leads to 
frequent or continuous dosing and if drugs are delivered by the intraperitoneal route, this creates 
problems such as increased risk of infection. Conjugation to icodextrin has the potential to overcome 
these issues. Due to its molecular size, icodextrin is absorbed slowly from the peritoneal cavity 
mainly via the lymphatic system, icodextrin has a residence time of more than 12 h in the peritoneal 
cavity.261 To date there have been several studies investigating icodextrin as an intramolecular drug 
delivery vehicle. These have included its clinical evaluation for the delivery of the cytotoxic drug 5-
fluorouracil and an anti-HIV agent.271-273 It was also shown to improve retention and peritoneal 
distribution of adenovirus in a murine model.274 In these studies the therapeutic agent was made as a 
solution in icodextrin and the pharmacophore was not covalently linked to icodextrin. Conjugation 
to icodextrin may be able to further improve peritoneal retention. Drugs which may benefit from 
conjugation to icodextrin include, but are not limited to, small molecule therapeutics intended for the 
treatment of cancers localised in the peritoneal cavity. These could be designed based on the 
requirements of the specific drug. For example, allowing increased retention in the peritoneal cavity 
or slow release of the drug into the peritoneal cavity. Thus there seem to be many reasons supporting 
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further exploration of icodextrin for drug delivery in peritoneal cancer due to its chemical properties 
and its establishment in the clinic.  
6.5 Dendrimers as drug carriers 
Dendrimers are also widely being investigated as drug delivery systems. The conjugate described in 
chapter 3 is likely to be rapidly removed from the peritoneal cavity because although conjugation to 
a dendrimer increases the molecular mass of the drug, it is still only 8 kDa which may not be 
sufficient to prevent its clearance. Dendrimers above 5th generation may be better retained in the 
peritoneal cavity as due to their larger molecular weight. It would be worth investigating the retention 
of dendrimers greater than 5th generation in the peritoneal cavity, as dendrimers are ideal drug carrier 
candidates due to their uniform size and multiple sites of attachment.  
There are other potential therapeutic uses for an autotaxin inhibitor conjugated to a dendrimer. 
Dendrimers have the potential to improve the pharmacokinetic profiles of lipophilic drugs, such as 
the autotaxin inhibitor S32826 as was described in chapter 3. The inhibitor was rapidly metabolised 
in systemic circulation when tested in vivo, whereas it had shown high biological activity in vitro.83 
Further to increasing the metabolic stability of drugs, the multiple sites of attachment suggest that 
other molecule could be attached to the dendrimer alongside the drug. These molecules could target 
the conjugate to the site intended. One such molecule which has been investigated is folate. The 
folate receptor is associated with tumours, and binds to folate with a high affinity, folate drug 
conjugates have already been shown to target tumours.275 
Furthermore, as previously discussed, autotaxin inhibitors also have the potential to be beneficial in 
inflammatory diseases; a dendrimer-autotaxin inhibitor conjugate could increase the retention time 
of autotaxin inhibitors in other cavities or at the site of inflammation.  
6.6 Further studies 
To confirm the icodextrin-autotaxin inhibitor conjugate has therapeutic potential a few key 
investigations are required. An appropriate xenograft model is required. Initial results suggest that 
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the 3E3 cell line, which overexpresses autotaxin, could be used. These cells were able to establish 
ascites forming tumours in the peritoneal cavity. The first step will be to demonstrate the icodextrin-
autotaxin inhibitor conjugate can reduce LPA production in vivo. This would be achieved by 
measuring LPA levels at set times after administration of the conjugate. Once LPA reduction has 
been established demonstration of activity in a xenograft study will be investigated. The conjugate 
will be investigated in combination with carboplatin for its ability to increase tumour response to 
carboplatin. The conjugate will also ideally be investigated in a model for ovarian cancer metastasis.  
6.7 Concluding remarks 
So far there has been limited translation of the autotaxin inhibitors into animal models. Although 
research into the ATX/LPA signalling pathway has rapidly expanded over the past decade, 
establishing autotaxin inhibitor activity in animal models will be essential for translating autotaxin 
inhibitors into the clinic.  
This thesis has demonstrated that in principle an autotaxin inhibitor can be attached to a polymer and 
retain its pharmacological activity. Attaching an autotaxin inhibitor to icodextrin also has the 
potential to increase the residence time of the inhibitor in the peritoneal cavity. This conjugate has 
the potential to be therapeutically beneficial for the treatment of ovarian cancer. The icodextrin-
autotaxin inhibitor conjugate described in this thesis will be investigated for the ability to reduce 
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